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 Despite progress in detection and treatment, lung cancer remains the leading 
cause of cancer-related death in the United States.  The United States Preventive Services 
Task Force (USPSTF) recommends adults at high risk for lung cancer undergo annual 
low-dose computed tomography (LDCT) screening, however, lung cancer screening 
(LCS) uptake remains low.  Qualitative research on family physician (FP) perceptions 
and experiences with LCS has been limited since USPSTF publication and Centers for 
Medicare and Medicaid Services (CMS) decision memo.  We conducted a qualitative 
study to assess FP knowledge and perceptions of LCS and gain insight into their current 
experiences with LDCT.  A convenience sample of FPs were asked to participate in 
Skype audio interviews.  A semi-structured interview guide was used to navigate the 
interviews.  A theme codebook was developed using the constant comparison technique. 
All interviews were coded by two reviewers.   
We found that FP knowledge about the scientific evidence and patient eligibility 
criteria for LDCT was suboptimal.  Age and smoking history were the primary drivers of 
a FPs decision to discuss LCS.  Most FPs knew that they should initiate LDCT 
discussions with high risk patients, however, they indicated that they would be willing to 
screen patients outside of the specified criteria.  LDCT cost and lack of time were cited as 
barriers.  Facilitators included screening tools in the clinic waiting room and electronic
medical record notifications.  These results indicate a need for FP education about LCS, 
as well as tools to assist providers in the clinic. 
vi 
 As LCS becomes more widely adopted, more lung cancers will be detected at an 
earlier stage.  While tumor molecular testing (MT) is currently recommended for patients 
with metastatic disease, MT could increasingly be used in early stage patients to guide 
initial treatment decisions.  Disparities in MT and targeted therapy utilization may exist.  
We quantitatively evaluated factors related to MT and erlotinib utilization and the impact 
of these on overall survival (OS). 
 Stage IIIB/IV non-small cell lung cancer (NSCLC) cases diagnosed between 
January 1, 2002 and December 31, 2012 and available through the South Carolina 
Central Cancer Registry were linked to SC State Employee Health Plan (SCSEHP) and 
Medicaid administrative claims data.  MT and erlotinib utilization were independently 
categorized as “yes” or “no” based on claims data.  We found several characteristics 
associated with MT, including younger age, having an out-of-state provider, being 
diagnosed in 2010 or later, adenocarcinoma histology, and low tumor grade.  Risk of 
death was reduced and OS was longer for patients with MT.  Younger age, female sex, 
SCSHEP insurance, having an out-of-state provider, adenocarcinoma histology, and 
having molecular testing were associated with erlotinib utilization.  Risk of death was 
lower for patients treated with erlotinib and OS was longer.  These results suggest that 
tumor MT and erlotinib utilization lead to improved patient survival.  Additional research 
should evaluate these important factors in nationally representative datasets.
vii 
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Statement of the Problem
In the United States, an estimated 1,688,780 new cases of cancer will be 
diagnosed in 2017.1 Of these, approximately 222,500 cases of lung cancer will be 
diagnosed and an estimated 155,870 individuals will die from the disease.1  In North 
Carolina and South Carolina, collectively, 12,261 new cases are estimated (NC: 7,940; 
SC: 4,321) and deaths are estimated.1  Lung cancer is the second most frequently 
diagnosed cancer and is the leading cause of cancer mortality among both males and 
females, with five-year survival rates of 18% among all races.1  Over half (57%) of cases 
are diagnosed with distant disease, meaning the patient has advanced or metastatic 
disease at the time of diagnosis.1  Only 22% of cases are diagnosed with localized or 
regional disease.1  Five year survival is better for those diagnosed with local disease 
(54%) compared to those with regional or distant disease (27% and 4%, respectively).2   
 Since 1990, a decrease in the lung cancer mortality rate has been observed in both 
males and females, but the decline has been greater for males.1  Hopefully, this 
decreasing trend will remain stable or improve in future decades, as improvements in 
lung cancer detection and treatments are made.  Lung cancer screening with low-dose 
computed tomography (LDCT) and treatment with molecularly targeted therapies are two 
approaches to the control of lung cancer in the United States, both of which have become 
2 
popularized within the last two decades.  The goal of LDCT is to identify lung cancer in 
earlier stages, when the disease is more treatable, while the goal of molecularly targeted 
treatment is to improve survival and quality of life (QOL).   
 This dissertation will consist of three lung cancer research manuscripts.  The first 
will focus on family physician (FP) lung cancer screening perceptions and practices 
(Chapter IV).  The second and third manuscripts will focus on: 1) factors related to 
molecular testing and its impact on survival (Chapter V); and 2) factors related to 
utilization of erlotinib and erlotinib’s impact on survival (Chapter VI). 
Lung Cancer Background  
Lung cancer is among the most commonly diagnosed cancers and is the number 
one cause of cancer death among adults in the United States.1 Broadly, lung cancer can 
be divided into two subtypes:  non-small cell lung cancer (NSCLC) and small cell lung 
cancer.  NSCLC can be further sub-categorized as adenocarcinoma, squamous, or large 
cell carcinoma.  NSCLC is the most common type, comprising 85% of cases. A new lung 
cancer screening approach, low-dose computed tomography, allows for detection of early 
stage lung cancer that can be curable3.  For patients diagnosed with early stage NSCLC, 
surgical resection is the cornerstone of their treatment, however, approximately 70% of 
patients diagnosed with NSCLC present to the clinic with late stage disease.1 Patients 
with late stage NSCLC experience widespread disease and surgical resection alone is not 
sufficient. Historically, the treatment of metastatic NSCLC has relied heavily on 
platinum-based doublet chemotherapies with a meager median overall survival of ~8 
months and low response rates of approximately 20%.4 
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Advances in the molecular profiling of lung tumors have led to the discovery of 
many molecular abnormalities, which has led to a more personalized approach to lung 
cancer treatment, especially for those patients whose tumors are of the adenocarcinoma 
subtype.  Molecular testing can identify patients whose tumors do not harbor clinical 
actionable alterations and who are unlikely to respond to targeted drug therapies, sparing 
these patients and payers the cost of non-efficacious therapy. For those patients whose 
tumors do have clinically actionable molecular abnormalities, targeted drug therapies, 
such as EGFR tyrosine kinase inhibitors (TKIs) and ALK inhibitors, are FDA approved 
and are the preferred treatment. Patients with EGFR-mutated lung cancers who received 
targeted therapies in clinical trials have experienced significant improvements in tumor 
response rates (RR) and median progression-free survival (PFS) and have experienced 
fewer side effects and an improved quality of life.5-9 While PFS has been favorable for 
patients receiving targeted drugs, increased overall survival (OS) has not been observed 
in patients participating in clinical trials10-12 possibly due to drug crossover in randomized 
studies.10  Still, use of targeted therapies is considered by the National Comprehensive 
Cancer Network (NCCN) as the best choice to treat patients with advanced NSCLC 
whose tumors harbor molecular abnormalities. 
Specific Aims 
Study 1. Family Physician Perceptions and Experiences with Low-Dose Computed 
Tomography Screening for Lung Cancer 
 Recently, new guidelines for lung cancer screening using low-dose computed 
tomography (LDCT) have been published by the United States Preventative Services 
Task Force (USPSTF) and supported by many professional cancer societies and advocacy 
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groups, such as the American Cancer Society, American Society of Clinical Oncology, 
American College of Radiology, and National Comprehensive Cancer Network (Table 
1.1).  As a result, the Centers for Medicare and Medicaid Services (CMS) approved 
coverage for annual lung cancer screening using LDCT in select, high risk adults.  Since 
the announcement of the CMS coverage decision memo and publication of requirements 
for reimbursement on February 5, 2015 (Table 1.2),13 qualitative literature published on 
family physician perceptions and experiences towards LDCT has been sparse.14,15 
Quantitative data previously collected and published was obtained through the 
administration of an electronic and paper questionnaire from family physician members 
of the South Carolina Chapter of the American Academy of Family Physicians16 and 
primary care physician employees at Carolinas HealthCare System17 and was used to 
inform the development of an interview guide for this study.  Follow-up interviews were 
conducted with a subset of physicians who completed the questionnaire and who agreed 
to be contacted for future research to obtain qualitative data.  The specific aims of this 
qualitative study are to: 
1. Assess family physician knowledge surrounding the current scientific evidence on 
LDCT for lung cancer screening 
2. Assess family physician knowledge with regards to current patient eligibility 
criteria defining patients at “high risk” for lung cancer 
3. Explore family physician attitudes on implementation of lung cancer screening 
discussions, including shared decision-making processes 
4. Explore barriers and facilitators to lung cancer screening 
5. Explore current LDCT referral and follow-up practices 
5 
Study 2. Factors Predicting Molecular Testing and Erlotinib Utilization and their Impact 
on Survival in Patients with Advanced, Non-Small Cell Lung Cancer 
State and national cancer registries do not collect data on the molecular 
characteristics of lung tumors. Thus, it has been difficult to evaluate the public health 
significance of molecular testing and targeted therapies at a population level.  
Specifically, utilization of molecular testing, factors associated with receipt of testing, 
and survival of patients with NSCLC undergoing molecular testing and treatment with 
targeted therapies has not been previously evaluated at the population level across the 
time period evaluated in this study.  This study will use an administrative claims database 
linked to a state cancer registry database to examine these topics.  In this study, 2002-
2014 data from South Carolina (SC) Central Cancer Registry NSCLC cases will be 
linked to SC State Employee (SCSEHP) and SC Medicaid members to examine these 
topics at the state level.  Knowledge on utilization and factors associated with molecular 
testing and erlotinib use can give us insight to the current landscape o across SC and can 
allow us to identify factors associated with non-utilization.  
Published research on the utilization of molecular testing and erlotinib in patients 
with NSCLC at the population level across these years is extremely limited. Research 
addressing lung cancer molecular testing and erlotinib utilization in the US and their 
impact on survival has not previously been conducted using SC linked administrative 
claims and cancer registry data.  By combining administrative claims data with 
population-based cancer registry data, we have the advantage of being able to capitalize 
on the strengths of each dataset while minimizing their weaknesses when used alone.  For 
example, SCCCR does not collect data on whether or not a patient had molecular testing, 
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but this information is available by searching for molecular testing Common Procedure 
Terminology (CPT) codes in SCSEHP and Medicaid claims. The results of this study will 
characterize the current landscape of molecular testing in NSCLC patients and identify 
disparities in utilization among SC residents. Increasing the number of patients who 
receive molecular testing (and when appropriate, targeted therapy) can lead to decreases 
in the cost of supportive care that would result from treating chemotherapy toxicity and 
may lead to increased quality of life for more patients.  Additionally, it may also spare 
chemotherapy in patients that are unlikely to benefit. 
The specific aims of this study are to: 
1. Identify factors that are associated with molecular testing and erlotinib utilization  
2. Estimate propensity scores for each case to predict molecular testing and to 
predict erlotinib utilization 
3. Evaluate the relationship between molecular testing and survival 
4. Evaluate the relationship between erlotinib utilization and survival 
Significance 
Lung cancer screening with low-dose computed tomography is underutilized and most 
lung cancers are diagnosed late-stage. 
Historically, lung cancer screening methods in the US have included chest x-ray, 
computed tomography, and sputum cytology, however, no mortality benefit was observed 
with any of these approaches.  Recently, the National Lung Screening Trial reported a 
20% reduction in lung cancer mortality and a 6.7% reduction in overall mortality with 
annual screening using LDCT for three years.18  Because of these findings, the United 
States Preventative Services Task Force recommended LDCT screening for high 
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risk patients at the grade B level in 2014.19  A grade B level recommendation requires 
lung cancer screening to be provided free of charge to patients covered under the 
Affordable Care Act.  Subsequently, the Centers for Medicare and Medicaid Services 
(CMS) announced coverage for high risk adults defined as those aged 55–77 years who 
are asymptomatic for lung cancer, have a tobacco smoking history of at least 30 pack-
years, are current or former smokers (quit within the past 15 years) and have 
documentation of a counseling and shared decision-making visit prior to LDCT 
screening.13   
Currently, about 70% lung cancers are diagnosed late or advanced stage (III or 
IV).20 Of these, roughly 40% have metastatic disease and despite surgery or combined 
therapy are considered incurable, while about 40% have locally advanced disease and 
will undergo multimodal therapy.21  Lung cancer screening with LDCT can identify 
earlier stage lung cancer that is more likely to be treated with surgical resection alone. 
Median overall survival in NSCLC patients is low with chemoradiation. 
Multiple treatment modalities exist for lung cancer patients.  Surgical resection, 
systemic chemotherapy, and radiotherapy are the cornerstones of lung cancer therapy.  
However, surgical resection is mostly limited to those presenting with early stage disease.  
Most unresectable, advanced stage patients are treated initially with one of four platinum 
doublet chemotherapy regimens (e.g., cisplatin plus paclitaxel or docetaxel, cisplatin plus 
gemcitabine, or carboplatin plus paclitaxel)21 with concurrent radiation therapy (if 
tolerable), as this combined approach has yielded the best overall survival.20,22  An 
Eastern Cooperative Group (ECOG) evaluation of these four regimens was recently 
conducted in 1,207 patients, of which 1,155 were eligible for analysis.  The median 
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overall survival was 7.9 months (95% CI: 7.3-8.5), with no meaningful difference in 
survival by chemotherapy regimen.  One and two-year survival rates were 33% and 11%, 
respectively (95% CIs: 30-36% and 8-12%, respectively).  More recently, the ECOG 
evaluated overall survival of the drug pemetrexed (a folate antimetabolite) versus 
carboplatin plus pemetrexed.23  In this randomized trial of 205 eligible patients, a small 
increase in overall survival was observed in the carboplatin-pemetrexed group (median 
OS = 9.3 months, 95% CI: 7.4-11.2 months) with a more favorable toxicity profile.23  
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has also 
emerged as a therapeutic drug in the treatment NSCLC.  In a multicenter, phase II study, 
patients treated with paclitaxel-carboplatin plus bevacizumab (PCB) combination therapy 
had significantly better overall survival compared to those treated with paclitaxel-
carboplatin (PC) alone, although an increase in treatment-related deaths was observed.  
Median OS for those on the PCB arm was 12.3 months compared to 10.3 months on the 
PC arm (HR=0.79; P=0.003).24  While chemotherapy does have its place in the treatment 
of NSCLC patients, newer drug therapies, including targeted therapies and 
immunotherapies, are quickly emerging as efficacious treatment modalities. 
Clinically relevant molecular abnormalities have been identified in patients with NSCLC. 
Within the past one to two decades, knowledge of molecular markers has 
proliferated.  The three most studied clinically relevant molecular abnormalities in 
NSCLC include Kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth 
factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), and these abnormalities 
are typically mutually exclusive.20,25  However, other molecular abnormalities also exist 
(i.e. MET, ROS-1).25-27  This dissertation focuses on molecular testing in general and 
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focuses on the utilization of the EGFR TKI, erlotinib (Tarceva; Genentech). EGFR is a 
cell surface receptor that is activated either by protein overexpression, increased gene 
copy number or genetic mutation.  EGFR is involved with cell proliferation, suppression 
of apoptosis (cell death), cell motility, invasion and angiogenesis (formation of new 
blood vessels).20,25  Prevalence of EGFR mutated lung cancers range from 15%-80%, 
depending on racial and behavioral characteristics.  Those most likely to have EGFR 
mutated lung tumors include Asian ethnicity, females, never smokers, and those with 
adenocarcinoma histology.25  The RAS family mutations (including KRAS) encode for 
proteins on the cells surface and are involved with cell proliferation, survival, and 
metastasis.20  In adenocarcinoma patients, prevalence of KRAS mutated lung cancers 
ranges from 20%-30%, with higher prevalence among Caucasians and ever-smokers.20,25   
The availability of molecular tests to predict response to targeted therapies is increasing. 
Molecular testing can be conducted using both FDA-approved tests (“companion 
diagnostics”) and other non-FDA approved laboratory developed tests.  Some tests are 
run individually, while some are run as a “panel” and may assess multiple biomarkers in 
one test administration (e.g., Lung Cancer Panel, Solid Tumor Mutation Panel by Next 
Generation Sequencing).  Local Coverage Determinations published by Medicare 
administrative contractors are used to establish Medicare coverage guidance for existing 
and newly developed laboratory diagnostic tests. Historically, clinical laboratories have 
billed payers, such as Medicare, using a technique call “code stacking”. This method-
based approach to billing uses combinations of CPT or Healthcare Common Procedure 
Coding System (HCPCS) codes to bill for molecular tests. This approach can result in a 
variety of code combinations, as well as costs, for one molecular test.  
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As the availability of molecular testing has increased, the need for distinct, 
individualized, gene-specific codes emerged.  Revisions to the coding systems were 
drafted and a new set of CPT codes were published in 2013 that are more accommodating 
to the modern molecular testing performed in laboratories.  For example, Palmetto GBA, 
the administrative servicer for South Carolina’s Medicare program, has approved the 
code 81235-22 (EGFR, common variant) for EGFR testing of tumor and plasma 
specimens.28 
Molecular testing is used to assist providers in selecting targeted therapies based on 
tumor characteristics and these therapies have yielded improved outcomes. 
Several targeted therapies have been approved by the FDA to treat patients with 
NSCLC whose tumors harbor EGFR mutations, including the EGFR TKIs erlotinib, 
afatinib, and gefitinib. Improvements in progression-free survival and overall response 
rates have been noted.6,29  Additionally, targeted drug therapies are less toxic than 
systemic chemotherapy regimens and studies have reported low frequencies of both 

















AATS ALA NCCN 
 
CMS 













55 to 74 
years 



















have quit in 
past 15 
years 
55 to 79 
years 
30 pack 







































 Current or 






































Yes Yes Yes 
Year 
Updated 
2013 2015 2012 2012 2015 2015 2015 
Abbreviations: AACP-American College of Chest Physicians, AATS-American Association for Thoracic Surgery, ACR-American 
College of Radiology, ACS-American Cancer Society, ALA-American Lung Association, ASCO-American Society of Clinical 
Oncology, CMS-Centers for Medicare and Medicaid Services, NCCN-National Comprehensive Cancer Network, NLST-National Lung 
Screening Trial, USPSTF-U.S. Preventive Services Task Force. 








Table 1.2. Requirements for CMS Coverage of LDCT Screening for Lung Cancer  
 
Initial Screening 
Age • 55-77 years 
Symptoms • None; asymptomatic patients only 
Tobacco smoking history • ≥30 pack years 
Current smoking status • Current or former smokers; former smokes must have quit 
within the last 15 years 
Health Care Professional • Physicians or qualified non-physician practioners 
(physician assistants, nurse practioners, clinical nurse 
specialist (as defined by Section 1851(r)(1) of the Social 
Security Act)) 
Shared decision-making visit • Determination and documentation of age, lack of 
signs/symptoms of lung cancer, calculation of smoking 
pack-years, and report of current smoking status 
• Use of 1+ decision aids that describe the benefits and 
harms of screening 
• Counseling on the importance of adhering to LDCT 
screening schedule (annual LDCT), impact of 






treatment if suspicious findings are present 
• Written order for LDCT for lung cancer screening 
• National Provider Identifier (NPI) for ordering practioners 
Radiology imaging facility • Performs LDCT with volumetric CT dose index of 
≤3.0mGy for standard size patients and appropriate 
reductions/increases for smaller/larger patients 
• Uses standardized lung nodule identification, 
classification, reporting system 
• Provides information and interventions for smoking 
cessation in current smokers 
Reading radiologist  • Board certified/eligible with American Board of 
Radiology (ACR) or equivalent organization 
• Documented diagnostic radiology and radiation safety 
training and continuing medical education (according to 
ACR standards) 
• Involvement in supervision/interpretation of at least 300 
chest CTs within past 3 years 
• Conduct LDCT screening in a radiology facility that meets 






Lung cancer screening registry • Radiology facility must collect/submit data to CMS-
approved registry for each LDCT screening performed.  
Minimum data submission includes: facility identifier, 
NPI, patient identifier, CT manufacturer/model, indication 
for screening, nodule identification system employed, 
patient smoking history, radiation dose delivered, 
screening date 
• Establishment of steering committee/governance board to 
oversee registry 
• Registry management plan with identification of key 
registry personnel 
• Operation plan describing plan for collecting and 
submitting data to the registry and from registry to CMS, 
including agreement to use CMS-approved data dictionary 
• Registry catchment area and list of facilities participation 
in the registry 
• Description of methods to permit linkage of registry data 
to external databases (e.g. Medicare claims) 
• Description of data management, quality review and 
validation 







Health Care Professional • Physicians or qualified non-physician practioners 
(physician assistants, nurse practioners, clinical nurse 
specialist (as defined by Section 1851(r)(1) of the Social 
Security Act)) 
Shared decision-making visit • Not required, however if practioners decides to conduct a 
lung cancer screening shared decision-making visit, the 
same requirements as the initial screening apply 






Low-Dose Computed Tomography for Lung Cancer Screening
Historical Summary of Lung Cancer Screening 
For over 60 years, research has been conducted on the efficacy of various lung 
cancer screening methods, including chest radiography, sputum cytology, and low-dose 
computed tomography, but until recently, no recommendation was made as to which 
method, if any, increased lung cancer survival.  In the 1950s, the earliest clinical trials in 
the United States and London evaluated chest x-ray, sputum cytology, or the combination 
of both and were usually evaluated at six month intervals.  These early trials had major 
limitations including lack of randomization and control groups.  In the 1970s, the 
National Cancer Institute (NCI) sponsored three randomized controlled trials, specifically 
aimed at examining mortality from lung cancer.  These trials were conducted at Johns 
Hopkins University (JHU), the Mayo Clinic, and Memorial Sloan-Kettering Cancer 
Center (MSKCC).  Each trial had a slightly different design and the goals was to evaluate 
the efficacy of sputum cytology.  At JHU and MSKCC, both the intervention and control 
groups received annual chest x-rays and the intervention group received chest x-ray plus 
sputum cytology screening every four months.  At the Mayo Clinic, the intervention 
group received chest x-ray and sputum cytology every four months and while the control 
group received these services annually.  This trial was designed to evaluate the effect of 




that screening detects earlier stage lung cancers and that case-survival rates were 
improved however, mortality rates did not differ. Additionally, these trials suffered from 
length-time, lead and patient selection bias, common biases of screening studies.31  Other 
studies conducted around the same time period in Czechoslovakia and Germany had 
similar results.32,33  As a result of these studies, in 1989, neither the American Cancer 
Society, the American College of Radiology, the National Cancer Institute, the United 
States Preventive Services Task Force, or the Canadian Task Force recommended any 
screening test at any frequency for lung cancer.34 
Observational, Single Arm Studies Involving Low-Dose Computed Tomography 
Advances in multidetector helical computed tomography resulted in better scan 
images with decreased radiation exposure.35 Other advantages include increased scan 
speed, improved spatial resolution, and a clearer detection of lung nodules due to the 
cross-sectional data display.36  During the 1990s and early 2000s single arm, 
observational studies demonstrated improved identification of lung nodules and early-
stage lung cancers37 with low-dose helical computed tomography.  Also during this time, 
the Prostate, Lung, Colorectal, and Ovarian (PLCO) began and completed enrollment to 
assess mortality benefit for lung cancer screening using chest x-ray compared to usual 
care.38  Ultimately no mortality benefit was established,38 confirming the need for 
research on other lung cancer screening methodologies. 
Studies such as the Early Lung Cancer Action Project (ELCAP) and the 
International Early Lung Cancer Action Project (I-ELCAP), both initiated in 1993, were 
instrumental in reporting not only the benefits of LDCT in terms of increased nodule 




lung nodules compared to chest radiograph39 and that LDCT screening led to the 
detection of cancers that could be cured.3  The I-ELCAP reported that 85% of cancers 
detected by LDCT lung cancer screening were classified as clinical stage I and the 
estimated 10-year survival was 88%.3  A similar trial was conducted in Japan among 
1,611 asymptomatic patients ages 40-79 years. The Anti-Lung Cancer Association 
(ALCA) study reported that 71% of cases at initial screening were Stage IA and 82% of 
cases at diagnosed at repeat scan were stage IA.40  Many other single arm studies of 
LDCT were conducted during this time period (Figure 2.1).40-50 Trials such as these 
ultimately lead to the development of several large, randomized clinical trials of LDCT in 
the United States and Europe.  
Randomized Clinical Trials Involving Low-Dose Computed Tomography 
The Lung Screening Study (LSS) was a feasibility study evaluating the use of 
LDCT versus chest x-ray (CXR).  A total of 3,318 subjects participated in the study. 
Eligible subjects were between 55 and 74 years old, had at least a 30 pack-year history of 
cigarette smoking, and were either a current smoker or a former smoker (if former, had to 
have quit within last 10 years).51 
 Any non-calcified nodule ≥4mm found during screening was considered a 
positive screen. A total of 25.8% of LDCT and 8.7% of CXR scans were positive at the 
baseline scan and 48% and 40% of cases were diagnosed as stage I cancer, in the LDCT 
arm and CXR arm, respectively.  This study was the first to demonstrate that a 
randomized clinical trial evaluating LDCT was feasible in the United Sates and 




In 2002, the United States launched a larger, randomized trial comparing annual 
LDCT to CXR.36  The NLST, sponsored by the National Cancer Institute (NCI), enrolled 
53,454 “high risk” subjects ages 55-74 with a 30 pack-year history of cigarette smoking, 
who were current or former smokers.  Former smoker must have quit within the past 15 
years.18 Subjects were randomized to either three annual LDCT scans or three annual 
CXR scans. Across all three rounds of screening, there was a higher rate of positive 
screening tests with LDCT compared to CXR (T0, 27.3% vs 9.2%; T1, 27.9% vs 6.2%; 
T2, 16.8% vs 5%).18  A high proportion of positive screening tests were followed up with 
further diagnostic evaluation (90%), such as additional diagnostic imaging and more 
invasive procedures (thoracotomy, bronchoscopy, needle biopsy), at T0 compared to the 
other time points. Across the three rounds, a high proportion of the positive screening 
tests were false-positives (96.4% LDCT; 94.5% CXR).  Despite a high number of false-
positives resulting in additional follow-up, the majority of patients had no complications 
resulting from the additional procedures (99.6% LDCT; 99.7% CXR).  Among those with 
at least one complication, rates were similar or higher for the LDCT arm compared to the 
CXR arm for all complications assessed.  The most striking result from this trial was the 
reduction in lung cancer mortality observed with LDCT, 20% (p=0.004).  Additionally, 
the rate of all-cause mortality was reduced by 6.7% with the use of annual LDCT 
(p=0.02).  For the first time, lung cancer screening, using LDCT, resulted in a mortality 
benefit. 
The Nederlands Leuvens Longkanker Screeningsonderzoek (NELSON) study is 
the largest LDCT screening trial conducted in Europe.  Starting in 2003, subjects aged 




cigarettes per day for ≥30 years, and who were current or former smokers were enrolled.  
Former smokers must have quit within the past 10 years.  The original study design called 
for three screening rounds (baseline, 1 year later, 2 years later, 2.5 years later) included 
15,822 subjects, mostly males. The goal was to demonstrate a 25% reduction in the risk 
of lung cancer death with LDCT compared to no screening 10 years after 
randomization.52,53 However, a fourth round was added in 2009 (5.5 years later) to 
evaluate the inclusion of a 2.5-year screening interval (n=7,915).54  Over the first three 
screening rounds, 493 positive LDCT scans were reported and of these 40.6% were 
diagnosed with lung cancer.  Of these lung cancer cases, 70.8% of lung cancers were 
diagnosed as stage I and 8.1% were diagnosed as stage IIIB/IV.53  Most subjects were 
diagnosed with adenocarcinoma (51.2%).  In the fourth screening round, more patients 
were diagnosed with late-stage lung cancer (17.3%, p=0.02) and squamous-cell (21.7%), 
bronchoaveloar (8.7%), and small-cell carcinomas (6.5%) compared to the second round 
of screening (p=0.001).54 
A recent randomized trial conducted in the United Kingdom compared a single 
screen LDCT to standard care in high risk patients.55  Individuals age 50-75 years old and 
residing specific geographic areas were identified through population Primary Care Trust 
records and were asked to complete a questionnaire to identify those at high risk of lung 
cancer.  High risk patients were defined as those who scored a 5-year lung cancer risk of 
≥5% on the Liverpool Lung Project version 2 risk model.56  Those who were deemed 
high risk were asked to participate in the United Kingdom Lung Screening (UKLS).  Of 
the 249,988 who were identified through Primary Care Trust records, 4,061 consented to 




individuals who received a LDCT screen, 34 (1.7%) were diagnosed with lung cancer at 
baseline.  A total of 47.7% of participants underwent at least one additional screen due to 
a nodule finding on the baseline scan, resulting in a total of 42 diagnosed lung cancers.  
The majority of diagnosed lung cancers were adenocarcinomas (59.5%).  A total of 
85.7% of the diagnosed cancers were stage I or II and 83% had surgery as their primary 
treatment.  Mortality reports on this data are expected in coming years.55   
The NLST and NELSON studies are the largest performed to date.  Other 
randomized clinical trials of LDCT include the Danish Lung Cancer Screening Trial 
(DLCST),57 ITALUNG,58 Lung Cancer Screening Intervention (LUSI),59 and the 
Multicentric Italian Lung Detection (MILD).60 
Risks and Benefits of Lung Cancer Screening with Low-Dose Computed Tomography 
 Proponents of lung cancer screening with LDCT argue that the benefits of 
screening justify its use, however, most agree that, as with many screening tests, there are 
some inherent risks.  False positive scans are one such risk61 and are perhaps the leading 
concern for screening.  False positive scans also contribute to the overall cost of 
screening.  The false-positive screening rate in most studies involving LDCT is high.  For 
example, in the NLST, the false-positive rate for LDCT was 96.4%, but this was only 
slightly higher than the false-positive rate for CXR (94.5%).18 Inclusion of the Lung-
RADS classification (introduced in May 2014) reduced the false positive rate but also 
slightly reduced test sensitivity.62 The Lung-RADS classification changes the criteria for 
a positive screen slightly. The definition of a positive screen using Lung-RADs includes a 




growth for preexisting nodules as opposed to the NLST, which required only a 4-mm 
greatest transverse diameter.62   
Conversely, another harm of lung cancer screening is false negatives.  There may 
be instances where a lung cancer is not detected on a screening test and may give patients 
a sense of “protection” from lung cancer and false reassurance. 
Overdiagnosis is a common risk of any cancer screening program including lung 
cancer screening with LDCT.61,63,64  Overdiagnosis can occur when a patient is diagnosed 
with an indolent or slow growing cancer that would not otherwise have been detected 
without screening.  Persons may in fact die of other reasons without ever being 
diagnosed. The USPSTF modeling study reported a 10-12% of screen-detected cancer 
cases are overdiagnosed.19 
Another risk of lung cancer screening is increased exposure to radiation.61,64,65  
Persons undergoing LDCT screening may be exposure to additional radiation, not only at 
the time of LDCT screening, but also at screening follow-up. For a LDCT the average 
effective dose value is about 2 mSv for an average size patient compared to 7 mSv for a 
standard CT.66  Brenner et al evaluated the estimated risk of lung cancer due to radiation 
exposure from screening.  If 50% of current or former smokers ages 50-74 residing in the 
United States received annual LDCT screening, the estimated number of lung cancer 
cases would increase by 1.8% (95% CI: 0.5 – 5.5%).65  Excess risk of radiation-induced 
lung cancer is greatest for those around 55 years of age.65  Unfortunately, this 
corresponds to the appropriate age range for lung cancer screening.  Increased risk for 




person has, and other sources of radiation exposure.19 One scan is not the concern; it is 
the cumulative amount of radiation that is concerning.  
Discovery of incidental findings on a lung cancer screening LDCT present 
another potential harm of screening.  A NELSON sub-study found a non-clinically 
relevant incidental finding (e.g., emphysema, thyroid nodule) rate of 73% and a possibly 
clinically relevant incidental finding (e.g., liver lesion, aortic aneurysm > 6 cm) rate of 
8% (of which 79% were actually clinically relevant after further evaluation).67  A report 
of 2,812 patients by Gareen et al reported a significant incidental finding (e.g. abdominal 
aortic aneurysms and renal cysts) rate of 12.2%.  While some studies report that 
incidental findings are commonly picked up by LDCT screening, the USPSTF stated 
there was insufficient evidence on harms of incidental findings identified through LDCT 
screening.19 
Lastly, complications resulting from diagnostic work up procedures68,69 may also 
present a potential harm to persons undergoing screening with LDCT.  Following a 
positive screening, a person may need to undergo additional follow-up, such as additional 
CT imaging or needle biopsy, which may present additional harm.  Overall, the NLST 
reported few and minor complications arising from diagnostic evaluations following a 
positive screen (1.6% in the LDCT arm).18  In the NLST, risk of major complications 
following surgical procedures for benign nodules was 4.5 per 10,000 for the LDCT arm 
compared to 1.5 for the CXR arm.69 
Benefits of lung cancer screening with LDCT include reduction in risk of lung 




normal CT scan, and the opportunity to incorporate smoking cessation into lung cancer 
screening decision making discussions.68  
Cost of Lung Cancer Screening with Low-Dose Computed Tomography 
A NLST cost-effectiveness analysis compared LDCT to no screening. Black et al 
reported that lung cancer screening with LDCT cost an additional $1,631 per person 
(95% CI: 1,557-1,709). LDCT provides an additional 0.0316 life-years per person (95% 
CI: 0.0154-0.0478) and 0.0201 quality adjusted life years (QALYs) per person (95%CI: 
0.0088 - 0.0314). Incremental cost-effectiveness ratios (ICERs) were $52,000 per life-
year gained (95% CI: 34,000 – 106,000) and $81,000 per QALY gained (95%: 52,000 – 
186,000).70 This amount is similar or less than other cancer screenings. The authors state 
that the cost effectiveness of screening will depend on how screening programs are 
implemented.70 
Another study conducted by Mahadevia et al in 2003 simulated data to evaluate 
mortality and cost-effectiveness of LDCT compared to no screening for hypothetical 
cohorts of 100,000 current, quitting, and former heavy smokers aged 60 years while 
incorporating known screening biases and assuming 50% stage shift.  Their simulated 
models revealed the cost-effectiveness of lung cancer screening with LDCT was 
$116,300 for the current smoker cohort, $558,600 for cohort of quitting smokers, and 
$2,322,700 for the former smoker cohort, respectively, per QALY gained.71  Sensitivity 
analyses were also conducted to evaluate cost-effectiveness under a variety of efficacy 
assumptions.  Age at first screening, stage shift, and length of follow-up were also varied.  
Under extremely ideal model conditions (e.g., lower probabilities for non-adherence, 




QOL for localized stage), the cost-effectiveness of LDCT screening would drop to 
$42,500 per QALY for current smokers. Important to note, the simulated models did not 
include costs related to incidental findings.71   
The UKLS trial described previously also included a cost effectiveness 
component.  The ICER for single-screen LDCT screening was ₤8466 per QALY.55  This 
translates to approximately $11,071, which is substantially less the found in the NLST, 
but differences in the frequency of screening in addition to resource expenses are likely to 
explain this difference.55  
Physician Attitudes, Perceptions, and Experiences with Low-Dose Computed 
Tomography  
 Several studies have evaluated primary care physician attitudes, perceptions and 
practices regarding lung cancer screening with LDCT, prior to and following the 
publication of the NLST.  The first quantitative study on primary care physician’s lung 
cancer screening beliefs and recommendations was published in 2010.72  Klabunde et al 
conducted a nationally representative survey of practicing PCPs from 2006-2007.  A total 
of 962 physicians responded (70.6% response rate; 76.8% cooperation rate).  Physicians 
were unsure of the USPSTF and American College of Radiology recommendations 
(38.8% and 58.2%). Overall, LDCT was perceived as a somewhat or very effective 
screening tool and was viewed as more effective than CXR or sputum cytology.  
Approximately 31% of the physicians believed that LDCT was effective in reducing lung 
cancer mortality.72   
 Physicians were also presented with clinical scenarios in which age, smoking 




recommended, interestingly, physicians more frequently chose screening with CXR 
compared to LDCT or sputum cytology. Most physicians would screen the current 
smoker scenario (84.4%; CXR=40.1%, LDCT=17.2%).  Few physicians reported that 
they would screen the age 50, never smoker (17.4%; CXR=16.5%, LDCT=0.2%).72 
The first qualitative study, published by Henderson et at in 2011, conducted five 
telephone-based focus group with 28 primary care physicians (PCPs) in the United States 
to evaluate the factors influencing a PCPs decision to screen patients for lung cancer.73 
The focus groups were conducted in May and June 2009, prior to the publication of the 
NLST results.  Physicians reported CXR as outdated and not sensitive enough to detect 
lung cancer.  Some PCPs viewed CTs favorably stating that CT scans are efficacious and 
can detect small nodules.  Most physicians were aware of the recommendations published 
by USPSTF and ACS. Some physicians reported using the recommendations to direct 
practice while others did not.  Physicians who had multiple patients undergo follow-up 
for what turned out to be benign lesions had a negative view of lung cancer screening.  
Most physicians based their decision on whether to order lung cancer screening based on 
their perception of their patient’s risk of lung cancer, however, the physician’s perception 
of risk varied.  Smoking was cited as the most important risk factor, however, other risk 
factors considered by physicians included family history, immunocompromised status, 
personal cancer history, secondhand smoke exposure, and history of pulmonary disease.  
Most physicians ordered a lung cancer screening test regardless of their knowledge of 
screening efficacy, when a patient requested the test.73 
Physician practice regarding ordering lung cancer screening was also assessed.  




while 55% ordered chest radiography and 22% ordered LDCT.74  Almost 70% of 
physicians had at least one patient ask about lung cancer screening in the previous year.  
The authors noted that several factors influenced PCP ordering of LDCT.  Time since 
graduating from medical school, being in a practice with 6-15 physicians, believing that 
at least one expert group recommended screening, recommending lung cancer screening 
for asymptomatic patients regardless of smoking exposure, and having patients ask about 
lung cancer screening all increased the odds of ordering LDCT.74 
 Approximately two years after the dissemination of the NLST results (2013),  
Lewis et al surveyed 293 PCPs (response rate = 60%) via email at a large academic 
medical center75 to assess use of lung cancer screening, perceived screening 
effectiveness, knowledge of screening guidelines, perceived barriers to LDCT use and 
interest in screening education.75  PCPs reported that the USPSTF, ACS, and ASCO 
guidelines influenced their practice (88.4%, 71.8%, 46.0%, respectively).  Only 42% of 
PCPs viewed LDCT as very or moderately effective in reducing lung cancer mortality 
and 30% did not know about the benefit in reducing lung cancer mortality.  PCPs who 
reported more than 15% of their practice consisting of current or former smokers and 
those who knew at least three of the guideline components (e.g., age, annual screening, 
start screening age of 50, end screening age of 75 or 80, 20 or 30 pack-year smoking 
history, and not including individuals exposed to only secondhand smoke) were more 
likely to perceive LDCT as very or moderately efficacious (OR=3.0, 95%CI: 1.1-8.4, 
OR=5.1, 95%CI: 2.6-9.9, respectively).  Interestingly, colonoscopy, pap smear, and 
mammography had higher rates of perceived effectiveness (92.9%, 99%, 95.7%, all 




LDCT.75  Almost one-quarter of physicians reported using CXR to screen for lung cancer 
(21.3%, 95%CI: 16.0%-27.5%)75, despite the results of the NLST reporting no mortality 
benefit with CXR by the time of this survey.  Only 12.3% reported using LDCT (95%CI: 
8.2%-17.5%).  Knowing three or more guideline components significantly predicted 
likelihood of LDCT ordering (OR=3.0, 95%CI: 1.1-8.6).  Most physicians (79.8%) were 
open to receiving further information and education on lung cancer screening.75  
Perceived major barriers to lung cancer screening reported by PCPs in this cohort 
included patient financial cost (86.9%), potential harm from false-positives (82.7%), 
patient knowledge (81.3%), potential patient harm, incidental findings requiring further 
workup (81.3.%), and insurance coverage/cost (80.1%).75  Geographic availability, was 
also reported as a perceived barrier; approximately 25% of physicians reported 
geographic availability as a major or minor barrier.75  A report by Eberth et al confirmed 
this perceived barrier and reported that while most LDCT screening centers were located 
in counties with the highest lung cancer incidence in the Northeast and East North 
Central states, in four states (Oklahoma, Nevada, Mississippi, and Arkansas) geographic 
availability of LDCT screening centers may be a concern.76  A second study published by 
the Eberth team, surveyed members of the Society of Thoracic Oncology to determine 
availability of LDCT lung cancer screening programs.  Fourteen states, including those 
where availability of LDCT screening centers was a concern, had no screening center 
respond to their survey.77 
 A qualitative assessment of PCP attitudes and beliefs occurred just prior to the 
Centers for Medicare and Medicaid services coverage determination announcement in 




Mexico clinics serving rural and urban minority patients from February-September 
2014.78  The interviews (n=10) focused on a range of lung cancer related topics, including 
tobacco cessation, perceptions of the NLST results, and perceptions and attitudes toward 
informed decision making for cancer screening.  Prior to the interviews, physicians were 
given information on screening guidelines and results of the NLST.  Some physicians 
were not aware of changes to screening lung cancer screening guidelines.  No physicians 
reported ordering LDCT scans for lung cancer screening; however, some physicians 
reported ordering CXR and believed that this was in alignment with screening guidelines.  
No physicians reported a patient demand for LDCT services.  Some providers were not 
aware of the NLST results.  When presented information on the NLST, physicians 
perceived the absolute mortality risk to be small and were concerned about the high rate 
of false-positives and the risks of screening.  Physicians also reported concerns over long 
term radiation exposure.78 
PCPs reported being cautious to begin to offer LDCT screening in their clinics.  
Some PCPs stated that they would feel more obligated to offer screening if it were 
incorporated into performance measures.  Additionally, some physicians reported 
concerns over whether New Mexico radiology facilities had the ability to support high 
quality screening programs and listed this a potential barrier.  Other patient related 
barriers reported by PCPs included, travel expenses to get to a screening facility, as well 
as the costs of follow-up testing and potential treatment.  Such costs would make 
screening for lung cancer unreasonable for their patients.  Physicians were also concerned 
about the potential resource barriers they might face (e.g. time and effort), stating that 




In addition to increased time required by physicians to conduct lung cancer 
screening visits, PCPs were also concerned about the responsibility of explaining such a 
complex screening test to their patients with limited appointment times and the low 
literacy of most patients.  Physicians also voiced concern about discussing follow-up of 
abnormal findings with patients.78 
A report by Volk and Foxhall published in August of 2015 surveyed 350 PCPs on 
their current lung cancer screening practices and readiness to implement lung cancer 
screening programs at two Continuing Medical Education events in late 2014 (following 
the USPSTF recommendation and draft CMS coverage decision memo).79  Most PCPs 
reported being somewhat or very familiar with the current guidelines, however, only 
10.1% had a formal lung cancer screening program in their practice.  Over half (56.0%) 
planned to refer patients to high-quality screening programs, however, less than half were 
currently doing so (25.0% in practices that do not train residents; 43.1% in practices that 
offer residency programs).  There were some concerns also reported.  PCPs requested 
clarity on screening coverage, information on screening centers that offered LDCT, and 
decision aids and educational materials.79 
A qualitative study by Kanodora et al assessed the perceptions and perspectives 
on lung cancer screening among Veteran’s Affairs PCPs and patients.15  A total of 13 
PCPs in South Carolina participated in focus groups in 2014.  PCPs at this site had 
participated in lung cancer screening programs since 2012.  Their program consisted of 
clinical reminders built into the electronic medical records to notify VA PCPs that a 
patient was eligible, then the PCP made a referral to a lung cancer screening nurse 




in the clinic all facilitated conversations about screening.  More than half aware of the 
PCPs were aware of USPSTF recommendations for screening, however there was 
variation in commitment and enthusiasm for LDCT.  Additionally, some PCPs continued 
to believe CXR is effective.15  
PCPs interviewed preferred that the lung screening nurse coordinator to review 
details with patients, like continued surveillance and the features of the scan (low-dose).  
The providers reported that a majority of patients willing to have screening, but some 
feared cancer diagnosis or other illness.  Lung cancer screening discussions were met 
with little resistance and that resulted in shortened discussions, however, PCPs still 
reported not having enough time to have sufficient depth screening discussions.  Only 
23% of PCPs made referrals to local smoking cessation clinic and admitted to not 
devoting enough time to smoking cessation counseling.15 
PCPs reported that patients with recent cancer deaths in the family or heavy 
smokers were more likely to request screening, but that they most often requested CXR.  
Some patients were concerned about exposure while in the military that may increase 
their risk for lung cancers.15 
Another recent study, published in 2017 by Simmons et al, used focus groups 
consisting of Florida PCPs (e.g., physicians, nurse practioners, and  physician assistants) 
to assess knowledge and attitudes towards lung cancer screening.14  Prior to the focus 
group, PCPs were provided a summary of the current evidence for lung cancer screening, 
patient eligibility criteria, risks and benefits of screening, and reimbursement 
requirements in a webinar format.  The majority PCPs stated that patients did not inquire 




few reported still requesting CXR for screening purposes.  The majority said they 
currently had limited information about screening, although most said they would 
recommend it if they had more information.  Some providers also mentioned lack of 
understanding of the testing process and follow-up of abnormal results.  After viewing 
the webinar on lung cancer screening, a few PCPs reported screening to be more 
complicated than they initially thought.14 
Early detection was reported as the main benefit.  PCPs also discussed that lung 
cancer screening discussions can motivate smoking cessation and overall outcomes.   
Others benefits included coverage for patients with insurance/Medicare, low-dose of 
radiation with the scan, and patient reassurance that they do not have cancer.14 
The most common barriers to lung cancer screening were cost, time, and potential 
for false positives.  The time barrier includes a simple lack of time to discuss, as well as 
concerns over the complexity of discussion required for the SDM reimbursement.  Again, 
EMR pop-up reminders to indicated patient eligibility were viewed as facilitators to lung 
cancer screening.14 
In the past couple years, several other quantitative assessments of primary care 
physician knowledge, perceptions, and utilization have been reported.80-83  Earlier this 
year, Jemal et al reported extremely low rates of patient self-reported LDCT for lung 
cancer screening (<4%) between 2010 and 2015.84  Despite these prior studies, research, 
education, and promotion of lung cancer screening is still of importance.  Since the 
finalized CMS coverage decision memo was released in February 2015 and the use of 




published, no mixed methods studies evaluating family physician perception and 
practices surrounding LDCT have been reported. 
Molecular Testing in Non-Small Cell Lung Cancer 
Over the last two decades, knowledge of the biology of cancer and the molecular 
pathways involved in cancer has flourished and a variety of treatments have been become 
standard, including targeted therapies and immunotherapies (Table 2.1).  Identification of 
genetic anomalies, including mutations, gene rearrangements, and copy number changes, 
identified within cancer initiation and progression pathways have led to the development 
of personalized medicine and targeted therapeutics.  Many lung cancer biomarkers have 
been researched and published however, only a few biomarkers for lung cancer have use 
in the clinic and directly impact patient treatment.  Despite the clinical benefit of 
molecular testing and clinical guidelines for its use, molecular testing is likely still 
underutilized by thoracic oncologists, especially in the community-based setting85. 
Clinically Actionable Biomarkers for NSCLC 
 Several clinically actionable biomarkers have been identified in tumors of patients 
with NSCLC.  For example, 15-25% of patients harbor KRAS mutations,25,27 3-7% 
harbor ALK fusions/translocations,27,86,87 2-5% harbor MET amplifications,25,27 and 1-2% 
of patients have tumors that are ROS-1 rearranged.25,27 
Among the most prevalent is the epidermal growth factor receptor (EGFR; also 
referred to as ErbB1).  EGFR is a member of the ErbB family of receptors.88,89  The 
EGFR signaling pathway is visualized in Figure 2.2.  The most common EGFR 
abnormalities are point mutations and in-frame deletions.90 Other abnormalities in EGFR 




and EGFR protein expression.91  EGFR is most frequently mutated in either exon 19 and 
21 (L858R, L861Q) (Figure 2.3).88  In exon 19, four amino acids are deleted. In exon 21, 
most commonly, a T to G mutation at nucleotide 2,573 leads to a substitution of arginine 
for leucine at position 585.92  EGFR resistance mutations can also occur (exon 20 
insertions and T790M).93   
The EGFR mutation was first discovered in 2004 and is present in 10-35% of 
patients; it more frequently occurs in females and never smokers.27,88,92,94,95  Incidence is 
higher in the Asian population; approximately 22-62% of East Asians with lung 
adenocarcinoma harbor EGFR mutations.27,96,97   
EGFR testing is important for both predictive and prognostic implications. 
Presence of activating EGFR mutation indicates potential response to an EGFR TKI, 
such as gefitinib or erlotinib.  Progostically, patients with EGFR mutations have better 
outcomes compared to patients whose tumors are EGFR wild-type. 
 Currently in the clinical setting, EGFR, ALK, and ROS-1 are the most frequently 
used biomarkers to direct therapy and resistance mutations have emerged (e.g. EGFR 
T790M).  A number of other mutations in lung adenocarcinomas exist, including BRAF, 
KRAS, HER2, PTEN, MEK1, AKT, FGFR, c-MET and PIK3CA,22,26,95,98 however these 
mutations are not clinically actionable and are still under clinical investigation.  Methods 
to molecularly profile tumors vary and include polymerase chain reaction (PCR), 
immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH), and 
chromatic in situ hybridization (CISH).  Next generation sequencing (NGS) allows for 




panel-based molecular profiling.  Whole genome NGS provides the most comprehensive 
assessment of the tumor.99 
FDA Approved Diagnostic Tests for EGFR Mutations 
 Several clinical assays are FDA approved for the detection of EGFR mutations, 
including the EGFR pharmDx, Therascreen EGFR RGQ PCR, and cobas EGFR Mutation 
Test.26  These tests are performed using tumor tissue resected from the patient via biopsy 
or surgical resection.  A blood-based EGFR test was also approved in 2016, cobas EGFR 
Mutation Test v2.100  NGS, a broad molecular profiling approach, also has the ability to 
detect EGFR abnormalities.   
Disparities in ordering molecular testing for lung cancer are likely to exist.  A 
recent abstract presented at the ASCO Annual Meeting in 2014 revealed that academic 
oncologists were more likely than community oncologists to order a NGS molecular test 
(59.4% vs 33.4%, p=0.01).101 Community oncologists are likely to be less knowledgeable 
and have less experience with NGS compared to their academic counterparts.101 
Historically, billing for these tests was complex.  There were no unique Current 
Procedural Codes (CPT) to test individual genes.  Thus, laboratory billing managers 
billed by method of analysis (e.g. lysis of cells, extraction of highly purified nucleic acid) 
used to perform for the test in a technique called “code stacking”.  Code stacking results 
in different total costs depending on how each laboratory performs molecular testing and 
stacks the CPT codes.  An example of three different KRAS testing code stacks is 





To address this problem, the American Medical Association organized a 
workgroup to construct a new section of the CPT Pathology and Laboratory manual.  The 
workgroup recommended a two-tiered, volume based coding format.  Tests (including 
non-oncology) that are performed most frequently are assigned a Tier 1 level.  Each tier 
has its own CPT code.  At the time of publication of an article authored by Klein, 120 
analytes and procedures were assigned to Tier 1 and 599 tests were placed into Tier 2 (9 
levels).  Each level had a CPT code used for that level.  Test level is assigned based on 
the resources required to carry out the test.  These new codes were published on January 
1, 2013.  The 2015 CPT edition now also includes sections for Multianalyte Assays with 
Algorithmic Analyses (MAAAs), Genomic Sequencing Procedures (GSPs), and Other 
Molecular Multianalyte Assays (for coding NGS).102  
Clinical Practice Guidelines for EGFR Testing in Lung Cancer 
 Clinicians often rely on clinical practice guidelines (CPG) to direct and justify 
therapy.  CPGs are systematically produced statements that guide practioners in decision-
making throughout the healthcare spectrum, from preventive medicine to disease 
treatment and follow-up.  Good CPGs present validity, reliability, reproducibility, clinical 
applicability, clinical flexibility, and clarity.103  They consist of a multidisciplinary 
review process and document evidence for a particular procedure or treatment, as well as 
suggest areas for future research.103,104  CPGs provide decision support tools that 
incorporate references and consider healthcare costs and coverage.103 
By 2011, the National Comprehensive Cancer Network recommended the use of 
molecular testing in patients with brain, breast, colon, lung, and prostate cancers and 




published a provisional clinical opinion (PCO) regarding the use of EGFR mutation 
testing for patients with advanced, NSCLC considering first-line treatment with an EGFR 
TKI, such as erlotinib or gefitinib.104  The 2011 ASCO PCO reports that patients with 
EGFR-mutated NSCLC treated with EGFR TKIs have significantly higher rates of 
response and progression-free survival, however, no overall survival benefit from the 
selection of patients for EGFR testing had been observed at that point.  They based their 
opinion on the results of five clinical trials of gefitinib and erlotinib.  At the time of 
publication and currently, the clinical opinion is that patients with non-squamous NSCLC 
who are being considered for first-line therapy with an EGFR TKI should have their 
tumor evaluated for EGFR mutations to guide therapy decisions.104 
Around the same time, a consensus meeting of Asian and Canadian medical 
oncologists, pulmonologists, and molecular pathologists also produced a standardized 
EGFR mutation testing protocol.91  They recommended that Asian patients with non-
squamous, NSCLC, particularly adenocarcinoma, be routinely tested for EGFR 
mutations.  Testing in patients with squamous histology may be considered, except for 
males and heavy smokers, but is not recommended.  Their report also included detailed 
laboratory considerations and methodologies and asks the pathology community to 
consider the emergence and growth of multiple biomarker tests, as done in the 
Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination 
Trial (BATTLE).91,106,107 
In 2013, a joint guideline was released by the College of American Pathologies 
(CAP), International Association for the Study of Lung Cancer (IASLC), and Association 




evidence-based recommendation for lung cancer molecular testing required to guide 
treatment with both EGFR and ALK-targeted therapies.  A total of 37 guideline 
recommendations were made.  Major recommendations included the emphasis on testing 
for EGFR mutations and ALK fusions in all patients with advanced, lung 
adenocarcinoma (including those with mixed subtypes), regardless of sex, race, smoking 
history, or other clinical risk factors.  EGFR testing was not recommended in squamous 
or large cell carcinomas.  The consensus group also prioritized EGFR and ALK testing 
over other molecular tests. The group recommended that EGFR testing be conducted at 
the time of diagnosis for patients who present with advanced stage disease and at time of 
recurrence or progression for those who initially presented with earlier stage disease and 
were not previously treated.  The guideline also included information on specimen 
sample quality, processing, testing validation, and result reporting.103  The European 
Society of Medical Oncology (ESMO) largely agrees with the previously described 
guidelines for EGFR-mutated NSCLCS in its metastatic NSCLC guideline.108  The 
ASCO officially endorsed the guideline issued by the CAP/IASLC/AMP team in 
2014.109,110   
Epidemiologic Studies Evaluating EGFR Testing in Lung Cancer Patients 
Few studies evaluating the utilization of molecular diagnostic testing, specifically 
EGFR testing, in a population-based setting currently exist.  In a retrospective, 
observational study published in 2013, several proprietary and publicly available datasets 
were merged to evaluate hospital use of the EGFR assay among lung cancer patients.85  
Multivariate logistic regression was performed to identify factors associated with a 




institutions.  Non-federal acute care hospitals ordered the largest proportion of EGFR 
tests (76%).  Geographically, California, Florida, Illinois, New York, and Pennsylvania 
hospitals ordered the highest number of tests.  Interestingly, North Dakota (a state with 
no National Cancer Institute (NCI) Cancer Center or hospital with cytogenetic testing 
accreditation) had the highest percentage of lung cancer cases tested (17.6%).  However, 
these hospitals had academic medical school affiliations, participated in NCI cooperative 
group studies, were located in urban areas, and had above average education and 
income.85   
 In the multivariate models, affiliation with an academic medical center (OR=1.48; 
95% CI:1.20-1.83), participation in NCI cooperative group studies (OR: 2.06; 95% CI: 
1.66-2.55), ability to perform PET scans (OR: 1.44; 95% CI: 1.07-1.94), located in a 
metropolitan county (OR: 2.08;  95% CI: 1.48-2.91) and above average education and 
income (OR: 1.46; 95% CI: 1.09-1.96 and OR: 1.46; 95% CI: 1.04-2.05, respectively) 
were significantly associated with ordering molecular tests.85  Annual number of lung 
cancer cases, inpatient chemotherapy, and race were not related to assay ordering. 
 Pan et al assessed EGFR biomarker testing using US Oncology data from the 
iKnowMed™ database, billing claims, and chart reviews.111  Of 26,381 patients with 
existing or newly diagnosed non-squamous NSCLC, 1,168 met the additional eligibility 
criteria, which included, but was not limited to, only those patients diagnosed with stage 
IIIB/IV disease and who initiated second-line therapy between January 1, 2007 and June 
30, 2011.  Few patients received testing for EGFR (11.0%) prior to date of initiation of 
second-line therapy.  When the analysis was restricted to only those whose index date 




significantly increased to 15.2% in 2010 (p<0.0001) and increased again to 32.0% in the 
first six months of 2011 (p<0.0001).  Half of patients with EGFR-mutated NSCLC were 
treated with erlotinib-containing regimens. 
 Another US study assessed the real-world patterns of EGFR testing in the 
population-based setting.112  Enewold and Thomas used Surveillance, Epidemiology, and 
End Results (SEER) database to identify a random sample of patients diagnosed with 
NSCLC and conducted a National Cancer Center Patterns of Care (POC) study.  Eligible 
patients included those diagnosed in 2010 with invasive, histologically confirmed, 
primary NSCLC.  Patients with a history of cancer, diagnosed with a second cancer 
(within 60 days), diagnosed at autopsy or death certificate, those with neuroendocrine 
carcinomas, those with unknown stage, and those younger than 20 years old were 
excluded. The medical records of sampled patients were reviewed and the physicians of 
sampled patients were queried using POC survey instruments.112 
 A total of 1,358 patients diagnosed with NSCLC were included in the analyses.  
The majority of patients were stage III (18.2%) or stage IV (55.3%).  Overall, 16.8% of 
patients with NSCLC had EGFR testing performed.  More adenocarcinomas were tested 
than other histologies (20.8%).  EGFR testing was also more frequently performed in 
patients with stage IV disease (19.9% for all histologies; 22.6% for adenocarcinoma), 
however, no statistically significant differences were found by stage.  Of all patients with 
an EGFR mutation, 33.6% received erlotinib, while 48.3% of stage IV patients with an 
EGFR mutation did.  Factors significantly associated with EGFR testing in stage IV 
patients included Hispanic and Asian Pacific Islander heritages (p<0.01), married status 




(p=0.04), adenocarcinoma or other non-specified carcinoma histology (p<0.01), having 
no comorbidities(p<0.01), and living at least two months post-cancer diagnosis (p<0.01). 
 In 2017, two epidemiologic studies of EGFR testing in NSCLC patients were 
published. One study, conducted by Shen et al, used data from Truven Health 
MarketScan (commercial health plans and Medicare supplemental plans) from patients 
diagnosed between January 2013 and June 2014,113 while the study by Lynch et al used 
Veterans data from patients diagnosed between 2011 and 2013.114  Both of these studies 
assessed EGFR testing only, not broad molecular testing. 
 In the study by Shen et al, 18% of included all NSCLC patients (overall cohort) 
had a claim for EGFR testing within 6 months of diagnosis. Increasing rates of EGFR 
testing were observed over time, 16%-21% over the study period. When limited to 
adenocarcinoma histology, this increased to 37%.  When limited to patients who received 
the drug erlotinib, the testing rate was 42%.  Mean time from diagnosis to EGFR testing 
was 40 days.  In the overall cohort, patients who were younger, female, residing in the 
western region of US, and had lower comorbidity scores were more likely to receive 
EGFR testing.113 This population-based assessment of EGFR testing indicates that EGFR 
testing rates in the US are still low, despite recommendations by oncology groups 
supporting its use. 
 Lynch et al also reported subpar rates of EGFR mutation testing in their 
population of Veterans.114  Approximately 34% of patients who were eligible for EGFR 
testing had testing performed.  The majority of patients tested had adenocarcinoma 
histology.  In 7% of the tested cases, EGFR sensitizing mutations were detected, which is 




develop in non-smokers, this finding is expected.  Veterans have a higher smoking rate 
compared to the general US population. 
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors 
Overview of FDA Approved Targeted Therapies for EGFR-mutated NSCLC 
EGFR mutations can be treated with both monoclonal antibodies (e.g., cetuximab) 
and tyrosine kinase inhibitors (TKIs).27  Three EGFR TKIs are FDA approved for use in 
EGFR-mutated NSCLC, gefitinib, erlotinib, and afatinib (Figure 2.4).  One EGFR TKI, 
osimertinib, is only approved for patients whose tumors were EGFR+ (exon 19 and 21 
L858R) and developed resistance. 
Gefitinib (IRESSA) was the first to receive FDA approval (accelerated) for lung 
cancer treatment in unselected populations in 2003,92 however, its approval was later 
withdrawn from the market due to failure to reach clinical efficacy endpoints in 
confirmatory trials.115  The drug’s manufacturer later designed and executed clinical trials 
of gefitinib in selected (EGFR-mutant) patient populations with greater success and 
gefitinib was approved for use in patients whose tumors harbor EGFR+ (exon 19 and 21 
L858R) mutations in the US in 2015.  The administration of gefitinib in patients is 
contingent upon use of a companion diagnostic to identify the required mutations 
(therascreen EGFR RGQ PCR Kit).116 
Afatinib was approved in the US in 2013.117  Afatinib (Gilotrif) is indicated for 
use as first-line therapy in patients whose tumors harbor EGFR (exon 19 and 21 L858R) 
mutations.  Afatinib was approved for use with the companion diagnostic test therascreen 




Erlotinib (Tarceva), some would say, has dominated the US EGFR TKI market in 
recent years, first gaining approval in 2004 for the treatment of unselected patients with 
locally advanced or metastatic NSCLC after failure of one prior chemotherapy 
regimen.118  Erlotinib also received approvals in 2010 and 2013, for maintenance therapy 
and for first line treatment in the selected, EGFR-positive (exon 19 and 21 L858R), 
respectively.  Patients must undergo EGFR testing with erlotinib’s companion diagnostic 
test, the cobas EGFR Mutation Test.119   
Randomized Phase 3 Clinical Trials Involving Erlotinib 
 Multiple preclinical and early phase (I and II) trials of erlotinib have been 
conducted globally.120-125  Randomized phase III trials evaluating response rate (RR), 
progression-free survival (PFS), and overall survival (OS) have also been conducted 
internationally, in various settings and patient populations (Table 2.2). In selected patient 
subgroups, RR and PFS have mostly been increased with erlotinib, however, trials 
assessing OS have reported mixed results. 
Second line and beyond 
 The first FDA approval for the use of erlotinib in the second-line setting and 
beyond was based on data from the BR.21 study published by Shepherd et al.11 The 
randomized, placebo-controlled, double blind trial evaluated erlotinib (150 mg) versus 
placebo following failure of first-line or second-line chemotherapy.  OS, PFS, overall 
response rate (ORR), duration of response, toxicity, and quality of life were assessed.  
Eligible patients included those who met the following criteria: Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) of 0-3, pathological evidence of 




hypernephroma, no symptomatic brain metastases, no clinically significant cardiac 
disease within past 12 months, no ventricular arrhythmias and no clinically significant 
ophthalmologic or gastro-intestinal abnormalities.  Patients were not required to have 
EGFR-mutated NSCLC.  A total of 731 patients were randomized to erlotinib (n=488) or 
placebo (n=243).11 
 Overall response rate (partial and complete responses) was better in the erlotinib 
arm (8.9%) compared to the placebo arm (<1%; p<0.001).  Response rate (RR) for 
patients with EGFR-positive tumors was 11.3% compared to 3.8% for patients with 
EGFR-negative tumors (p=0.10). Duration of response was also better for the erlotinib 
arm compared to placebo (7.9 vs 3.7 months (mos), p<0.001, respectively).  Additionally, 
PFS and OS was improved for the erlotinib arm compared to placebo.  Progression-free 
survival was 2.2 vs 1.8 months (Hazard ratio (HR): 0.61, p<0.001).  Overall survival was 
6.7 vs 4.7 months (HR: 0.70, p<0.001).11  After adjustment for treatment and other 
significant factors, adenocarcinoma subtype (HR: 0.8, 95%CI: 0.6-0.9, p=0.004), Asian 
origin (HR: 0.7, 95% CI: 0.5-0.9, p=0.01) and never-smoking status (HR: 0.8, 95% CI: 
0.6-1.0, p=0.048) were significant predictors of survival.  Toxicities (rash and diarrhea) 
and quality of life were acceptable with erlotinib therapy.11   
Subset analyses of patients from the BR.21 study assessed the role of EGFR 
protein, copy number and mutation status in response and survival outcomes126.  Female 
sex (p=0.007), Asian origin (p=0.02), never smoker status (p<0.001), adenocarcinoma 
subtype (p<0.001), and polysomy or amplification of EGFR (p=0.03) were associated 
with response.  Increased response to erlotinib for patients with EGFR- mutated tumors 




in response between the groups was not significant (16% vs 7%, p=0.37).  OS was not 
influenced by EGFR expression, copy number or mutation status.126 
 Another study that evaluated erlotinib in the second line setting was published by 
Garassino et al in 2013.127  The TArceva Italian Lung Optimization tRial (TAILOR) trial 
assessed the efficacy of erlotinib compared to the standard second-line chemotherapy, 
docetaxel, in patients with EGFR wild-type NSCLC tumors.  The primary endpoint was 
overall survival and secondary endpoints included PFS, RR, and QOL.  Patients included 
in the trial were those who failed previous chemotherapy (pemetrexed, vinorelbine, 
gemcitabine), were not previously treated with taxanes or anti-EGFR drugs, and had 
ECOG PS of 2 or less.127   
 A total of 222 patients were randomly assigned to received either erlotinib 
(n=122) or docetaxel (n=110).  Tumor response in the erlotinib group was not longer than 
the docetaxel group (3.0 vs 15.5 months (mos), p=0.003).  Median PFS was 2.4 months 
in the erlotinib group compared to 2.9 months in the docetaxel group HR:0.71, 95% CI: 
0.53-0.95, p=0.02).  Median OS was shorter in the erlotinib arm compared to the 
docetaxel arm (5.4 vs 8.2 mos, HR=0.73, 95% CI: 0.53-1.00, p=0.05).  The results of this 
study demonstrate that treatment with docetaxel is preferred to erlotinib in the second-
line, EGFR wild type setting.127 
The Tarceva in Treatment of Advanced NSCLC (TITAN) study was conducted 
concurrently with the SATURN maintenance therapy study.98  However, unlike 
SATURN (which included patients without disease progression), the TITAN study 
enrolled patients who rapidly progressed on standard chemotherapy (within four cycles).  




TITAN also included ECOG PS 2 patients.  The primary endpoint of this randomized, 
international trial was OS.  RR and OS were also assessed.  There were no statistically 
significant differences in RR, PFS, or OS. The results of the TITAN study were not 
impressive, however, the study suffered from multiple limitations (e.g., underpowered, 
unbalanced baseline factors progostically benefiting the chemotherapy arm).98 
A Greek randomized study by Karampeazis et al evaluated erlotinib compared to 
pemetrexed in the second line and beyond setting.9  The primary endpoint of this trial was 
time to progression (TTP), and RR, PFS, and OS were evaluated as secondary endpoints.  
Biomarker status was also assessed. Eligible patients included those who were diagnosed 
with stage IIIB/IV NSCLC with a ECOG PS of 0-2, were pemetrexed and TKI-naïve, and 
progressed after one or two lines of chemotherapy.  Those patients with second primary 
tumors, active infections, severe heart disease and uncontrolled diabetes were excluded.9   
A total of 179 patients were randomized to the erlotinib arm; 178 were randomized 
to receive pemetrexed.  RR was better for the pemetrexed arm compared to the erlotinib 
arm (11.4% vs 9%, p=0.469).  PFS and OS did not differ significantly between the 
pemetrexed and erlotinib groups (2.9 vs 3.6 mos, p=0.136 and 10.1 vs 8.2 mos, p=0.986, 
respectively).  There were no differences in RR or OS by EGFR mutation status.9 
First line combination therapy 
A phase III trial of erlotinib evaluated the drug in combination with standard 
chemotherapy (carboplatin and paclitaxel) in the first-line setting.128  The primary 
objective of the TRIBUTE trial was OS.  Other objectives included time to progression 
(TTP), ORR, and safety.  PFS was not assessed.  Eligible patients include those with 




prior systemic chemotherapy, symptomatic or untreated brain metastases, unstable 
disease that would preclude use of chemotherapy, and inadequate laboratory values were 
excluded.  EGFR protein expression was not an eligibility requirement.  Patients were 
randomly assigned to receive daily erlotinib plus chemotherapy concurrently (n=539) or 
placebo plus chemotherapy concurrently (n=540). 
There was no significant difference in objective RR, TTP, or OS in the TRIBUTE 
trial.  Objective RR for the erlotinib plus chemotherapy arm was slightly higher 
compared to the placebo plus chemotherapy arm (21.5% vs 19.3%, p=0.36).  Median OS 
was similar between the arms (HR:0.995, 95% CI: 0.86-1.16, p=0.95).  In a subgroup 
analysis, the only group to demonstrate a survival advantage with the addition of erlotinib 
to standard chemotherapy was in never smokers.  Never smokers who received erlotinib 
plus chemotherapy survived longer compared to those who received placebo plus 
chemotherapy (22.5 vs 10.1 mos, HR=0.49, 95% CI:0.28-0.85).  Never smokers who 
received erlotinib also had an increased TTP compared to the placebo group (6.0 vs 4.3 
mos, HR=0.50, 95% CI: 0.31-0.80). Rash, diarrhea, and nausea were higher in the 
erlotinib arm.128 
Erlotinib was also evaluated in combination with chemotherapy (cisplatin and 
gemcitabine) in the first line setting in the Tarceva Lung Cancer Investigation Trial 
(TALENT).129  TALENT was an international study designed to evaluate OS, TTP, RR, 
duration of response, and QOL.  Eligible patients included those with histologically 
confirmed, unresectable, locally advanced, recurrent, or metastatic NSCLC (stage 
IIIB/IV) with EGOG PS of 0-1, and adequate laboratory values.  Patient with previous 




excluded.  Patients with unstable systemic disease, other prior malignancies (within 5 
years), and significant ophthalmologic abnormalities were also excluded.129 
Of the eligible patients, 1,159 were randomly assigned and started study therapy.  
Patients received either erlotinib plus chemotherapy (cisplatin and gemcitabine) or 
placebo plus chemotherapy for six cycles.  RR was similar between the two arms; 31.5% 
of patients responded to treatment with erlotinib plus chemotherapy and 29.9% responded 
to treatment with placebo plus chemotherapy.  There was no difference in OS survival 
between the arms (43 vs 44.1 weeks (wks); HR=1.06,95% CI: 0.90-1.23, p=0.49).  EGFR 
expression (by IHC) was not correlated with response or survival outcomes.129 
First line monotherapy 
Following positive RR, PFS, and OS results with erlotinib in the second-line and 
beyond setting,11 several studies evaluated the drug as monotherapy in the first-line 
setting.7,12,130  The first trial to evaluate erlotinib in the first-line monotherapy setting was 
conducted by Zhou et al in China.7  The purpose of the OPTIMAL trial was to evaluate 
the efficacy (RR, PFS) and tolerability of erlotinib versus standard chemotherapy 
(carboplatin/gemcitabine).  The open-label, randomized trial included patients with 
histologically confirmed stage advanced or recurrent IIIB/IV NSCLC with activating 
EGFR exon 19 deletion or exon 21 L858R point mutation.  Other eligibility criteria 
included presence of measurable disease, EGOG PS of 0-2, and adequate laboratory 
values.  Patients with uncontrolled brain metastases and those who had received previous 
systemic therapy for advanced cancer were excluded.7  
A total of 165 patients were randomized (83 to erlotinib arm; 82 to standard 




response compared to 36% for the standard chemotherapy arm (p<0.0001).  Median PFS 
was significantly better for patients treated with erlotinib compared to patients treated 
with standard chemotherapy (13.1 vs 4.6 mos, HR=0.16, 95% CI: 0.10-0.26, p<0.0001).  
OS data were not mature at time of publication.  Erlotinib administration was associated 
with a higher incidence of skin rash and diarrhea, but were low in severity (73% vs 19%, 
p<0.0001 and 25% vs 6%, p=0.00085, respectively).7 
Also in the first line, monotherapy setting, the EURTAC trial, conducted in 
France, Italy, and Spain by Rosell et al, evaluated the safety and efficacy of erlotinib 
compared to standard platinum-based chemotherapy (cisplatin/docetaxel or 
cisplatin/gemcitabine; carboplatin was allowed for patients unable to tolerate cisplatin).12  
Inclusion criteria included histologic confirmation of stage IIIB/IV NSCLC, 
measurable/evaluable disease, and no history of chemotherapy for metastatic disease.  
Only patients with activating EGFR mutations (either exon 19 deletion or exon 21 L858R 
mutation) were enrolled.  Additionally, patients with asymptomatic, stable brain 
metastases were allowed.  Patients were randomized in a 1:1 fashion to receive either 
erlotinib (n=86) or standard chemotherapy (n=87).  Trial endpoints included RR, PFS, 
OS and safety.  64% of patients treated with erlotinib achieved a response compared to 
only 18% in the standard chemotherapy group.  Median PFS was significantly longer in 
the erlotinib arm compared to the standard chemotherapy arm (9.4 vs 5.2 mos, HR=0.42, 
95% CI: 0.27-0.64, P<0.0001).  OS did not differ significantly between the two arms 
(19.3 mos for erlotinib vs 19.5 mos for standard chemotherapy, HR=1.04, 95% CI: 0.65-




Following the positive interim analysis, the trial was halted and full data analysis 
was conducted.  A slight increase in PFS was observed in the erlotinib arm compared to 
the standard chemotherapy arm (9.7 vs 5.2 mos, HR=0.37, 95%CI: 0.25-0.54, p<0.0001).  
FDA approval for use of erlotinib monotherapy in the first line setting was based on the 
results of the EURTAC trial. Updated RR, PFS and OS data are included in the erlotinib 
package insert.  RR continued to be better for the erlotinib group compared to the 
standard chemotherapy group.  PFS remained better for the erlotinib group compared to 
the standard chemotherapy group (10.4 vs 5.2 mos, HR=0.34, 95% CI: 0.23-0.49, 
p<0.001), however, there also remained no significant difference in OS (22.9 vs 19.5 
mos, HR=0.93, 95% CI: 0.64-0.35).131 
Lee et al evaluated erlotinib as first line monotherapy therapy in the TOPICAL 
trial.130  Conducted in the UK, this randomized, placebo-controlled trial evaluated 
efficacy (RR, PFS, OS), toxicities and quality of life.  Patients included in the trial were 
those with stage IIIB/IV newly diagnosed, pathologically confirmed NSCLC who were 
chemotherapy naïve, and deemed unsuitable for chemotherapy due to performance status 
≥2.   Patients were not required to have EGFR mutations.  The treatment arms were 
slightly imbalanced with 350 patients treated with erlotinib and 320 patients receiving 
placebo.130 
Response rate was better in the erlotinib group compared to the placebo group 
(4% vs 2%).  A small, but significant improvement is PFS was observed with first line 
erlotinib monotherapy compared to placebo (2.8 vs 2.6 mos, HR=0.80, 95% CI: 0.68-
0.93, p=0.0054).  No difference in OS was observed (3.7 vs 3.6 mos, HR=0.92, 95% CI: 




Interestingly, a subgroup analyses of first-cycle rash revealed improved PFS and OS for 
those in the erlotinib arm who had rash compared to those who did not have rash 
(HR=0.24, 95% CI: 0.16-0.35, p<0.0001).130 
Maintenance therapy  
Erlotinib has also been evaluated as maintenance therapy.  The Sequential 
Tarceva in Unresectable NSCLC (SATURN) trial evaluated the administration of 
erlotinib as switch maintenance therapy in an international study.132  The objectives of 
this study were to evaluate PFS in patients with both wild-type and EGFR-mutated 
tumors.  Patients with histologically confirmed, measurable unresectable or metastatic 
NSCLC with EGOG PS of 0-1 were included. Other eligibility criteria included lack of 
previous exposure to anti-EGFR agents, uncontrolled, symptomatic brain metastases, or 
other malignancies within past 5 years.  Finally, patients were only eligible if they had 
participated in the run-in phase of the study and had not progressed following first-line 
platinum based doublet chemotherapy (investigators choice of seven regimens).132 
Tumor response rate was better with erlotinib compared to placebo (11.9% vs 
5.4%, p=0.0006).  Median PFS was longer in the erlotinib group compared to placebo 
(12.3 vs 11.1 weeks, HR=0.71,95% CI: 0.62-0.82, p<0.0001) in the overall population 
and was also prolonged in the EGFR-mutant population (12.3 vs 11.1, HR=0.69, 0.58-
0.82, p<0.0001).  OS was significantly longer in the erlotinib arm compared to the 
placebo arm in the overall population (12.0 vs 11.0 mos, HR=0.81, 95% CI:0.70-0.95, 
p=0.0088).132  FDA approval for erlotinib in the maintenance setting was based on the 




Another trial evaluated the sequential administration of chemotherapy plus 
erlotinib vs chemotherapy plus placebo (switch maintenance) among 451 unselected 
patients.  Wu et al published the results of the FASTACT2 trial, conducted in China, in 
2013.133. The primary endpoint was PFS and other endpoints included RR and OS.  
Eligible patients were those diagnosed with stage IIIB/IV NSCLC, had a ECOG PS of 0-
1 and had measurable disease. Excluded patients included those with brain metastases, 
spinal cord compression, or HIV, those previously treated with agents targeting the HER 
axis, and those with recent surgery or radiation therapy.133 
Patients were randomized in a 1:1 fashion to receive cisplatin or carboplatin plus 
gemcitabine followed by erlotinib or placebo (n=226 and n=225, respectively).  In the 
overall population, RR was better in the erlotinib group compared to the placebo group 
(44% vs 16%, p<0.0001).  Median PFS was longer in the erlotinib group compared to the 
placebo group, as was OS (7.6 vs 6.0 mos, HR=0.57, 95% CI: 0.47-0.69, p<0.0001 and 
18.3 vs 15.2 mos, HR=0.79, 95%CI: 0.64-0.99, p=0.04200).  
In the EGFR-positive population, increases in both response and survival 
endpoints were observed.  In this population, 84% of patients in the erlotinib group 
achieved response compared to only 15% in the placebo group (p<0.0001).  Median PFS 
and OS were also significantly improved for erlotinib group compared to placebo group 
(16.8 vs 6.9, HR=0.25, 95% CI: 0.16-0.39, p<0.0001 and 31.4 vs 20.6 mos, HR=0.48, 
95% CI:  p=0.0092).133 
Epidemiologic Studies of Erlotinib 
 Several epidemiologic studies, described previously, that assessed EGFR testing 




EGFR testing was significantly associated with erlotinib use.  Approximately 5% of 
patients received erlotinib treatment.113  
Enewold and Thomas reported that 6.3% of all NSCLC patients received erlotinib 
in their study.  Of patients with an EGFR mutation, 33.6% of all patients and 48.3% of 
stage IV patients received erlotinib.  Erlotinib was less likely to be prescribed to in 
smokers (OR=0.27, 95% CI: 0.12-0.59) and patients with non-adenocarcinoma 
histologies (OR=0.14, 95% CI: 0.04-0.54). Erlotinib was not associated with increased 
survival.112   
Approximately half (56%, n=36) of patients whose tumors were EGFR-positive 
received erlotinib in a study of Veterans.114  Erlotinib was also prescribed to patients that 
were EGFR-negative (10%), had non-sensitizing EGFR mutations (11%), or whose 
EGFR status was unknown (17%).  Erlotinib utilization was in agreement with the EGFR 
test results in 87% of the cohort cases.  Patients who had an EGFR mutation and were 
treated with erlotinib had the best survival outcome (median=921 days, range=56-3730 








Tables and Figures 
Table 2.1. Selected FDA Approved Systemic, Targeted and Immune Therapies for Non-Small Cell Lung Cancer  
 
Patient Population First Line Second Line and beyond 
   
No EGFR mutation Carboplatin/pemextrexed/pembrolizumab Nivolumab 
 Pembrolizumab* Docetaxel 
 Carboplatin/pemextrexed/bevacizumab Ramucirumab/docetaxel 
 Carboplatin/paclitaxel/bevacizumab Pembrolizumab** 
 Carboplatin/pemextrexed Atezolizumab 
 Carboplatin/paclitaxel Pemetrexed 
 Carboplatin/gemcitabine Gemcitabine 
 Carboplatin/docetaxel  
   
EGFR mutation Afatinib Nivolumab 
 Erlotinib Pembrolizumab** 
 Gefinitib Ramucirumab/docetaxel 
 Osimertinib Docetaxel 
  Osimertinib 
  Atezolizumab 
  Pemetrexed 
  Gemcitabine 
   
Abbreviations:  FDA, Food and Drug Administration 
*For use in patients with high (≥50%) PD-L1. 











Table 2.2. Randomized, phase 3 clinical studies of erlotinib 
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731 8.9 vs <1.0* 2.2 vs 1.8* 6.7 vs 4.7* 
Bold text indicates a study in which FDA approval was based. 
*Indicates statistical significance of p<0.05. 
Abbreviations:  IHC, immunohistochemistry; INT, international; NA, not assessed; NI, not interpretable; NR, not reported; OS, 
overall survival; PFS, progression free survival; PS, performance status; RR, response rate; SEQ, sequencing (DNA); UNS, 
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OBJECTIVES AND METHODS 
Study 1: Family Physician Perceptions and Experiences with Low-Dose Computed 
Tomography Screening for Lung Cancer 
Objectives 
 The main objective of this study was to quantitatively and qualitatively evaluate 
current family physician perceptions and experiences towards lung cancer screening with 
LDCT.  Specifically, we assessed FPs’ knowledge of the evidence supporting lung cancer 
screening and patient eligibility criteria.  Additionally, we explored attitudes and 
experiences related to patient selection, shared decision-making visits, LDCT referrals, 
and LDCT follow-up practices. 
Methodology 
This sequential explanatory mixed-methods134 research approach consisted of 
quantitative electronic questionnaire data followed by the collection of qualitative guided 
audio interview data.  First, a quantitative questionnaire was administered to two primary 
care physician cohorts using Qualtrics software (Appendix A).  In January 2015, 
members of the South Carolina chapter of the American Academy of Family Physicians 
(SCAFP) were sent an email containing a link to the survey (n=1,330).  A follow-up 
email reminder was sent on January 22, 2015. The questionnaire consisted of a total of 32 
questions (22 multiple-choice, 7 fill in the blank, 3 Likert scale) and took approximately 
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20 minutes to complete.  A total of 85 SCAFP physicians started the electronic survey, 
with 65 completing the survey. To increase sample size, additional paper questionnaires 
were distributed to physicians attending the SCAFP Summer Breakaway and Annual 
Assembly (June 7-12, 2015).  Paper questionnaires were placed in registration bags 
(n=135) and physicians were directed to submit the completed questionnaires at the 
University of South Carolina exhibitor booth.  A total of 16 physicians completed the 
paper questionnaire (total sample size = 101).  The last question in the questionnaire 
asked physicians if they agreed to be contacted for future research.  A total of 19 
physicians provided contact information.  Additionally, primary care physician 
employees of the Carolinas HealthCare System (CHS) were surveyed.  These physicians, 
located in North and South Carolina, were emailed a link to the survey in May 2015, 
several months after the CMS coverage announcement decision was made.  A total of 57 
physicians responded to the email survey.  Results of this quantitative assessment were 
published in 2016.16,17  Importantly, the results of the survey were used to develop the 
qualitative interview guide. 
Qualitative data was obtained through convenience sampling to better and more 
deeply understand both urban and rural family physician perceptions towards and 
practices surrounding lung cancer screening.  Participants in the qualitative phase of this 
study included a subset of those who participated in the quantitative survey.  
Additionally, we mailed personalized invitations to a sample of family physicians from 
North and South Carolina identified from the American Medical Association (AMA) 
Physician Masterfile.  FPs were asked to return the invitation, using a provided RSVP 
card, to indicate their interest in participating.  FPs were also recruited by referral from a 
 
65 
non-profit cancer advocacy group in North Carolina.  The interviewer followed a semi-
structured interview guide (Appendix A).  Questions were developed based on responses 
to the survey, as well as Cabana’s framework.135 
Data Collection 
The interviews took place until thematic saturation was reached and took 
approximately 30-40 minutes to complete.  Due to the geographic spread of physicians in 
the SCAFP and CHS cohorts, the interviews were conducted via Skype and were limited 
to audio recordings only.  No video recordings were made.  Interviews were audio 
recorded using Call Recorder for Skype, transcribed verbatim, and reviewed for accuracy 
to ensure data quality.   
Analysis Plan 
Following quality review, the interview transcripts were assessed to develop a 
theme dictionary. Transcripts were then uploaded to NVivo qualitative data analysis 
software (QSR International Pty Ltd. Version 10, 2012) for thematic coding.  Using a 
constant comparison technique, transcribed interviews were reviewed throughout data 
collection and the interview guide was adapted along the way to further explore relevant 
concepts identified during the initial interviews. The interview transcripts were then 
critically assessed to identify themes and subthemes by two separate persons.  Any 




Study 2: Molecular Testing Utilization and Targeted Therapy (Erlotinib) 
Administration and Survival Among Patients with Late Stage Non-Small Cell Lung 
Cancer  
Objectives 
The main objective of this study was to identify factors associated with receipt of 
molecular testing and erlotinib in patients diagnosed with late stage NSCLC residing in 
South Carolina.  Additionally, we evaluated overall survival among molecular testing 
(yes/no) and erlotinib (yes/no) groups. 
Methodology 
This study involved the use of state-level data obtained from the South Carolina 
Central Cancer Registry (SCCCR) and the SC Revenue and Fiscal Affairs Office (RFA).  
The SCCCR is a population-based system that collects data on newly diagnosed cancer 
cases in South Carolina.  Data in the SCCCR includes information on demographics, 
diagnosis date, cancer location and histology, treatment, and overall survival.  The 
majority of information on cancer cases in the SCCCR is reported electronically from 
hospitals with existing cancer registries.  However, some information is collected by 
SCCCR staff (i.e., independent pathology labs, free-standing treatment centers and 
physician offices, and non-registry hospitals).  The quality of data from the SCCCR is 
good and undergoes quality control audits.  The SCCCR has received Gold or Silver 
certification from the North American Association of Central Cancer Registries every 
year since 1997.   
The SC Revenue and Fiscal Affairs Office (RFA) is an independent agency that 
houses administrative claims data from both the SC State Employee Health Plan 
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(SCSEHP) and SC Medicaid plan members. The RFA developed a series of algorithms 
using various combinations of personal identifiers to create its own unique identifier, 
enabling statistical staff to “link across” multiple providers and settings.  Hence, it allows 
for linkages while protecting confidentiality of the client. The SC RFA and SC Central 
Cancer Registry frequently work together to complete data linkage requests for 
researchers in SC. 
A cohort of patients from the SCCCR with a diagnosis of stage IIIB/IV non-small 
cell lung cancer from January 1, 2002 through December 31, 2012 was assembled.  The 
cohort was linked to the same patients in the SCSEHP and Medicaid datasets. The 
resulting combined dataset was used to conduct all analyses.   
In this project, we evaluated utilization of molecular testing and the EGFR TKI, 
erlotinib, using CPT codes and National Drug Codes (NDC), respectively, to identify 
patients who received molecular testing or erlotinib after diagnosis of lung cancer. CPT 
and NDC codes to be used in this analysis are listed in Appendix C.  Additionally, we 
identified factors associated with molecular testing and erlotinib use.  Lastly, we 
evaluated the impact of molecular testing and erlotinib on survival. 
Analysis Plan 
Descriptive statistics for patient and provider characteristics were summarized for 
the overall cohort and by 1) molecular testing status and 2) erlotinib status. Comparisons 
between molecular testing and erlotinib groups were performed using chi-square tests for 
categorical variables and a two-sample t-test for age. Univariable and multivariable 
logistic regression were used to identify factors that significantly predicted molecular 
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testing or erlotinib utilization.  Odds ratios (OR) and corresponding 95% confidence 
intervals (CI) will be estimated.  Covariates included in the final multivariable model will 
be determined using backwards elimination procedures. 
Kaplan–Meier techniques will be used to estimate survival distributions and log-
rank tests compared the survival distributions for the 1) molecular testing and 2) erlotinib 
groups.  Univariable Cox proportional hazards regression was used to identify individual 
prognostic factors predictive of overall survival and multivariable Cox proportional 
hazards regression was used to evaluate the independent impact of the covariates and 
molecular testing status on overall survival.  Unadjusted and adjusted hazard ratios (HR) 
and corresponding 95% CIs were estimated.  Cox proportional hazards models were also 
estimated using propensity scores as covariates in parsimonious and non-parsimonious 
models.  
All statistical analyses were performed using Statistical Analysis Systems 
software, version 9.2 (SAS Inc., Cary, NC). All hypothesis testing was 2-sided with a 
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Objectives: The United States Preventive Services Task Force recommends lung cancer 
screening (LCS) in high risk patients using low-dose computed tomography (LDCT).  In 
2015, the Centers for Medicare and Medicaid Services announced coverage of LCS 
shared decision-making counseling visits and LDCT.  Despite this, LDCT utilization 
remains extremely low.  This study assessed family physician (FP) knowledge of the 
evidence supporting LCS and patient eligibility criteria, as well as explore attitudes and 
experiences related to patient selection, shared decision-making visits, LDCT referrals, 
and LDCT follow-up. 
Methods: We conducted a qualitative interview study using thematic content analysis.  A 
convenience sample of 15 FPs in the Carolinas completed semi-structured Skype audio 
interviews.  No information about LCS was provided prior to the interview.  Interviews 
were transcribed verbatim and analyzed using NVivo software. 
Results:  Most FPs reported making a LDCT referral, however, the majority of FPs 
reported suboptimal awareness of the scientific evidence for LCS, patient eligibility 
criteria, and documentation and billing procedures.  Smoking history was the primary 
driver of a FP’s decision to discuss LCS.  FPs were less likely to discuss LCS in patients 
with short life expectancies, comorbid conditions, or without insurance.  While FPs knew 
they should limit discussions about LCS to high risk patients, they expressed willingness 
to screen outside of established criteria in certain circumstances.  FPs preferred to 
conduct LCS discussions during annual visits, but acknowledged that many eligible 




cost and administrative complexities, including lack of support resources and difficulties 
with documentation and billing.  
Conclusions:  FPs have varying degrees of knowledge about and experiences with LDCT.  
FPs are open to using LDCT as a LCS tool, with additional education and support. 
Introduction  
Despite advances in lung cancer treatment, lung cancer remains a major cause of 
cancer-related death in the United States, due in part to the fact that the majority of 
patients are diagnosed with advanced disease.  Early lung cancer screening approaches 
(e.g., sputum cytology, chest x-ray) were largely unsuccessful and no improvement in 
lung cancer mortality was reported.  In 2011, the National Lung Screening Trial (NLST) 
concluded that annual screening for lung cancer using low-dose computed tomography 
(LDCT) resulted in a 20% reduction in lung cancer mortality and a 6.7% reduction in 
overall mortality compared to chest x-ray.18  Subsequently, the United States Preventive 
Services Task Force (USPSTF) published an updated guideline recommending annual 
LDCT screening in high risk patients at the Grade B evidence level in December 2013.19 
As a result, high risk patients with private insurance were allowed the option to have 
LDCT screening at no cost under the Affordable Care Act.  High risk was defined as a 
patient aged 55 to 80 years who had at least a 30 pack-year smoking history, who 
currently smokes or has quit smoking within the past 15 years. Shortly thereafter, in 
February 2015, the Centers for Medicare and Medicaid Services (CMS) released a 
decision memo announcing coverage of LDCT screening for high risk adults.  CMS 
defines high risk individuals similarly to USPSTF criteria; however, the age range was 




asymptomatic.  CMS requires documentation of smoking history and a counseling visit 
with the use of decision aids to review the risks and benefits of lung cancer screening 
(i.e., a shared decision-making visit; SDM).  The SDM counseling visit should include 
discussions of the importance of annual screening, patient comorbidities, and patient 
willingness to undergo further evaluation and treatment if a suspicious lung nodule is 
identified, as well as undertake smoking cessation.13  Thus, specific patient eligibility 
criteria must be met and documented for Medicare reimbursement.  Professional 
organizations, in general, describe the implementation of SDM visit, smoking cessation 
counseling, and promote standardized follow-up for abnormal LDCT results as 
components of successful lung cancer screening programs.13,19,136 
While LDCT screening in now approved in high risk patients, current research 
indicates that uptake of lung cancer screening guideline adoption has been slow in the 
primary care setting. A recent study by Jemal et al reported low rates (<4%) of self-
reported LDCT utilization from 2010-2015.84  Several quantitative studies have assessed 
family physician’s knowledge and attitudes following USPSTF recommendations and 
CMS coverage announcements.16,80-82  However, only one qualitative study, to our 
knowledge, has assessed family physician (FP) knowledge, attitudes, and practices since 
the CMS decision memo announcement that FPs could obtain Medicare reimbursement 
for LCS counseling visits.14  To enhance the existing literature, we conducted a 
qualitative study to assess North and South Carolina FPs’ knowledge of the evidence 
supporting LCS and patient eligibility criteria.  Additionally, we explored attitudes and 






A qualitative interview study was conducted using thematic content analysis.  We 
selected this approach because of the highly structured nature of the research questions 
we had, which were broad.  We wanted to capture a holistic understanding of LCS in the 
Carolinas, from physicians’ knowledge-base of lung cancer screening to following up 
with patients after LDCT screening was performed. 
A convenience sample of physicians were asked to participate in a 30-45-minute 
telephone interview between March 2016 and August 2017.  Physicians were recruited 
via multiple methods including postal mail, email, and telephone. First, physicians that 
provided contact information upon completion of a questionnaire on LCS that we 
administered in 201516,17 were contacted via email and/or phone and invited to participate 
in this follow-up study. Additionally, we mailed personalized invitations to a sample of 
FPs from North and South Carolina identified from the American Medical Association 
(AMA) Physician Masterfile.  FPs were asked to return the invitation, using a provided 
RSVP card, to indicate their interest in participating.  FPs were also recruited by referral 
from a non-profit cancer advocacy group in North Carolina.  The sample size goal was 12 
interviews, based on the recommendation of Guest, Bruce, and Johnson,137 however, we 
continued recruitment until we felt that thematic saturation was achieved. All physicians 
gave verbal consent to participate as part of the audio recorded interview.  The University 
of South Carolina Institutional Review Board approved the study.  
Data Collection 
One interviewer (JLE) conducted all the FP interviews using a semi-structured 




guidelines for lung cancer screening, who to approach for lung cancer screening 
discussions, how the conversation about lung cancer screening was performed, making a 
referral for screening, and following up after a LDCT.  The interview guide was 
developed in an iterative fashion, with input from epidemiologists, medical oncologists, 
and nurses.  Prior to finalization, the guide was tested with a FP and lung cancer 
screening thought leader.  We did not provide any structured education to FPs prior to the 
interviews.  Additionally, we emailed participating FPs educational materials published 
by the Agency for Healthcare Research and Quality (ARHQ) upon completion of the 
interview. 
Interviews were executed via Skype with the Call Recorder for Skype [Ecamm, 
North Andover, MA].138  All interviews were recorded in their entirety and transcribed 
verbatim by individuals trained in dictation.  Transcribed interviews were then reviewed 
for quality by the interviewer (JLE) and revisions to the transcribed interviews were 
made if required.  Quality-checked interviews were then imported into NVivo® 
Qualitative Data Analysis Software version 11.4.139  While interviews were reviewed for 
quality, an initial codebook was drafted (JLE) using a directed approach to content 
analysis.140,141  The codebook was continuously reviewed and revised using the constant 
comparison technique142 with input from two reviewers (JLE, GT).  
Data Analysis and Interpretation 
Reviewers independently coded each interview using NVivo® and codes 
documented by each reviewer were compared.  A Cohen’s Kappa coefficient was 
calculated for each node for each interview.  An overall interview Kappa was calculated 




measure inter-rater reliability while accounting for the amount of agreement that could 
result by chance.143  Interviews with overall Kappa coefficients approximately ≤ 0.75 (or 
excellent agreement)144 were further compared and discussed among the reviewers until 
consensus was reached.  We then queried the NVivo® database to build a report for each 
individual code and reviewed all the content within that code.  Codes were refined and 
combined to identify key themes.  A key theme was defined as a theme that occurred in 
the majority of FP interviews.  The coding reports were then reviewed a final time and 
representative quotes were selected.   
Results 
Interviews ranged from 27-52 minutes.  Overall interview kappa statistics ranged 
from 0.75-0.88.  A total of 15 physicians completed the interview (NC=7, SC=8).   
Physician and practice characteristics 
Table 4.1 reports physician characteristics.  About half were male.  Almost all 
were non-Hispanic White and were at least 40 years old. Most were in a group practice.  
FPs practicing in 12 different counties in North or South Carolina participated.   
About half of the FPs worked in clinics with at least 5 other employees and most 
worked full-time.  There was a mixture of rural and urban clinics, as well as a mixture of 
hospital-based, academic, and community-based single or group practices.  All but two 
FPs reported accepting Medicare/Medicaid patients and most saw a high proportion of 
these patients.  The two FPs that did not accept Medicare/Medicaid worked at free clinics 
and submitted no claims for billing.  A few FPs described having LCS programs in place 




All FPs saw middle age and senior patients and the majority described seeing 
patients with a “grab bag” of chronic diseases (e.g., heart disease, chronic obstructive 
pulmonary disease, diabetes, hypertension, arthritis, pain).  FPs mentioned that in patients 
with comorbidities, the focus was compliance with therapies for their chronic disease and 
less importance was placed on preventive services and screening.  Additionally, a few 
FPs described other cancer screenings as taking priority.  All FPs described having 
patients with either active or remissive lung cancer and the majority reported seeing 
many smokers or heavy smokers.   
Evidence and guideline knowledge 
Table 4.2 includes a list of key themes and supporting quotes from participating 
FPs. The majority of FPs interviewed had suboptimal awareness of the scientific evidence 
for LDCT screening.  Most physicians were aware of some of the evidence in support of 
LDCT screening (including the NLST and/or the PLCO studies), but few could recite 
specific details.  A few were completely unaware of the scientific evidence supporting 
LDCT screening in high risk patients.  Most physicians were able list at least some the 
organizations that supported LDCT screening, but a couple noted that these organizations 
have made “mistakes” or have changed their recommendations in the past.  A few FPs 
reported inaccuracies about gender, stating that reductions in mortality observed from 
LCS in the scientific literature were not applicable in women.   
Most FPs also had suboptimal awareness of patient eligibility criteria for LDCT 
screening.  The majority of physicians incorrectly recited at least one of the main criteria 
(e.g., age, smoking pack-years, or current/quit smoking status).  Only a few physicians 




of care.  A few FPs reported screening patients with symptoms (e.g., cough, weight loss), 
even though current recommendations pertain to asymptomatic patients.  
Deciding on which patients to discuss lung cancer screening  
A patient’s smoking history (e.g., length of time, volume smoked) was cited as the 
primary driver of a FP’s decision to counsel patients on LDCT screening.  Patient age 
also was frequently reported as a driver of whether counseling should be initiated.  A few 
FPs discussed various other patient exposures (e.g., cotton dust, secondhand smoke, coal 
dust, asbestos, silicon dust) that would motivate them to initiate counseling, and a few 
described targeting individuals with known lung disease as candidates for screening, even 
though these patient groups are not listed in the current criteria defining high risk 
patients.  A few FPs incorrectly reported that gender should also be considered and that 
screening “doesn't apply to women”.   
The majority of FPs felt that screening should be limited to those who fit the 
criteria for high risk, although there was sometimes uncertainty about the specific criteria. 
Some FPs reported not approaching patients with short life expectancies or comorbid 
conditions, in alignment with current recommendations.  Some FPs also reported 
choosing not to engage in counseling about LDCT screening with uninsured patients due 
to concerns over the patient’s ability to pay for the LDCT and follow-up diagnostics.  
Some FPs also described that it “wasn’t fair” to discuss screening with a patient that 
would likely not be able to afford screening.  Other FPs felt that counseling about LDCT 
should be done with all high risk patients, regardless of insurance status and that 
“judgements” about a patient’s ability to pay for screening should not dictate the decision 




Most FPs indicated that they know that they should initiate discussion in high risk 
patients only, but are willing to engage in counseling and make LDCT screening referrals 
for patients who do not fit the criteria for high risk if the patient requested screening or if 
“anything strikes them…that they should undergo screening”, indicating that they felt 
other factors would influence their decision to initiate a screening discussion.  Henderson 
et al reported that physicians were more likely to order screening when a patient 
requested it.73   Importantly, when discussing lung cancer screening in lower-risk 
patients, FPs frequently described explaining to their patients that they may have out-of-
pocket radiology costs and that “they [the patient] will have to see if their insurance 
would cover it”.  However, FPs reported that they felt most patients were not interested 
or “do not want to know [if they have lung cancer]” and rarely initiated screening 
discussions themselves. Of the few patients who do ask, FPs described patients to be 
former or current smokers, more education or health conscious or to have a family 
member recently diagnosed with cancer.  A few providers stated that their patients asked 
for chest x-ray, not LDCT.  Only a few FPs described dissuading lower risk patients from 
having screening and steering the conversation more towards smoking cessation. 
Lung cancer screening discussion and low-dose CT referral 
Most FPs felt that the screening discussion and referral is their responsibility 
because FPs knew the patient's values and social issues (e.g., transportation needs).  
When asked if pulmonologists could or should discuss lung cancer screening with 
patients, FPs felt that pulmonologists were certainly qualified to have these discussions.  
However, concern that not all patients would have access to a pulmonologist deters FPs 




pulmonology clinics. Additionally, one FP expressed concern that pulmonologists and/or 
radiologists may not truly be able to give an unbiased explanation of the pros and cons of 
lung cancer screening because they stand to profit from low-dose CTs.  While most 
physicians felt comfortable conducting shared decision-making (SDM) counseling visits 
with their patients, some FPs reported the need for additional education on the risks and 
benefits of lung cancer screening to truly implement SDM properly. One FP stated, “I 
would be comfortable. I probably need to review the specifics of the risks and benefits of 
the procedure first, but yeah, I would be comfortable doing it.” Many described scenarios 
where they present screening pros and cons and then let the patient make the decision.  
One FP described SDM as an “arm twist” where he explains to the patient that he 
“doesn’t have to do this” and states that usually patients will agree to it if you’re 
recommending it.  Only a couple of FPs reported that they took a more paternalistic 
approach.  One felt that the decision to engage in SDM or paternalism is really patient-
driven.  The FP said, “I guess the way I described it sounds more like benign paternalism, 
or benevolent paternalism…but umm, I do try to engage my patients in that shared 
decision-making, and then the ones who I feel like would be willing to cooperate, I will 
bring things out…tell me what your values are, and…I’ll tell you the kind of things I 
recommend.  I try to bring that stuff out, but it doesn’t really work for everybody. So, I 
can’t say that I always take that approach.”  No FPs mentioned the use of decision aids as 
a tool to conducting SDM. 
Most FPs prefer to conduct lung cancer screening discussions during annual or 
wellness visits.  While this was the preferred setting, some FPs were concerned that the 




acute health issues and often missed annual wellness visits.  One FP stated, “I can’t really 
get them to come to the office dependably once a year…usually [they schedule a visit] 
for some acute need and we just wouldn’t get around to that [lung cancer screening].”  
Most FPs reported challenges to conducting SDM during acute or sick visits and stated 
that they were less likely to have adequate time (if any).  Some of these challenges 
included addressing other health concerns (i.e. ongoing chronic conditions, such as 
hypertension and diabetes, or acute needs, such as flu or infections) or the need to discuss 
“higher priority” cancer screenings (e.g. breast, cervical, or colon).   
Most providers felt they could adequately conduct shared decision-making for lung 
cancer screening in 10 minutes or less during planned annual or wellness visits, however, 
some FPs reported the length of the discussion is dependent on the patient's questions and 
whether they were on schedule that day.  One FP stated that they would consider 
initiating SDM “...if I’m not behind…” but quickly added “I’m so frequently not ahead”.  
Scheduling the patient for a separate visit was an option discussed by FPs when time is 
limited, but FPs stated multiple reasons as to why they would prefer not to make a 
follow-up appointment solely for lung cancer screening purposes.  These included 
additional cost of patient co-pays and patient compliance. One FP simply said that “it’s 
hard for me to make appointments for just that [lung cancer screening]” and explained 
that the patient was unlikely to show up. 
FPs reported that education on smoking cessation is a key component to counseling 
patients on LDCT screening.  Some FPs also described conversations where they 
presented the patients with details on the risks and benefits of screening.  Several FPs 




exposure.  Less emphasis was placed on educating patients on the need to complete 
screening annually, with only a few FPs mentioning this topic. 
Overall, FPs agreed that counseling for LDCT screening was feasible in their clinic, 
but that adjustments and processes to do this type of visit had either already been 
implemented or needed to establish.  Many FPs reported making at least one referral for 
LDCT screening, however, a couple FPs confused screening with diagnostic testing and 
upon additional questioning, it was determined that they really made a diagnostic CT 
referral for a symptomatic patient.  Only one physician reported making no LDCT 
referrals.  Most FPs reported no major challenges making the referral, even in clinics 
without organized lung cancer screening programs.  A few FPs described having minor 
challenges (e.g., radiologists had a question or there was pushback from the billing 
processor) before a lung cancer screening program was implemented in their practice. 
Low-dose CT follow-up 
The majority of FPs described feeling responsible for informing their patients of 
their LDCT screening results, however, some agreed that pulmonologists or radiologists 
could conduct SDM adequately.  One FP had an opposing view and described one way to 
administer a lung cancer screening program would be through radiology clinics.  She 
went on to describe how she could refer the patient to that department where, in the same 
day, the radiologist they could handle the SDM discussion, perform the LDCT scan, and 
give feedback on the results.  She also suggested that the radiology clinic be responsible 
for following up with the patient if additional scans or procedures are needed.  She 




Most FPs did not report any challenges in getting the result from LDCT scans.  
Many reported the scan being immediately available in their electronic medical record 
(EMR).  Many FPs reported using phone calls to give good news or reports of “negative” 
scans and asking patients to come back to clinic to receive bad news about a “suspicious” 
finding.  There were varying approaches to the management of suspicious findings.  One 
FP reported making an immediate referral to a general oncologist and some FPs reported 
that their local oncologists would not see the patient until after an official diagnosis was 
made by tissue biopsy or bronchoscopy.  One FP admitted not knowing what she was 
supposed to do regarding further follow-up and replied “I think I may have to beg 
ignorance. I’m not exactly sure what kind of result I’d get. Do I get something like a 
mammogram, where I’d see something suspicious on their CT and they’d need a biopsy 
next?  I don’t know enough about what the next step would be. If that would be a referral 
to a general surgeon or cardiothoracic, biopsy, bronchoscopy, I don’t know.” 
Pulmonary nodule clinics could play a role in lung cancer screening, but FPs had 
varying levels of knowledge as to whether pulmonary clinics existed in their geographic 
area.  Only a couple FPs reported with certainty that they had a pulmonary nodule clinic 
in their area dedicated to evaluating suspicious lung nodules.  A couple of FPs described 
patients having to travel too far to receive that type of specialty care or not having access 
to specialty care at all. 
Barrier and facilitators to implementing lung cancer screening in the clinic 
Not surprisingly, a majority of FPs reported cost (e.g., patient visit co-pay or 
radiology fee) as a barrier to LDCT screening, even for insured patients.  Most FPs 




we don’t know the prices, we don’t know the costs, and many, many, many folks ask 
questions about what this is going to cost.”  For most FPs, there were no LDCT financial 
assistance programs in their area for asymptomatic patients, although some financial 
assistance programs were available for symptomatic patients to get diagnostic scans.  
While most FPs reported getting LDCTs paid for as a barrier, most FPs described no 
issues with getting a patient treated if a lung cancer was diagnosed. In fact, one FP stated 
“yeah, it’s a done deal after the diagnosis is made, that’s not even a problem.”   
Emergency Medicaid and indigent care programs were reported as approaches for getting 
lung cancer treated in uninsured patients.  One FP described “fabricating symptoms” to 
move a patient into the “diagnostic” category so that the scan would be covered or using 
different, more historical approaches, such as calcium scoring exams to get an image of 
the lungs.  This particular FP thought ordering calcium score exams were a “2-for-1” 
approach to disease detection.  He stated that this exam captured information most of the 
lungs (85%) as well as the heart.  Using this approach, he felt, provided information on 
detecting both lung cancer and coronary artery disease, two diseases in which smoking is 
a risk factor. 
Some FPs mentioned administrative barriers to LDCT screening that included 
lack of support staff to assist with preparation or execution of SDM counseling visit (e.g., 
nurses, other ancillary staff) and no established practice quality metrics requiring lung 
cancer screening to be performed (as is the case with other cancer screenings).  A 
majority of FPs had suboptimal knowledge on the complex documentation and billing 
procedures for LDCT screening.  Many either did not know that they could submit claims 




requirements for a Medicare claim to be processed (e.g., LDCT written order with 
documentation of age and smoking history, evidence of SDM visit with use of a decision 
aid, and smoking cession counseling). 
All FPs reported some type of time constraint as a barrier to lung cancer 
screening discussions.  Some FPs reported time constraints that resulted from overbooked 
schedules and reported often “running behind” and others discussed time barriers in 
reference to competing health issues being prioritized over lung cancer screening during 
already short office visits.  Of the entire group of FPs interviewed, only one FP felt so 
strongly about lung cancer screening that she reported “always” making time for it, 
despite her overloaded schedule and time constraints. 
FPs had some ideas that would facilitate lung cancer screening discussions with 
their patients. Patient education (e.g., take-home materials, print and video media 
campaigns) and systematic approaches to identifying guideline appropriate patients in the 
clinic were suggested.  EMR pop-up reminders, paper chart notifications, and patient 
completed screening tools (used in the waiting room) addressing multiple screening 
topics were systematic approaches described by FPs as facilitators.  “…one of the 
answers would be a good EMR. What do they call them, kiosks? You know or patient 
check in module things? Well, yeah, it’s interactive too…and keep going down menus 
based on their answers. Just like a human interview would do. So that will be helpful.” 
Few providers mentioned patient financial assistance programs as potential facilitators.  
Discussion 
This qualitative assessment aimed to provide an in-depth look at family physician 




not implementing) screening in their practice. In comparison to other recently published 
qualitative studies on this topic,14,15,78 we did not provide any structured education on 
lung cancer screening prior to our interviews, allowing us to gain insight into what 
practicing FPs may know and practice without any direct influence. While the FPs we 
interviewed described many challenges, the majority felt that LCS was feasible in their 
clinics, with some additional education, planning, and assistance.  
FPs had suboptimal knowledge of the scientific evidence and patient eligibility 
criteria for LDCT screening, but welcomed education on these topics.  Uncertainty about 
who is eligible for screening and the scientific evidence that underlies screening 
guidelines has been reported across both quantitative and qualitative research studies, 
rural and urban geographic areas, physicians and advanced care providers, and 
community-based, Veteran, and academic-based practices.14,15,73,75,78,80,82,83 Raz et al 
reported that less than half (47%) of primary care physicians surveyed in Los Angeles 
county were aware of the USPSTF recommendations for lung cancer screening and many 
could not identify when LDCT was recommended and not recommended.  Another 
survey study, conducted by Duong et al found that only 31% of PCP providers answered 
age and smoking criteria correctly.83  Simmons et al conducted telephone focus groups 
with physicians, nurse practitioners, and physician assistant and reported that the majority 
of the providers had limited knowledge on LCS.14  Despite limitations in knowledge, 
providers across studies were open to receiving additional education about lung cancer 
screening and incorporating it into their practice,14,83 similar to the providers in our study.    
The FPs interviewed in this study also were uncertain about the requirements for 




highlighted.  Interestingly, despite the CMS requirement that a shared decision-making 
counseling visit incorporated the use of a decision aid, not one FP we interviewed 
described using a decision aid in their LCS discussions.  This lack of emphasis on the 
importance of using a decision aid is in contrast to a recent electronic survey study by 
Triplette et al where 51% of PCP and pulmonary providers reported decision aids as an 
important facilitator to LCS discussions.82  When asked about billing for lung cancer in 
general, many physicians reported not being aware that they could bill for SDM 
counseling visits and/or LDCT. 
We found that smoking history, one of the criteria for defining high risk patients, 
was the primary driver of a FP’s decision to initiation LCS.  Smoking history and 
secondhand smoke exposure were also reported as drivers of the decision to initiate lung 
cancer screening discussions by Henderson et al in 2011.73  However, we also found that 
FPs were willing to screen patients outside the established criteria for a high risk patient 
if the patient was requesting screening or if the FP was motivated by factors not 
addressed in the recommendations, such as family history, secondhand smoke exposure, 
or occupational exposures.  Henderson (2011) described confliction over ordering LDCT 
in lower risk patients as something they coined the “physician struggle”, meaning that 
FPs may make decisions about screening that are contrary to their beliefs about screening 
as they contemplate other factors, such as patient requests or presence of other risk 
factors.  Propensity to screen patients outside of guidelines (over screening) has been 
reported previously,73 is a concern across cancer screening programs, and results in 
increased financial burden at the population level.  Other qualitative studies reported 




lung cancer being diagnosed;73,78 however, this concern was not described in any of our 
FP interviews.  
Some of the FPs in our study also reported using other approaches to get some 
form of screening for patients, such as use of other scanning modalities, or ordering 
diagnostic tests for truly asymptomatic patients.  Prior research has documented 
continued use of CXR or other less preferred computed tomography scans,14,15,73,78,81,82 
however, the use of CXR was not commonly reported amongst our FPs.  Hoffman et al 
reported in 2015 that no primary care providers had ordered a LDCT78 and other studies 
have reported subpar rates of LDCT utilization.74,75  More recently, Duong et al reported 
that 58% of providers surveyed reported ordering LDCT83 and in our qualitative 
assessment, most FPs reported making at least one LDCT referral, perhaps suggesting a 
shift away from the use of CXR.   
Several studies on LCS report financial concerns as a barrier to lung cancer 
screening.14,75,78,80,81  Some FPs in our study also exhibited concern over discussing 
screening in underserved or uninsured patients, while some FPs felt that this was not a 
concern.  This contradictory viewpoint appeared to be related to the availability of free or 
affordable screening for uninsured/underserved patients in their geographic area.  FPs 
also expressed concern over difficulty discussing the patient’s portion of the cost of 
screening, regardless of insurance coverage or type.  With the variety of insurance plans 
available, FPs felt they could not provide accurate estimates of what the patient out-of-
pocket cost for screening would be and must “speculate”.  A tool that could help 
providers determine the cost of a patient’s copay would be useful and would promote 




“hotline” for FPs to call for assistance. In addition to concerns about speculating on the 
cost of LDCT screening, FPs also had concerns about patient’s out-of-pocket costs for 
follow-up diagnostics (e.g., biopsies, bronchoscopies).   
Both quantitative and qualitative studies have reported that providers expressed 
the need for guidance (e.g., medical education)78,83 and assistance advising patients about 
screening and follow-up care (e.g., point-of-care materials, additional staffing, 
multidisciplinary input).15,78,82  A qualitative study by Kanodra et al described a LCS 
program administered in the Veteran’s Administration (VA) in South Carolina, where 
primary care providers were notified of LCS eligibility via electronic medical record 
(EMR) notification and could then refer their patient to a nurse navigator who engaged in 
SDM with the patients.15  VA providers viewed this LCS program structure as effective 
and efficient.  While the FPs in our study largely felt comfortable conducting SDM 
counseling visits for LCS on their own, many reported time as a barrier and nurse 
navigator programs could potentially be an approach to handling time constraints. FPs 
had several other suggestions to facilitate LCS in their practices.  EMR notifications were 
suggested by many FPs in this study as the best way to systematically identify patients, 
similar to other studies,14,15 however they noted that the EMR must include a way to 
capture detailed information, including volume of cigarettes and length of time smoked 
(pack year history) and type of exposure (e.g., personal or second-hand), information that 
is less likely to be captured in existing EMR systems.  
Several limitations should be considered when interpreting the results of this 
study.  Our interview focused mainly on evidence and guideline knowledge, making 




incorporate a broad range of topics, less emphasis was placed on documentation and 
billing for shared decision-making visits and LDCT follow-up.  For example, we did not 
specifically ask about what FPs did when a patient had a borderline nodule and only one 
FP described his approach (referral to pulmonary for long term follow-up).  Also, in our 
study, many FPs reported not knowing that they could bill for SDM counseling visits, 
limiting the questions we could ask about their billing processes.  Lastly, our study 
interviewed only family physicians, leaving out an important population of individuals 
(e.g. nurses, advanced care practioners) that can participate in SDM visits and LDCT 
referrals in the primary care setting.  These limitations highlight areas for further 
research.  We had a diverse group of FPs from different geographic areas and practice 
settings and reached thematic saturation across our interviews, despite our smaller sample 
size.   
Conclusions 
Even though LCS with LDCT is a recommended cancer screening that is now 
covered by most private insurers and Medicare, FPs still have varying degrees of 
knowledge and experiences with LCS counseling visits, and while LDCT referral seem to 
be increasing, LDCT remains underutilized.  This study suggests that FPs are open to 
using LDCT as an early diagnosis tool and consider SDM feasible in their clinics.  If 
given appropriate education and tools, they would be more likely to utilize low-dose 







Tables and Figures 
Table 4.1. Descriptive characteristics of family physician participants by 
recruitment cohort 
 
 SC AFP CHS AMA Referral Total 
Gender      
  Female 3 1 3 0 7 
  Male 5 1 1 1 8 
Race / ethnicity      
   Non-Hispanic White 7 2 4 1 14 
   Non-Hispanic Black 1 0 0 0 1 
Age range      
   20-29 1 0 0 0 1 
   30-39 1 0 0 0 1 
   40-49 2 2 3 0 7 
   50-59 1 0 0 1 2 
   60-69 3 1 0 0 4 
State      
   NC 0 2 4 1 7 
   SC 8 0 0 0 8 
Practice Setting      
   Group practice 3 2 4 1 10 
   Private practice 1 0 0 0 1 
   Hospital 1 0 0 0 1 
   Academic 2 0 0 0 2 
   Other 1 0 0 0 1 
Specialty      
   Family medicine 8 1 4 1 14 
   Internal medicine 0 1 0 0 1 
Abbreviations:  AMA, American Medical Association; CHS, Carolinas HealthCare 










Table 4.2. Key themes and supporting quotes 
 






scientific evidence  
“I’m aware that there is research and that it is 
favorable, but I don’t know the details, and it's 
because I haven't really been able to apply it very 
well at my current practice.” 
“I don’t know about the scientific 
evidence behind it.” 
 
 
  Suboptimal 
awareness of patient 
eligibility criteria 
"Umm, as far as who to screen, that’s what I’m not 
as confident about. I know that older people and 
people who have a long smoking history, umm, 
would be certainly would be greater candidates 
than younger people or people who didn’t smoke, 
but I don’t know exactly what the age is or how 
much, how many cigarettes or any of that. That’s 
the part that I would have to look it up." 
"I’ll have to be honest, as far as 
the specific patients or past 
history or patient age, I don’t. I 
am aware that CT exists as an 
option but as far as 
recommendations as to who 




discuss LCS  
Smoking history is 
the primary driver of 
FP decision to initiate 
lung cancer screening 
counseling visit 
“Yeah, when they come in to the clinic, they fill out 
a, uh, intake form that that describes smoking 
history and so based on that form, we'd, you can 
sometimes, you can make the decision at that point 
if they need to have screening..." 
"So I, yeah so all, all my smokers 
get a talking to..." 
  FPs are less to likely 
to discuss lung cancer 
screening in patients 
with short life 
expectancies and/or 
comorbid conditions  
"Well, [I wouldn't bring up screening in] people 
that are sick from other things, perhaps.  Um, you 
know that you don't anticipate them getting benefits 
based on how ill they already are." 
"...unlikely to survive long enough 
to benefit from, uh, having lung 








  FPs are less to likely 
to discuss lung cancer 
screening in 
uninsured patients 
"Hmmm, that's a tough situation.  Uh…I don’t even 
know that I would even bring it up for fear that it's 
going to be unaffordable.  They're going to feel like 
they don't get wat everybody else gets because they 
don't have insurance. I don't think I would probably 
mention it." 
"I don't think we have any 
programs in this community that 
pays for that.  We have free 
mammograms but we don’t' have 
any free stuff like that, so I'm not 
sure if I would mention it. It 
almost seems kind of cruel to 
mention it and know that they have 
no means to get it, but saying 
maybe when you're able or you 
know if your insurance goes 
through then and most people will 
get Medicare when they are 65, so 
if they're still appropriate then, 
then they can revisit it.  So, I may 
or may not discuss it, sorry." 
  PCPs are aware that 
they should focus 
lung cancer screening 
discussions to high 
risk patient  
"…wouldn’t recommend anything outside the 
guidelines." 
"…you have to be the right age, 30 
pack year history, not be a 15-year 
non-smoker, and willing to follow 
through with, if they have positive 
screenings, willing to follow 
through and willing to sustain and 
survive surgical recommendations 











Patients rarely initiate 
lung cancer screening 
discussions 
"I think that there’s, they know lung cancer is 
always there in the background, and umm they 
don’t ask for screens because they don’t want to 
know.  That, that’s kind of my feeling based on my 
patients. You know they’re not, they’re not asking, 
and even the ones that are savvy and have heard of 
it, uh they’re not. Mentally, they don’t want to 
know. I mean, they know every time they smoke, 
you know." 
"It’s rare, to be honest, but most of 
the ones that ask are usually 
moderate risk smokers tell me 
someone in their family was just 
diagnosed with lung cancer." 
  Physicians are willing 
to refer out of 
guideline patients for 
screening if a patient 
requests screening 
"So I mean if someone [who was not at high risk for 
lung cancer] asked me for something specific I try 
to either explain why I think it’s a good idea, or if I, 
or not a good idea and if they don’t, if they still 
don’t agree with me and they still want that thing, 
then we explore, you know, what the outcomes 
might be. You know, uh for instance, if you get a 
screening and you find something you weren’t 
expecting maybe it wasn’t along these lines and 
then they need to be worked up further, you know 
we talk about risk and benefits.  But, if people, 
people really want the screening and they are 
willing to pay for it even if their insurance doesn’t, 
I certainly would be fine with ordering it." 
"I would approach that with 
education. I would let them know 
that testing that they read about in 
Newsweek is only known to be 
helpful in these folks. For 
whatever reason, they don’t fall 
into that category and we don’t 
know if this test would be helpful 
for you and it may be 
harmful…because what they’re 
requesting is help. I’ve had some 
folks who insist on a screening test 
even though I don’t recommend it. 
I handle that like I would with any 
informed consent. I tend to lean on 
the side of getting the test for them 
and informed consent that the risk 
benefits may be more towards the 
risk and we are obligated to follow 












Providers feel that the 
screening discussion 
and referral is their 
responsibility 
"I mean, I see it like I do any other kind of 
screening. I think it’s my responsibility.  Umm, we 
screen for colorectal cancer and cervical cancer 
and breast cancer, so why should we not also be 
screening for lung cancer?" 
"Yeah, I think we need to do it 
because we are the front line and 
most folks see us first and they 
have that great relationship and 
trust with us so I think we need to 
be doing it absolutely." 
  Annual/wellness 
visits are the best 
time to conduct lung 
cancer screening 
discussions 
"If it’s an annual checkup, I feel obligated to make 
sure they are caught up on all of their screenings 
because they are coming in for that specific 
purpose, the way I look at it. If they are coming in 
for chronic disease management or an acute visit, 
then I still feel the responsibility to make sure that 
we have done the appropriate screening processing 
with them and if time allows we will try and do it, 
but if not we make sure before they leave they have 
a follow up appointment with me to get that done." 
“Certainly, screening tests are a 
huge part of discussion when you 
have someone in for that wellness 
visit, annual checkup, when we are 
already going through 
mammograms, bone density 
testing, colonoscopy, other 
immunizations, adult 
immunizations up to date. Um to 
add in, ‘this is your history, you’re 
at risk of lung cancer maybe we 
should consider this CT test’, I 
think it would feel natural. I would 
be willing, I guess that is my 
answer, willing to add that to the 
discussion.” 
 
  Shared decision-
making discussions 
can be completed in 
10 minutes or less 
"Well, it depends on how many questions the 
patient has. I if, if they just say, “well, ok sure,” 
then, I mean I think it could be a five-minute 
discussion, and, and they would know enough and 
we’d be done." 
“Let’s be honest, that’s a good 5-
10 minutes to really do what we’re 
supposed to be doing." 
  Providers are 
comfortable with 
shared decision-
"Yes, [I am comfortable with it].  I do it [shared 
decision-making] all the time.  I tell the patients the 
risks and benefits of lung cancer screening, and it’s 
"I mean I would say that I’m 
moderately at least moderately 







making approach to 
lung cancer screening 
discussions 
their decision, not mine.” accustomed to, umm like, the 
concept of ‘shared decision-
making,’ and when I have 
sufficient time and when I feel like 
my patients are willing to engage 
me on it, then I do that already, 
and I have discussed umm you 
know the guidelines as far as 
what’s recommended for lung 
cancer screenings." 
  Education on 
smoking cessation is 
a key component to 
lung cancer shared 
decision-making 
discussions 
"Nowadays our conversations typically go like, 
‘you’re not on any inhalers, your lungs sound 
clear, I would certainly encourage you to quit while 
you’re ahead before any damage has been done to 
your lungs’." 
"It’s supposed to be done in 
conjunction with the smoking 
cessation counseling as well." 
 
 
  Majority of primary 
care providers have 
made at least one 
referral for low-dose 
computed 
tomography  
"I am doing it. I do make those recommendations. 
Again, at the time of the office visit, with time being 
limited, do I do it as often as I should be? The 
answer is no but do I do it, yes... I’m not sure what 
it was, but something made me change my practice 
to where I do recommend more lung cancer 
screenings now than I did a year ago." 
"Yes, I have, but it’s umm I mean I 
could count the number of people 
who allow me to refer them on 
one, maybe two hands." 
  Challenges making 
referrals has resolved 
with time 
"I didn’t start making the referrals until I knew that 
there was a program in place. The place that I’ve 
been referring them to get the low-dose CT is not 
the usual place I refer for other radiologist studies. 
So, it’s kind of a special scenario. So, I guess some 
difficulty because it wasn't a facility I usually use. 
But almost everybody I attempted to schedule, the 
test has been performed." 
" I would say that prior to three or 
four months ago, yes it was very 
difficult because we had to order 
the CT scans ourselves and there 
was no option available for low-
dose CT for the purpose of lung 
cancer screening. Prior to the 







stepping in February or March it 
was really difficult to get the 
referral in Epic. Now it is much 
easier, we just type referral for a 
lung cancer screening and it will 
pop up and it is pretty nice." 
LDCT 
follow-up 
FPs believe it is their 
responsibility to 
inform patients of 
low-dose computed 
tomography results 
"Well…it, uh, us…me the primary doctor. That, we 
do that, the positive screening and then we talked to 
them about making a formal diagnosis." 
" I like to be more hands on with 
our patients and the local gals 
who do the mammogram know 
that. I’m always going to beat 
them to the punch before they call 
them back. There’s your answer, I 
would rather be the one to tell, 
you know share that with the 
patient. Walk them through it and 
make the plan." 
  No challenges 
obtaining scan results 
"No [problems], the, the reports are readily 
available on the computer." 
"Mhmm, yeah [scans are in EMR] 
and a lot of times they’ll 
[radiologists] call if something 
shows up."-Sum 
  Pulmonary nodule 
clinics could play a 
role in lung cancer 
screening discussions 
"We work pretty closely with the pulmonology 
clinic for our COPD patients and asthma patients 
and that kind of thing and I’m not aware of them 
ever recommending screening for high risk 
patients. So now that we talked about it I’m curious 
to know if they ever recommend it, and how we 
could complement each other in that way...I, I 
absolutely would consider that, um, but it would 
only cover a small part of the patients that would 
 “Um, usually if nodules that are 
kinda iffy, I refer to pulmonology 
and then they usually follow them 
for a couple of years and if they 
are stable, they just hand them 















"We have a strict policy of $80 copay [for 
counseling visits] just to see me if you don't have 
insurance and then I can talk about them [the 
recommendations for screening].  I can make 
recommendations and I can even give referrals but 
often times those referrals will get denied or not 
even scheduled because their insurance data, 
especially if their clean [asymptomatic].  Now if 
you are symptomatic, I am able to make a couple of 
phone calls and get the copay waived but general 
screening, that is a very difficult thing to do."  
"Specifically, you know, how well 
is this covered and what’s the out-
of-pocket costs associated with 
having the screening completed. 
Folks have, nowadays they can opt 
maybe to have higher co-pay or 
deductible insurances and 
sometimes the benefit is available 
but there are still associated costs 
out of pocket. So, we don’t know 
the prices, we don’t know the costs 
and many, many, many folks ask 
questions about what this is going 
to cost." 
  Lack of support staff 
and practice or 
quality metrics are a 
challenge 
"I mean, we have these elaborate electronic 
medical records but it still proves to be a challenge 
to keep track of all the little, um, quality 
parameters and I'm not aware of lung cancer 
screening being a quality parameter in our system." 
“I just don’t know how something 
like this [is doable], without 
having some kind of protocolized 
system where there is some other 
ancillary health person who can 













“You know, for a long time, we were still waiting 
on those codes, so even if we did it, how would we 
even get it done, and again a heavily weighted 
Medicare practice." 
"Uh, my colleagues who are trying 
to see two or three times as many 
patients as I do in a day, um, are 
just not going uh to generate the, 
the volume of documentation 
sufficient to satisfy these kinds of, 
uh, of audits and wind up, uh, 
frustrated with the amount of time 
that’s, uh, generated in the audit, 
and the negative impression that 
their patients get if they realize 
that their doctor/patient visit was 
not covered and they’re, uh, being, 
uh, charged that they [their 
doctor] didn’t document this 
discussion and so forth...just a few 
of those kinds of, uh, frustrations 
dissuade a lot of physicians from 
doing the right thing." 
  Busy schedule often 
leads to "running 
behind" 
“I feel l maybe 25% of the time, if someone is 
coming in, feasibly I could do it, umm, because I 
mean the issue with that, if I get really far behind 
because I’ve had that conversation with one 
person, then I won’t be able to have it with the next 
one.” 
"…if I’m not behind and umm the 
patient has fits the criteria and I 
haven’t spoken with it before, then 
it certainly would be a chance to 
grab them. Umm, I would I’m so 
frequently not ahead that I don’t 
frequently, don't want, to add 
those things to visits that uh umm 







  Patients have other 
competing health 
issues that are 
prioritized over lung 
cancer 
"I tend to prioritize, I do try and do it, but lung 
cancer screening really hasn’t gotten to the top of 
my radar quite yet, whereas breast cancer, cervical 
cancer, colon cancer screening are kind of already 
part of my problem visits, meaning that I’ll check 
and see if they are up to date and if they are not, 
then I will usually mention those.” 
"Make it streamlined for the very, 
very busy primary care providers 
in and you know under-resourced 
Medicare-heavy population 
because I’m very, even though I 
know who I should be talking to, 
I’m very challenged. Once I’m in a 
room with a patient and I’ve 
handled you know the five 
healthcare maintenance and the 
diabetes follow-up things and 
whatever, and then they hit me 
with three things they need you to 
do, I honestly don’t have time to 
talk about it." 
 Patient education 
materials facilitate 
lung cancer screening 
discussions  
"I think also something that would help us would be 
just more patient education. You know I’ve had so 
many people ask about, like, shingles vaccine when 
they see the commercial and you know it's like oh 
yeah, that's a great idea you know, um, so but just 
public information helps them to help us 
remember...yeah I mean people watch TV, that's 
how a lot of stuff, messages and things like that, 
maybe some flyers or something in the office would 
be helpful, but yeah people, really notice the 
commercials." 
"I get in the situation where I say 
you know this is what I 
recommend, but think about it for 
a minute, talk to your family about 
it. Let me know if you change your 
mind. I may ask you next time but I 
won’t fuss at ya. That kind of 
patient...it might be kind of helpful 
to have a little bit of a brochure. I 
might just hand ya a little 
brochure or pamphlet to say 
here’s a little bit more 
information, look at it and we’ll 








  Systematic 
approaches to patient 
identification 
facilitate lung cancer 
screening  
"This is a good place where electronic records and 
electronic checking systems could be helpful. We’ve 
played with some of those but never really found 
one that played well with our EMR. Those little 
kiosks that check-in and ask the basic screening 
questions and if they’re positive they keep going 
down to the menu so they can do a full screening. 
They can do all the screening tests. What’s your 
age range, pack year history? All of that. So... one 
of the answers would be a good EMR...patient 
check in module things...so that will be helpful." 
"Um, actually kinda like a lot of 
the other triggers we’ve built in 
for other stuff now, just sorta build 
the guidelines in so it’s easier to 
identify the patients um and that's 
probably the biggest thing, is just 
identifying the people that qualify 
and then just making a check, so 
saying has it been done or not, 
what interval and we decide to 
follow up from there." 
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Introduction: Lung cancer is the leading cause of cancer-related death in South Carolina 
(SC). Tumor molecular testing (MT) advances led to the development of precision 
medicine treatments, improving outcomes.  However, disparities in MT utilization may 
exist.  We evaluated factors related to MT utilization and the impact of MT on overall 
survival (OS). 
Methods: Cases diagnosed with stage IIIB/IV non-small cell lung cancer (NSCLC) 
between January 1, 2002 and December 31, 2012 and available through the SC Central 
Cancer Registry were linked to SC State Employee Health Plan and Medicaid 
administrative claims data.  Logistic regression (LR) was used to identify predictors of 
MT utilization.  Kaplan-Meier methods were used to estimate survival distributions and 
log-rank tests compared the survival distributions between MT and no MT groups. Cox 
proportional hazards modeling was used to assess the impact of patient demographic and 
clinical characteristics (including MT) on survival, while adjusting for other prognostic 
covariates.  Propensity scores were calculated and included as covariate in propensity-
score adjusted Cox models. 
Results: A total of 2,266 cases were eligible.  In the multivariable LR model, predictors 
of having at least one procedure claim for MT included younger age (p=.008), in-state 
providers (p=.003), low tumor grade (p=.008), adenocarcinoma histology (p=.015), and 
diagnosis year of 2010 or later (p<.001).  OS was longer in patients who received MT 
(median OS=13.0 vs. 6.0 months, p<.001).  When adjusting for significant prognostic 
factors, patients with MT had a 43% lower risk of death compared to patients without MT 





Conclusions:  Several characteristics are associated with MT utilization.  In patients with 
advanced NSCLC, MT may positively impact OS in the population-based setting.  
Introduction  
Lung cancer is the leading cause of cancer-related death in the United States and 
in South Carolina.1,145  In 2017, approximately 4,320 new lung cancer cases and 2,920 
lung cancer deaths are expected in South Carolina (SC) alone.1  Over half of patients with 
lung cancer are diagnosed with advanced disease, contributing to the dismal 5-year 
survival rate of approximately 4%.1  Historically, patients with advanced lung cancer 
have been treated with one of several platinum-based doublet chemotherapy regimens 
(e.g., cisplatin + paclitaxel or gemcitabine or docetaxel)or pemetrexed, none of which 
provided much hope for long-term response and improved survival.4,146  Precision 
medicine, including targeted and immunotherapy drugs, may offer improvements in 
outcomes. 
Within the last decade, advances in the genomic profiling of lung tumors have 
identified multiple alterations in lung tumor cells, especially non-small cell lung cancer 
(NSCLC), that can be targets for treatment.  Various laboratory procedures are used to 
identify alterations in tumors including immunohistochemistry (IHC) to evaluate protein 
expression, in situ hybridization (ISH) to evaluate abnormalities in a specific region of 
nucleic acid on a chromosome, polymerase chain reaction to identify gene mutations, and 
sequencing to evaluate alterations in deoxyribonucleic acid (DNA) and ribonucleic acid 
(RNA).147,148  For example, epidermal growth factor receptor (EGFR) is a cell surface 
receptor that can be evaluated using different laboratory approaches.  EGFR is altered 





EGFR is involved with cell proliferation, suppression of apoptosis, cell motility, invasion 
and angiogenesis.20,25  Other targetable alterations found in lung tumors include ALK, 
ROS1, BRAF, and MET.26,27   
Genomic, or molecular testing, has led to progress in treating advanced, NSCLCs 
and has allowed oncologists to use targeted approaches to treating selected patients, 
sparing many the systemic effects of cytotoxic therapies.  However, little is known about 
the factors influencing molecular testing utilization in population-based settings.  The 
purpose of this study was two-fold.  We determined factors associated with molecular 
testing utilization among patients with advanced stage, NSCLC residing in SC. We also 
assessed the impact of molecular testing on overall survival. 
Methods  
Study Design, Data Source, and Cohort Selection 
We conducted a retrospective cohort study using data from the South Carolina 
Central Cancer Registry (SCCCR) linked to administrative claims data obtained from the 
South Carolina Revenue and Fiscal Affairs (RFA) office. Eligible patients were those 
diagnosed with first primary stage IIIB/IV lung cancer between January 1, 2002 and 
December 31, 2012 who enrolled in the SC State Employee Health Plan (SCSEHP) or SC 
Medicaid during the study period.  Patients with secondary malignancies and those 
insured concurrently by an HMO plan or who had Medicare as the primary payer were 
excluded.   
Outcomes 
Two outcomes were examined among patients in this study: 1) use of any 





coded using a billing method called “code stacking”.147,149  This method utilized a 
combination of Common Procedure Terminology (CPT) codes, consisting of laboratory 
procedure codes and reporting codes, to bill for molecular tests.  Thus, different facilities 
could code for the same test in multiple combinations of stacked codes. In this study, 
patients with at least one procedure claim submitted with a CPT code indicative of 
molecular testing, codes 83890-83914, were categorized as having any molecular test 
(“yes”) and patients without any claims utilizing codes were categorized as not having 
any molecular test (“no”).   
Overall survival was measured from date of first primary cancer diagnosis to date 
of death from any cause.  Surviving patients were censored at the date of last SCCCR 
follow-up or December 31, 2014. 
Covariates 
Patient demographics 
Age at diagnosis was evaluated as both continuous and categorical variables (<52, 
52-57, 58-62, 63+ years).  Race was categorized as White, Black, Other and Hispanic 
ethnicity as Hispanic, non-Hispanic, or unknown. Marital status was categorized as 
married, not married, or unknown. Insurance status was categorized as SCSEHP or 
Medicaid.  Of note, all patients in this study had some form of insurance coverage, but 
did not have Medicare.  Patient metropolitan status was derived using rural-urban 
continuum codes assigned to each patient’s county of residence at diagnosis and were 








Histology was categorized using ICD-0-3 codes: adenocarcinoma (8140, 8250, 8252, 
8253, 8255, 8260, 8480, 8481), large cell (8012), squamous (8070, 8071), and mixed or 
other NSCLC (8000, 8010, 8046, 8560). Stage was limited to advanced stage and was 
categorized according to American Joint Committee on Cancer (AJCC) staging criteria 
(IIIB or IV).  Grade was categorized as low (grade I or II), high (grade III or IV) or 
unknown. Primary site was defined as main bronchus (including carina, hilum, bronchus 
intermedius; C340), lobe (including upper lobe, lingual, apex, and pancoast tumors, 
C341; middle lobe, C342; lower lobe and base, C343), overlapping lesion of lung (C348), 
and lung or bronchus, not otherwise specified (NOS; C349). We choose to dichotomize 
year of diagnosis (prior to 2010 or 2010 and later) and selected a cutoff year prior to the 
drafting and publication of clinical opinion papers and clinical practice guidelines for 
molecular testing,103-105,108,150 assuming some physicians were ordering molecular testing 
prior to 2010 for research and drug authorization purposes. 
Provider characteristics 
For each procedure claim, the submitting provider’s county of service was 
documented.  Each individual claim was categorized as “in-state” or “out-of-state”.  
Claims billed by providers in SC counties were classified as “in-state” and those 
submitted by providers not in a SC county were classified as “out-of-state”.  A patient 
with at least one claim submitted by an out-of-state provider was classified as out-of-








Descriptive statistics for patient and provider characteristics were summarized for 
the overall cohort and by molecular testing status. Comparisons between molecular 
testing groups were performed using chi-square tests for categorical variables and a two-
sample t-test for age.  
Univariate and multivariable logistic regression was used to evaluate the impact 
of patient and provider characteristics on receipt of molecular testing.  Factors included in 
the final model were identified using backwards elimination followed by forward 
selection modeling procedures (p<.05).  Unadjusted and adjusted odds ratios (OR) and 
corresponding 95% confidence intervals (CI) were estimated.   
Kaplan–Meier techniques were used to estimate survival distributions and log-
rank tests compared the survival distributions between the molecular testing groups.   
Univariable Cox proportional hazards regression was used to identify individual 
prognostic factors predictive of overall survival and multivariable Cox proportional 
hazards regression was used to evaluate the independent impact of the covariates and 
molecular testing status on overall survival.  Unadjusted and adjusted hazard ratios (HR) 
and corresponding 95% CIs were estimated.   
To reduce potential biases associated with molecular testing on survival, Cox 
proportional hazards models were estimated using propensity scores. Individual 
propensity scores were calculated using logistic regression using two separate approaches 
(non-parsimonious model and parsimonious model). The non-parsimonious model 
consisted of a logistic regression model using all available covariates, while the 





multivariable logistic regression model.  Next, individual patient propensity scores were 
calculated based on predicted probabilities from the logistic regression models.  Patients 
who had molecular testing were weighted by the inverse of the probability for getting 
molecular tested, while patients who did not have molecular testing were weighted by the 
inverse of the probability for not getting molecular tested.  The propensity scores were 
then used as a covariate to estimate the adjusted effect of molecular testing on survival in 
the Cox proportional hazards regression models.  We then compared the propensity 
score-adjusted Cox proportional hazards regression models to the model based on 
independent patient and provider prognostic factors.   
All p-values were from two-sided tests and p-values <.05 were considered 
statistically significant.  All analyses were performed with SAS® version 9.4 (SAS Inc., 
Cary, NC). 
Results 
A total of 3,842 stage IIIB/IV first primary lung cancer cases were identified 
during the study period (State Health Plan=341, Medicaid= 3,501).  During the same 
period, 467,832 medical procedure claims from the patients in our cohort were submitted 
to State Health Plan (115,087) and Medicaid (352,745).  Figure 5.1 shows the criteria for 
patient and claim exclusion.  After patient exclusions, 2,266 cases remained eligible for 
analysis.  Of these, 44 cases (1.9%) received molecular testing. 
Patient and physician demographics  
Table 5.1 details the patient and physician demographic characteristics for the 
entire study population and by molecular testing subgroup.  Mean age at diagnosis was 





half of the study population was White (56.9%) and the majority were non-Hispanic 
(98.0%).  The majority of included patients were covered by SC Medicaid (86.0%) and 
lived in metropolitan counties at the time of diagnosis (75.8%).  Similarly, most 
procedure claims submitted were from in state providers (75.7%).  There were no 
significant differences between those who received molecularly testing and those that did 
not receive molecularly testing by most demographic characteristics, except for age at 
diagnosis (p=.002), insurance (p=.007) and provider state (p=.004).  Approximately 4% 
of patients enrolled in SCSEHP received molecular testing, compared to only 1.6% of 
Medicaid patients.  Approximately 2%of patients with in-state only claims received 
molecular testing, compared to only 0.5% of patients with at least one out of state claim. 
Patient disease characteristics 
Over 77% of the lung cancer patients in the cohort were diagnosed with stage IV 
disease.  In over half the cases, grade was unknown (60.5%).  Adenocarcinoma was the 
most common histology (37.2%), followed by mixed or other NSCLC (31.0%) and 
squamous cell carcinoma (23.1%).  Lung lobe was the most common disease site 
(69.5%).  Significant differences between molecularly tested and not molecularly tested 
groups were observed for grade (p=.025) and histology (p<.001).  Low-grade patients 
were more likely to receive molecular testing compared high-grade patients (3.6% vs. 
0.9%, respectively).  Patients with adenocarcinoma had the highest rate of molecular 
testing (3.8%) compared to other histologies. 
Predictors of molecular testing 
Univariable logistic regression identified six individual prognostic factors of 





insurance, provider state, histology, grade, and year of diagnosis (Table 5.2).  Most 
variables that were significant in the univariable models remained independent prognostic 
factors in the adjusted logistic regression model, except for insurance status (p=0.131, 
Table 5.3).  Similar to the unadjusted models, the adjusted odds of having a molecular 
test were reduced by 50% for each decade increase in age (OR=0.95, 95% CI: 0.91-0.99, 
p=.008).  Patients with claims submitted by out-of-state providers were about 84% less 
likely to have molecular testing, after adjustment (OR=0.16, 95% CI: 0.05-0.53, p=.003).  
Patients with high and unknown grade tumors had reduced odds of having a molecular 
test compared to patients with low grade tumors (high grade: OR=0.17, 95% CI: 0.06-
0.53; unknown grade: OR=0.37, 95% CI: 0.16-0.86; p=.008) after adjustment.  Patients 
with squamous, mixed or other NSCLC, and large cell histologies were all less likely to 
have molecular testing compared to patients with adenocarcinoma histologies (squamous: 
OR=0.06, 95% CI: 0.01-0.47; mixed or other NSCLC: OR=0.46, 95% CI: 0.21-1.05; 
large cell: OR=0.53, 95% CI: 0.15-1.84; p=.015).  Patients diagnosed in 2010 or later 
were over 15 times more likely to having molecular testing compared to patients 
diagnosed prior to 2010 (OR=15.60, 95% CI: 6.48-37.53, p=<.001). 
Molecular testing and overall survival 
Median overall survival varied significantly by molecular testing status (log-rank: 
p<.001; Figure 5.2).  Overall survival was longer for patients with molecular testing 
compared to patients without molecular testing (median=13 vs. 6 months, CI: 8-25 vs. 5-
6, respectively).  The censoring rate was higher in the molecular testing group compared 





Factors that were individually associated with overall survival included age at 
diagnosis, insurance, provider state, stage, grade, histology, primary site, year of 
diagnosis, and molecular testing status.  All variables, except grade, remained significant 
in the multivariable model (Table 5.3).  There remained an increased risk of death for 
each additional decade of age (10%; HR=1.01, 95% CI: 1.00-1.01, p=.004) after 
adjustment.  Patients enrolled in SC Medicaid had an increased risk of death compared to 
patients enrolled in SCSEHP, once adjusted (HR=1.37, 95% CI: 1.21-1.56, p<.001).  
Patients who had at least one procedure claim for molecular testing submitted by an out-
of-state provider had a 36% reduced risk of death compared to patients whose claims 
were submitted by an in-state provider (HR=0.64, 95% CI: 0.57-0.71, p<0.001).  Stage 
IV patients had an 83% increased risk of death compared to stage IIIB patients (HR=1.83, 
95%CI: 1.64-2.04, p<.001).  Patients with mixed or other NSCLC (HR=1.17, 95% CI: 
1.05-1.30), large cell carcinoma (HR=1.09, 95% CI: 0.92-1.28), or squamous cell 
carcinoma (HR=1.12, 95% CI: 1.00-1.26) had increased risk of death compared to those 
with adenocarcinoma, after adjustment (p=.034). Patients with tumors in the lung and 
bronchus, not otherwise specified (HR=1.25, 95% CI: 1.11-1.39), overlapping lesions 
(HR=1.30, 95% CI: 1.00-1.68), or tumors in the main bronchus (HR=1.21, 95% CI: 1.01-
1.45) had increased risk of death compared to patients with tumors located in a lung lobe 
(p<0.001).  Patients diagnosed in 2010 or after had a 11% reduced risk of death compared 
to those diagnosed prior to 2010 (HR=0.89, 95% CI: 0.81-0.99, p=.027).   
Once adjusted for age at diagnosis, insurance, provider state, stage, histology, 





a reduced risk of death compared to patients without molecular testing, although this 
association was slightly attenuated (HR=0.57, 95% CI: 0.40-0.81, p=.002). 
The relationship between molecular testing and overall survival also was adjusted 
for using propensity scores calculated by both parsimonious and non-parsimonious 
logistic regression models.  Neither model differed greatly from the model based on 
independent patient and provider prognostic factors. Patients who had molecular testing 
had a 46% reduced risk of death compared to patients who did not have molecular 
testing, in both the parsimonious and non-parsimonious models (HR=0.54, 95% CI: 0.38-
0.78, p=.001 and HR=0.54, 95% CI: 0.38-0.78, p=.001, respectively; Table 5.4). 
Discussion 
Overall, this study found a very low rate of molecular testing for patients with 
advanced NSCLC in SC compared to other studies of EGFR-specific testing that reported 
EGFR testing rates between approximately 15-32%.111-113  Overall, ≈2% of patients in 
this study received any molecular testing with a higher proportion of patients diagnosed 
in 2010 or later having molecular testing (5.9%) compared to those diagnosed prior to 
2010 (0.37%).  This may indicate physician adoption of molecular testing in this 
population over time, likely as a result of the publication and dissemination of multiple 
molecular testing guidelines,103,104,108-110,151 increased integration and ease of molecular 
testing results in the clinic, and the approval of multiple effective targeted therapies (e.g., 
gefitinib, erlotinib, and crizotinib) since 2010.30,116,118 
Several patient and provider factors were predictive of having at least one CPT 
code for molecular testing.  These factors were age at diagnosis, provider state, grade, 





molecular tests were similar to several other studies.112,113  A recent study published in 
2016 by Enewold and Thomas112 examined EGFR testing only, as opposed to any 
molecular testing (e.g., KRAS, BRAF, ALK, ROS1).112  Their study found that patients 
with stage IV lung cancer who were younger, covered by Medicaid, uncovered or had 
unknown coverage, and diagnosed with large cell and squamous tumors were less likely 
to have molecular testing, similar to our study results.  Shen et al also reported younger, 
as well as female, patients more likely to have molecular testing, similar to our study.113  
Enewold and Thomas also found that EGFR testing was also associated with 
Hispanic/Asian Pacific Islander (API) heritages, marital status, smoking status, having no 
comorbidities, and living at least two months after cancer diagnosis.112  We found no 
relationship between molecular testing and Hispanic ethnicity or marital status and had 
insufficient information on the other factors.  However, our study included few Hispanic 
and API patients, and thus these results should be interpreted with caution.  Patient 
disease factors that were found to be associated with molecular testing, such as younger 
age and adenocarcinoma histology, in this study are reported in metastatic NSCLC 
molecular testing guidelines,103 suggesting that the early adopters of molecular testing 
were likely selecting appropriate patients for testing.  
We found that molecular testing status was predictive of overall survival.  Patients 
who received molecular testing had a 43% reduced risk of death compared to patients 
who did not receive molecular testing.  Patients with molecular testing also had a longer 
median survival compared to patients with no molecular testing (13 vs. 6 months, 
p<0.001).  Many clinical trials have assessed collectively the impact of molecular testing, 





but no population-based studies, to our knowledge, have evaluated the impact of broad 
molecular testing alone on overall survival.  Our results suggest that molecular testing 
alone, may benefit advanced NSCLC patients, presumably due to downstream effects, 
such as treatment with the best available agent for the patient’s tumor molecular profile.  
Alternately, our finding may indicate that patients who have molecular testing are cared 
for by providers with greater knowledge about precision medicine, resulting in higher 
quality care and ultimately longer survival. 
Strengths and limitations  
Perhaps the biggest limitation to this study is the inability specifically identify the 
genes analyzed by the ordered molecular tests.  This study evaluated patients diagnosed 
between 2002 and 2012, at which time the practice of code stacking was the only way for 
physicians to code and bill for molecular testing and EGFR testing was predominant.  
Code stacking is based on method performed, not gene assessed, thus it is impossible for 
us to know which genes were assessed.  Because the patients in this study were diagnosed 
between 2002 and 2012, however, we acknowledge that most patients were likely tested 
for abnormalities in the KRAS and EGFR gene pathways.  Additionally, there is the 
potential for misclassification of molecular testing status.  MT status may have been 
misclassified due to 1) incorrect claim coding, 2) lack of insurance coverage at the time 
of molecular testing, resulting in the claim not being included in our administrative 
claims dataset, 3) molecular testing that was covered as part of a clinical trial, 4) 
molecular testing that was paid by the patient out-of-pocket. 
Our cohort consisted of patients with some form of insurance coverage and thus 





patients with Medicare were excluded from this analysis.  We may observe fewer patients 
with molecular testing in cohorts of patients that have no insurance coverage or 
Medicare, although the latter is likely to be changing as companies that provide 
multigene molecular testing panels obtain local coverage determinations for their 
products.  As these data were obtained from SCCCR and RFA administrative claims, we 
also did not have information on several important variables that may impact molecular 
testing utilization and overall survival, including patient (e.g., socioeconomic status, 
smoking status, performance status and comorbidities) and provider variables (e.g., 
specialty, years since medical school graduation, practice setting).   
Our assessment of both patient and provider geographic location was limited at 
the county level.  Each provider-submitted claim included information on the county in 
which the claim originated.  Only one county in SC is designated as completely rural by 
the rural-urban continuum codes and only two counties were designated as 
nonmetropolitan counties not adjacent to a metropolitan area per United States 
Department of Agriculture rural-urban continuum codes152 (used to define rurality in the 
National Association of Central Cancer Registries). Thus, no molecular testing claims in 
this dataset were submitted in the rural setting.  As such, we assessed the provider 
geographic location variable as “in state” versus “out of state”.  Only 3 molecular tests 
were performed out of state, thus conclusions on the impact of provider geographic 
location must be interpreted with caution.   
While our analyses had some limitations, a strength of the study was the ability to 
provide an early assessment of the factors impacting molecular testing utilization based 





of this study is its ability to assess the impact of molecular testing alone on overall 
survival, an evaluation typically performed in clinical trials and in conjunction with 
molecular test results.  Finally, use of SCCCR and RFA administrative claims data 
allowed us to assess these outcomes across a wide geographic area and with a large 
number of cases.  Approximately one-third of SC’s population is rural.  Few academic 
medical centers and only one National Cancer Institute designated cancer center is 
located in SC, making this assessment of particular importance.  Prior research indicates 
disparities between academic and community-based provider knowledge and 
understanding of molecular testing.101 
Conclusions 
Several disease characteristics were found to be associated with increased 
molecular testing utilization in patients with advanced NSCLC, and molecular testing had 
a positive impact on overall survival. Future research could evaluate more recent data 
using the 2013 revised Tier 1 (gene specific; 81200-81383) and Tier 2 (molecular 
pathology; 81400-81408) codes and could consider various methods of molecular testing 
(e.g., tumor versus liquid biopsies).  Assessment of provider-level variables affecting 
these outcomes, such as geographic location, should be further investigated in national 
datasets, such as the Surveillance, Epidemiology, and End Results-Medicare data.  
Larger, more geographically diverse national datasets will provide more detailed data on 








Tables and Figures 
Table 5.1. Patient, physician, and disease characteristics for the overall population and molecular testing subgroups 
 
  All Patients                    
(N, %) 
Molecular Test - 
Yes                                         
(N, %) 
Molecular Test - No 
 (N, %) 
P value 
  2266 100 44 1.94 2222 98.06 - 
Patient/Provider Characteristics N % N % N  % - 
   Age at Diagnosis (years)             0.002* 
   Mean (SD) 57.4   53.0   57.5     
   Median 57.4   54.5   57.0     
   Range 23.0-90.0   32.0-71.0   23.0-90.0     
   Age at Diagnosis (years)             0.066 
   <52  608 26.8 17 38.6 591 26.6   
   52-57  571 25.2 14 31.8 557 25.1   
   58-62 523 23.1 8 18.2 515 23.2   








   Sex             0.438 
   Male 1372 60.6 24 54.6 1348 60.7   
   Female 894 39.5 20 45.5 874 39.3   
   Race             0.181 
   White 1289 56.9 29 65.9 1260 56.7   
   Black 953 42.1 14 31.8 939 42.3   
   Other 24 1.0 1 2.3 23 1.0   
   Hispanic             0.590 
   Non-Hispanic 2221 98.0 43 97.7 2178 98.0   
   Hispanic 23 1.0 1 2.3 22 1.0   
   Unknown 22 1.0 0 0.0 22 1.0   
   Marital Status             0.120 
   Not married 1203 53.1 23 52.3 1180 53.1   
   Married 690 30.5 18 40.9 672 30.2   
   Unknown 373 16.4 3 6.8 370 16.7   








   State health plan 318 14.0 13 29.6 305 13.7   
   Medicaid 1948 86.0 31 70.4 1917 86.3   
   Patient Metropolitan Status             >0.999 
   Non-metropolitan/rural 549 24.2 10 22.7 539 24.3   
   Metropolitan 1717 75.8 34 77.3 1683 75.7   
   Provider State              0.004* 
   Out of state 551 24.3 3 6.8 548 24.7   
   In state 1715 75.7 41 93.2 1674 75.3   
Disease Characteristics               
   AJCC Stage             0.587 
   IIIB 517 22.8 8 18.1 509 22.9   
   IV 1749 77.2 36 81.82 1713 77.1   
   Grade             0.025* 
   Low 250 11.0 9 20.45 241 10.8   
   High 646 28.5 6 13.64 640 28.8   








   Histology             <.001* 
   Adenocarcinoma 842 37.2 32 72.73 810 36.5   
   Large cell 196 8.7 3 6.82 193 8.7   
   Squamous 524 23.1 1 2.27 523 23.5   
   Mixed or other NSCLC 704 31.0 8 18.18 696 31.3   
   Primary Site             0.385 
   Main bronchus 140 6.2 1 2.27 139 6.3   
   Lobe 1575 69.5 36 81.82 1539 69.3   
   Overlapping lesion 62 2.7 1 2.27 61 2.8   
   Lung and bronchus, NOS 489 21.6 6 13.64 483 21.7   
   Year of Diagnosis             <.0001* 
   Prior to 2010 1619 71.5 6 13.6 1613 72.6   
   2010 or later 647 28.5 38 86.4 609 27.4   
Abbreviations: N, number; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; SD, standard deviation 










Table 5.2. Univariable and multivariable logistic regression results for molecular testing 
 
  Univariable Logistic Regression Multivariable Logistic Regression 
  Unadjusted OR 95% CI P value Adjusted OR 95% CI P value 
Patient/Provider Characteristics             
   Age at Diagnosis (years) 0.95 0.92-0.98 0.002* 0.95 0.91-0.99 0.008* 
   Sex     0.412       
   Male Reference       
   Female 1.29 0.71-2.34         
   Race     0.314       
   White Reference       
   Black 0.65 0.34-1.23         
   Other 1.89 0.25-14.47         
   Hispanic     0.722       
   Non-Hispanic Reference       
   Hispanic 2.30 0.30-17.47         








   Marital Status     0.146       
   Not married Reference       
   Married 1.37 0.74-2.57         
   Unknown 0.416 0.12-1.39         
   Insurance     0.004*       
   State health plan Reference       
   Medicaid 0.38 0.20-0.73         
   Patient Metropolitan Status     0.82       
   Non-metropolitan/rural 0.92 0.45-1.87         
   Metropolitan Reference       
   Provider State     0.013*     0.003* 
   Out of state 0.22 0.07-0.73   0.16 0.05-0.53   
   In state Reference Reference 
Disease Characteristics             
   AJCC Stage     0.461       








   IV 1.34 0.62-2.89         
   Grade     0.034*     0.008* 
   Low Reference Reference 
   High 0.25 0.09-0.71   0.17 0.06-0.53   
   Unknown 0.58 0.27-1.24   0.37 0.16-0.86   
   Histology     <0.001*     0.015* 
   Adenocarcinoma Reference Reference 
   Large cell 0.39 0.12-1.30   0.53 0.15-1.84   
   Squamous 0.05 0.01-0.36   0.06 0.01-0.47   
   Mixed or other NSCLC 0.29 0.13-0.64   0.46 0.21-1.05   
   Primary Site     0.357       
   Main bronchus 0.31 0.04-2.26         
   Lobe Reference       
   Overlapping lesion 0.70 0.10-5.20         
   Lung and bronchus, NOS 0.53 0.22-1.27         








   Prior to 2010 Reference Reference 
   2010 or later 16.77 7.06-39.88   15.60 6.48-37.53   
Abbreviations: CI, confidence interval; N, number; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; OR, odds ratio 
Note:  Only significant variables were included in the final model. 
*Significant at the p≤0.05 level. 
 
Table 5.3. Univariable and multivariable Cox proportional hazards regression for overall survival 
 
  Univariable Cox Proportional  
Hazards Regression 
Multivariable Cox Proportional 
Hazards Regression 
  Unadjusted HR 95% CI P value Adjusted HR 95% CI P value 
Patient/Provider Characteristics             
   Age at Diagnosis (years) 1.01 1.01-1.01 <0.001* 1.01 1.01-1.01 0.004* 
   Sex     0.091       
   Male Reference Reference 
   Female 0.93 0.85-1.01         
   Race     0.548       
   White Reference Reference 
   Black 0.96 0.88-1.04         








   Hispanic     0.167       
   Non-Hispanic Reference Reference 
   Hispanic 0.73 0.46-1.16         
   Unknown 1.34 0.87-2.06         
   Marital Status     0.124       
   Not married Reference       
   Married 0.90 0.82-1.00         
   Unknown 0.96 0.85-1.09         
   Insurance     0.003*     <0.001* 
   State health plan Reference Reference 
   Medicaid 1.21 1.07-1.37   1.37 1.21-1.56   
   Patient Metropolitan Status     0.922       
   Non-metropolitan/rural 1.01 0.91-1.11         
   Metropolitan Reference       
   Physician State     <0.001*     <0.001* 








   In state Reference Reference 
Disease and Molecular Testing 
Characteristics 
      
      
   AJCC Stage     <0.001*     <0.001* 
   IIIB Reference Reference 
   IV 1.76 1.58-1.95   1.83 1.64-2.04   
   Grade     0.002*       
   Low Reference       
   High 1.29 1.10-1.51         
   Unknown 1.29 1.12-1.49         
   Histology     0.001*     0.034* 
   Adenocarcinoma Reference Reference 
   Large cell 1.16 0.99-1.36   1.09 0.92-1.28   
   Squamous 1.08 0.97-1.21   1.12 1.00-1.26   
   Mixed or other NSCLC 1.23 1.11-1.36   1.17 1.05-1.30   








   Main bronchus 1.20 1.01-1.44   1.21 1.01-1.45   
   Lobe Reference Reference 
   Overlapping lesion 1.30 1.00-1.68   1.30 1.00-1.68   
   Lung and bronchus, NOS 1.33 1.20-1.48   1.25 1.12-1.39   
   Year of Diagnosis     0.005*     0.027* 
   Prior to 2010 Reference Reference 
   2010 or later 0.87 0.79-0.96   0.89 0.81-0.99   
   Molecular Testing     <0.001*     0.002* 
   Yes 0.53 0.37-0.75   0.57 0.40-0.81   
   No Reference Reference 
Abbreviations: CI, confidence interval; HR, hazards ratio; N, number; NOS, not otherwise specified; NSCLC, non-small cell lung 
cancer 















Table 5.4. Comparison of adjustment methods estimating the impact of molecular testing on overall survival 
 
  Comparison of Adjusted Cox Proportional  
Hazards Regression Methods 
Method Adjusted HR 95% CI P value 
Cox PH model 0.57 0.40-0.81 0.002* 
Propensity score, parsimonious 0.54 0.38-0.78 0.001* 
Propensity score, non-
parsimonious 0.54 0.38-0.78 0.001* 
Abbreviations: CI, confidence interval; HR, hazards ratio; PH, proportional hazards 























SCCCR cases with SHP or Medicaid coverage 
(SHP=341, Medicaid=3,501) 
 








Remaining SCCCR cases 
(n=3,744) 
 
Medical procedure claims for SCCCR cases 
(SHP=115,087, Medicaid=352,745) 
 




Excluded procedure claims missing 
physician metropolitan status 
(n=16,559) 
Remaining procedure claims 
(n=463,856) 
 
Remaining procedure claims 
(n=447,297) 
 
Reduced to one procedure claim per case 
(n=2,317) 
 
Final cases eligible for analyses 
(n=2,266) 
 
Excluded cases not included in both SCCCR 





Abbreviations:  NSCLC, non-small cell lung cancer; SCCCR, South Carolina Central 
Cancer Registry; SHP, State Health Plan 
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Introduction:  Epidermal growth factor receptor (EGFR)-directed therapies are approved 
for selected patients with non-small cell lung cancer (NSCLC); however, little 
information on predictors of utilization and efficacy in the population-based setting has 
been reported.  We aimed to identify predictors of early erlotinib prescribing and evaluate 
the impact of erlotinib on survival in patients diagnosed with stage IIIB/IV NSCLC 
residing in South Carolina (SC). 
Methods: SC Central Cancer Registry cases diagnosed between January 1, 2002 and 
December 31, 2012 were linked to SC State Employee Health Plan (SCSEHP) and 
Medicaid administrative claims data.  Logistic regression (LR) was used to identify 
predictors of erlotinib utilization.  Kaplan-Meier methods were used to estimate survival 
distributions and log-rank tests compared the survival distributions between erlotinib 
groups. Cox proportional hazards (PH) modeling was used to assess the impact of patient 
demographic, disease, and treatment characteristics on survival, while adjusting for other 
prognostic covariates. Multivariable LR models were used to estimate propensity scores, 
which were then used as covariates in adjusted Cox PH models.   
Results: A total of 1,623 patients were eligible.  Independent predictive factors for having 
at least one erlotinib claim, included younger age at diagnosis (p=.004), female sex 
(p=.048), SCSEHP (p<.001), out-of-state providers (p<.001), adenocarcinoma histology 
(p<.001), and having molecular testing (p=.018).  Overall survival (OS) was longer for 
patients who received erlotinib (median OS=14 versus 7 months, p<0.001).  After 




reduced risk of death compared to patients with no erlotinib (HR=0.65, 95% CI: 0.56-
0.75, p<.001). 
Conclusions:  Several factors were associated with erlotinib utilization and disparities in 
access may exist.  Erlotinib utilization was associated with a reduced risk of death in 
patients with NSCLC in SC. 
Introduction  
Lung cancer is the leading cause of cancer-related death in the United States and 
in South Carolina.1,145  In 2017, approximately 4,320 new lung cancer cases will be 
diagnosed and 2,920 lung cancer deaths will occur.1  Most lung cancer patients are 
diagnosed with advanced disease and the overall 5-year survival rate is 18%.1  Until 
recently, patients with advanced, non-small cell lung cancer have mostly been treated 
with platinum-based chemotherapy doublets or pemetrexed.  None of these systemic 
regimens have demonstrated significant improvement in long-term response or 
survival.4,146 
Recently, advances in the genomic profiling (or molecular testing) of tumors have 
identified multiple alterations in lung tumors that can be targets for treatment, providing 
personalized targeted and immunotherapy options for patients with specific molecular 
abnormalities.  For example, epidermal growth factor receptor (EGFR) is a cell surface 
receptor that is activated either by protein overexpression, increased gene copy number or 
genetic mutation.  EGFR is involved with cell proliferation, suppression of apoptosis (cell 
death), cell motility, invasion and angiogenesis (formation of new blood vessels).20,25   
Patients whose tumors harbor EGFR mutations can be treated with one of several EGFR 




have demonstrated increased tumor response rates and median progression-free survival 
and decreased toxicity in clinical trial patients.6,7,9,10,121,153  Prior to Food and Drug 
Administration (FDA) approval, clinical investigators and treating physicians identified 
several patient characteristics that appeared to be associated with response and therefore 
would benefit patients receiving EGFR TKI therapy. As reported at annual oncology 
meetings and in early publications, these characteristics included female sex, Asian race, 
adenocarcinoma histology, and never-smoking history.92,94,122,154-156  
In 2003, gefitinib was the first EGFR TKI to gain FDA accelerated approval for 
use as monotherapy in patients with advanced non-small cell lung cancer after failure of 
platinum-based and docetaxel regimens.157  Just two years later, in 2005, gefitinib was 
restricted to use in patients currently or previously benefiting from gefitinib and/or 
patients participating in clinical trials on the basis of failure to show improvement in 
outcomes.158,159  
Around the same time (2004), the FDA approved erlotinib for use in patients in 
the similar, unselected patient population and erlotinib eventually gained approval in the 
maintenance setting (i.e., following stable or response after 4-6 cycles of first-line 
platinum-based chemotherapy) in 2010.  ‘Unselected’ means the use of the drug is not 
informed by a patient’s EGFR mutation status.  In 2013, the FDA revised the indication 
to restrict erlotinib use to a selected patient population, making it available in the first-
line setting for patients with metastatic NSCLC whose tumors harbored selected EGFR 
mutations (exon 19 deletion or exon 21 L858R mutated).  Erlotinib remained an option 
for second-line therapy and beyond in the unselected population.  While progression-free 




positive with regards to response, only small increases in overall survival (1-2 months) 
have been observed in the unselected population.11,29,132  Additionally, in a recent study 
by Enewold and Thomas using population-based data, no association between erlotinib 
and survival was reported.112   
Treatment of metastatic NSCLC continues to evolve at a rapid pace.  Little 
research has evaluated erlotinib in patients with NSCLC outside of the clinical trial 
setting.112,114  The purpose of this study was to determine factors associated with whether 
or not a patient received the EGFR TKI targeted therapy, erlotinib, among patients with 
advanced NSCLC residing in South Carolina and to determine if erlotinib use improved 
overall survival in the population-based setting. 
Methods  
Study Design, Data Source, and Cohort Selection 
We linked outpatient drug and procedure claims data from the South Carolina 
(SC) Revenue and Fiscal Affairs (RFA) administrative claims to eligible cases in the 
South Carolina Central Cancer Registry (SCCCR) to retrospectively evaluate erlotinib 
utilization and overall survival. Eligible cases were those included in the SCCCR 
diagnosed with stage IIIB/IV lung cancer between January 1, 2002 and December 31, 
2012, were enrolled in South Carolina State Employee Health Plan (SCSEHP) or SC 
Medicaid during the study period, and had at least one procedure and one drug claim.  
Patients with dual insurance coverage, HMO coverage, Medicare as the primary payer, 







Erlotinib utilization was determined using National Drug Codes (NDC) from drug 
administrative claims.  Patients with at least one claim for erlotinib, using one of the 
following NDC codes, were classified as “yes”:  '54868-5447-0’, ‘54868-5474-0', '69189-
0063-1', ‘50242-062-01’, ‘50242-063-01’, ‘50242-064-01’, or ‘54868-5290-0’.  Erlotinib 
claims were for any line of therapy.  Patients with all other NDC codes were classified as 
not utilizing erlotinib.  We assume that having at least one claim for erlotinib resulted in 
utilization of the drug.  Overall survival was calculated from the date of primary lung 
cancer diagnosis to the date of death for deceased cases.  Surviving cases were censored 
at the date of last follow-up or December 31, 2014. 
Covariates 
Patient and provider demographics 
Sex was categorized as male or female.  Age at diagnosis was evaluated as both a 
continuous and as a categorical variable (<52, 52-57, 58-62, 63+ years).  Race was 
categorized as White, Black, or other.  Hispanic ethnicity was categorized as Hispanic, 
non-Hispanic, or unknown. Marital status was categorized as married, not married, or 
unknown. Patient metropolitan status was derived using rural-urban continuum codes 
assigned to each patient’s county and were ultimately dichotomized as non-metropolitan 
versus metropolitan.152  Non-metropolitan included rural counties.   
Data on provider geographic location was not available for the drug claims, thus 
we used provider geographic location for molecular testing (obtained through procedure 
claims) as a proxy for drug claim provider geographic location.  Procedure claims 




claim submitted. All providers with procedure claims submitted in a SC county were 
categorized as ‘in state’, while providers with procedure claims submitted outside of SC 
were categorized as ‘out of state’.   
Patient disease 
Cases with the following ICD-0-3 codes were included in this study: 
adenocarcinoma (8140, 8250, 8252, 8253, 8255, 8260, 8480, 8481), large cell (8012), 
squamous (8070, 8071), and mixed or other NSCLC (8000, 8010, 8046, 8560).  Small 
cell lung cancer cases were excluded. Stage was limited to advanced stage and was 
categorized according to American Joint Committee on Cancer (AJCC) staging criteria as 
stage IIIB or IV.  Grade was categorized as low (grade 1 or 2), high (grade 3 or 4) or 
unknown. Primary site was defined as main bronchus (including carina, hilum, bronchus 
intermedius; C340), lobe (including upper lobe, lingual, apex, and pancoast tumors, 
C341; middle lobe, C342; lower lobe and base, C343), overlapping lesion of lung (C348), 
and lung or bronchus, not otherwise specified (NOS; C349).  Year of diagnosis was 
defined as prior to 2010 and 2010 or later.  2010 was selected as the cutoff year as this 
was the first year that erlotinib was approved as maintenance treatment for patients with 
locally advanced or metastatic NSCLC whose disease had not progressed after four 
cycles of first-line platinum-based chemotherapy regimen (or in other words, available in 
the first line setting).  Additionally, 2010 was just prior to the publication of many lung 
cancer guidelines supporting the use of molecular testing and targeted therapy 
approaches.103-105,108,150 Molecular testing was determined using Common Procedure 




testing method codes (83890-83914) were categorized as ‘yes’.  These include both 
EGFR specific and multigene testing. 
Statistical Analysis 
Patient demographic and disease characteristics were summarized for the overall 
cohort and by erlotinib use. Age was summarized as a continuous and a categorical 
variable. Frequencies and percentages were reported for all other variables. Comparisons 
between erlotinib groups were performed using chi-square tests for categorical variables 
and a two-sample t-tests for age.    
Univariable and multivariable logistic regression was used to evaluate the impact 
of patient and provider characteristics on erlotinib utilization.  Factors included in the 
final multivariable model were identified using backwards elimination followed by 
forward selection modeling procedures to confirm variables identified using backward 
elimination.  All variables significant at the p<.05 level were retained in the final model.  
Odds ratios (OR), corresponding 95% confidence intervals (CI) and p-values were 
estimated.   
Kaplan–Meier techniques were used to estimate survival distributions and log-
rank tests compared the distributions between the erlotinib groups.  Univariable Cox 
proportional hazards regression was used to identify individual prognostic factors 
predictive of overall survival.  Multivariable Cox proportional hazards regression was 
used to evaluate the independent impact of the covariates and erlotinib use on overall 
survival.  Hazard ratios (HR) and corresponding 95% CIs were estimated.  
Propensity scores were estimated to reduce potential biases associated with 




models. Two logistic regression models were estimated to calculate the predicted 
probability of erlotinib use (non-parsimonious and parsimonious). The non-parsimonious 
model included all 13 available covariates and the parsimonious model included only 
covariates found to be significant in our final multivariable logistic regression model. 
Individual propensity scores (weighted probabilities) were calculated based on predicted 
probabilities from the logistic regression models. Patients who received erlotinib were 
weighted by the inverse of the probability for getting erlotinib, while patients who did not 
have molecular testing were weighted by the inverse of the probability for not getting 
erlotinib.  The propensity score was then used as a covariate in the Cox proportional 
hazards regression models to estimate the adjusted effect of erlotinib utilization on 
survival.  We then compared the propensity score-adjusted Cox proportional hazards 
regression models to traditional multivariable models.  The results of the two propensity 
score-adjusted models were then compared to the model based on independent patient 
and provider prognostic factors. 
 All hypothesis testing was 2-sided with a p<0.05 level of statistical significance.  
The SAS statistical package V9.4 was used for data analyses (SAS Inc., Cary NC). 
Results 
A total of 1,623 cases met eligibility criteria and had at least one claim in both the 
procedures and drug claims datasets.  54,897 Medicaid and 19,533 SHP drug claims were 
used to categorize erlotinib use.  18.4% of patients were members of the SCCEHP, while 
81.6% were enrolled in SC Medicaid.  Of all eligible cases, 14.0% had at least one claim 




lung cancer registry case and corresponding procedure and drug claims inclusion and 
exclusion criteria.   
Patient and provider demographics 
For the overall cohort, mean age at diagnosis was 56.8 years (Median=57, Range: 
23-90).  A higher proportion of patients were male, White, and non-Hispanic (58.9%, 
58.1%, and 98.3%, respectively).  About half of the patients were not married (51.0%) 
and the majority had Medicaid insurance (81.6%).  Most patients lived in metropolitan 
areas at the time of diagnosis (75.4%).  Provider state was most often in-state (70.0%).  
Marital status, insurance, and provider state differed significantly by erlotinib status 
(p=0.004, p<0.001, and p=0.0345, respectively).  The rate of erlotinib utilization was 
higher for patients who were married, had SCSEHP coverage, and had at least one 
encounter with an out-of-state provider. 
Patient disease characteristics 
Most patients were stage IV at the time of diagnosis (75.9%).  Adenocarcinoma 
histology was most frequent (37.4%) followed by mixed or other NSCLC (29.8%), 
squamous (24.0%) and large cell (8.8%).  The majority of tumors were located in a lung 
lobe (71.2%).  Only 2.5% of patients received any molecular testing.  Histology (p<.001) 
and molecular testing (p=.002) varied significantly by erlotinib status, with a higher 
proportion of adenocarcinomas and patients with a molecular testing claim received 
erlotinib (55.1% and 5.7%, respectively).   
Predictors of erlotinib utilization  
Results from univariable analyses are presented in Table 6.2.  Individual 




marital status (p=.004), insurance (p<.001), provider state (p=.031), histology (p<.001), 
and molecular testing (p=.001).   
In the adjusted logistic regression models, most variables remained significant 
predictors of erlotinib use, with the exception of marital status (p=0.322; Table 6.2).  For 
each increasing decade, the odds of erlotinib utilization were reduced by 30%, (OR=0.97, 
95% CI: 0.96-0.99, p=.004).  Patients with Medicaid and non-adenocarcinoma histologies 
also had reduced odds of receiving erlotinib compared to patients with SCSEHP 
(OR=0.29, 95% CI: 0.20-0.42, p<.001) and adenocarcinoma histologies (mixed/other 
NSCLC OR=0.64, 95% CI: 0.46-0.91, squamous OR=0.36, 95% CI: 0.29-0.68, large cell 
OR=0.28, 95% CI: 0.13-0.60, p<.001).  Patients with at least one claim submitted by an 
out-of-state provider were over two times more likely to receive erlotinib compared to 
patients with only in-state claims (OR=2.03, 95% CI: 1.43-2.89, p<0.001).  Lastly, 
female patients and patients with molecular testing were more likely to receive erlotinib 
compared to males and patients without molecular testing (OR=1.35, 95%CI: 1.00-1.81, 
p=0.048 and OR=2.37, 95% CI: 1.16-4.85, p=0.018, respectively).   
Erlotinib and overall survival 
Overall survival for patients with erlotinib claims was longer than for patients 
with no erlotinib claims (median OS=14 versus 7 months, p<0.001; Figure 6.2).  The 
censoring rate was slightly higher in the erlotinib group (10.13%) compared to the no 
erlotinib group (9.31%). 
Seven covariates were found to be predictors of overall survival.  Univariable 




included age at diagnosis (p<.001), provider state (p<.001), stage (p<.001), grade 
(p=.005), primary site (p=.001), molecular testing (p=.005), and erlotinib use (p<.001).   
Age at diagnosis, provider state, stage, primary site, year of diagnosis, molecular 
testing, and erlotinib use all remained significant predictors of overall survival in the 
multivariable analysis (Table 6.3).  Grade no longer remained significant (p=0.126), 
however, year of diagnosis was a significant predictor of overall survival in the 
multivariable model.  A 10% increase in the risk of death was observed for each 
additional decade of life (HR=1.01, 95% CI: 1.00-1.01, p<.007).  Patients with at least 
one claim submitted by an out-of-state provider had a 24% reduced risk of death 
compared to patients with only in-state claims (HR=0.76, 95% CI: 0.68-0.85, p<.001).  
As expected, patients diagnosed with stage IV disease had an increased risk of death 
compared to those diagnosed with stage IIIB (HR=1.96, 95% CI: 1.73-2.23, p<.001). 
Patients with a primary site of disease outside the lung lobe (main bronchus, overlapping 
lesions, and lung/bronchus NOS) also saw an increased risk of death compared to patients 
with a primary site of lung lobe (HR=1.20, 95% CI: 0.96-1.48, HR=1.36, 95% CI: 1.02-
1.84, OR=1.18, 95% CI: 1.04-1.35, p=.010, respectively).  Patients diagnosed prior to 
2010 had a reduced risk of death compared to patients diagnosed in 2010 or later 
(HR=0.87, 95% CI: 0.77-0.98, p=.020). 
The risk of death for patients with molecular testing and for patients with erlotinib 
claims did not largely change from the univariable model.  Reduced risk of death was still 
observed for those with molecular testing and erlotinib claims.  The adjusted results 
showed patients with molecular testing had 35% reduced risk of death compared to 




at least one erlotinib claim also had a 35% reduced risk of death compared to patients 
with no erlotinib claims (HR=0.65, 95% CI: 0.56-0.75, p<.001). 
Propensity score adjusted hazards 
Propensity scores were calculated using multivariable logistic regression to 
estimate the propensity for erlotinib given a set of covariates.  Using weighted propensity 
scores (inverse probability of treatment weights; IPTW) as a method of adjustment 
increased the reduction in the risk of death in both scenarios.  For the non-parsimonious 
(all available covariates) and parsimonious models (variables deemed significant using 
multivariable logistic regression), the risk of death was reduced by 41% and 43%, 
respectively (HR=0.59, 95% CI: 0.48-0.73, p<0.001; HR=0.57, 95% CI: 0.46-0.71, 
p<0.001), which was generally consistent with the adjusted results from the individual 
covariate model (Table 6.4). 
Discussion 
Treatment for advanced stage, NSCLC is rapidly evolving.  Targeted therapies 
have delivered on increasing survival and decreasing toxicity in patients who otherwise 
would have been treated with platinum-based chemotherapies.  Our study assessed 
predictors of targeted therapy (erlotinib) utilization and overall survival in a population-
based setting during the time period when erlotinib was only approved for use in 
unselected patients with locally advanced or metastatic NSCLC.  We found several 
factors associated with increased odds of receiving any line erlotinib treatment, including 
female sex, having at least one procedure claim submitted by an out of state provider, and 
having any molecular testing.  Our findings that females were more likely to receive 




EGFR-specific molecular testing in 2012-2014 using MarketScan data, published by 
Shen et al.113  These data also support the early clinical observations that responses to 
drugs, such as erlotinib, were more likely in specific patient demographic cohorts, 
including that of females.   
The current study found a low rate of molecular testing overall (2.5%).  While 
erlotinib did not receive a FDA indication for use exclusively in patients with EGFR 
mutated tumors until 2013, the link between EGFR mutation and benefit of drugs such as 
erlotinib and gefitinib was described as early as 2004.92,94 Additionally, there were early 
discussions of the clinical characteristics of patients more likely to benefit from EGFR 
therapy even before the EGFR mutation relationship was confirmed.  Thus, early 
prescribers of erlotinib were likely aware of the rapidly evolving scientific literature 
surrounding this class of drugs. 
We found that patients were more likely to have treatment with erlotinib if they 
had at least one procedure claim submitted by an out-of-state provider, however, this 
result should be interpreted with caution for several reasons.  First, we used a proxy 
variable for provider state based on molecular testing procedure claims.  We presumed 
that if a patient travelled outside SC for molecular testing, they likely travelled outside 
SC to receive treatment. Additionally, evaluation of molecular testing procedure claims 
identified only three patients with molecular testing claims from an out-of-state provider, 
thus, this result is based on very small numbers.  Shen et al reported that geographic 
region may influence EGFR testing, with patients diagnosed in the Western United States 




We also reported several factors associated with decreased odds of having at least 
one erlotinib claim including increasing age, Medicaid insurance, and non-
adenocarcinoma histology.  We found an approximately 26% decreased risk of receiving 
erlotinib for each decade of life.  Our result was similar to the inverse association 
(although non-significant) between age and erlotinib observed in a recent study.112  
Younger patients may be more likely to be prescribed erlotinib for several reasons.  They 
may be more suitable for therapy overall and thus more likely to receive multiple lines of 
therapy, increasing the likelihood of receiving erlotinib in the second-line setting and 
beyond. Younger patients may also be more motivated to research and explore cutting-
edge, novel therapies on their own and bring discussion of these options to their 
physicians.  Also, for working younger patients, an oral therapy, such as erlotinib, may be 
more accommodating to their lifestyles than an IV chemotherapy regimen.  Our result 
that patients with non-adenocarcinoma history are less likely to be prescribed erlotinib is 
similar to the Enewold and Thomas study and is likely to reflect the early use of clinical 
characteristics in selection of appropriate patients by oncologists.  Enewold and Thomas 
also found patients with Medicaid coverage  less likely to receive erlotinib,112 similar to 
our results.   Patients with Medicaid in our study were about 70% less likely to be 
prescribed erlotinib compared to patients enrolled on SCSEHP.  Patients with SCSEHP 
coverage are likely to be higher SES, compared to Medicaid patients, and may be more 
likely to have the resources to cover off-label copays.  Additionally, SCSEHP plans may 
have been more accommodating of off-label drug use requests. 
 Our results show a reduced risk of death for patients who received erlotinib and 




were treated with erlotinib had a 7-month increase in median OS compared to patients 
with no erlotinib claims.  This study evaluated erlotinib use early in its approval history.  
Patients who received erlotinib early on may have received this drug as part of a clinical 
trial, which may explain the similar survival length for patients in this study and patients 
in unselected clinical trials.128,129,132 
Limitations and Strengths 
While we had information on some of the demographic and clinical 
characteristics associated with increased response to erlotinib, which may impact 
likelihood of erlotinib prescribing, we were lacking information on other important 
characteristics identified through previous research, including never smoking status and 
Asian race.92,94,160  We were also unable to assess line of therapy (e.g., first, subsequent) 
in which erlotinib was administered.  Additionally, we did not have information on the 
provider geographic location for which the erlotinib claim was submitted and used 
provider location for molecular testing as a proxy variable.   
One strength of this study is that it included patients documented in a state-wide 
cancer registry.  This sample allowed us to evaluate predictors of erlotinib and its impact 
on survival in a diverse group of cancer patients coming from a variety of different 
treatment centers (e.g., academic, community-based).  Additionally, this is the first study 
to our knowledge to use IPTW propensity scores as an adjustment method for controlling 
for baseline covariates in analyses of erlotinib survival.  We found this method to result 
in a similar, although slightly reduced, risk of death compared to other adjustment 
methods where individual covariates were included in the model.  Correcting imbalance 




as covariates appears to be a useful strategy for adjustment in samples of diverse cancer 
registry patients. 
Conclusions 
Development, approval, and clinical use of targeted and immuno therapies is 
rapidly changing the treatment of patients with NSCLC.  Despite education attempts, the 
adoption of molecular testing and precision medicine utilization are low in South 
Carolina.  Reasons for this include the high costs of molecular tests that are needed to 
guide therapy decisions and the complexity of interpreting molecular reports.  As 
precision medicine becomes an increasingly major component of lung cancer diagnosis 
and treatment, providers must find ways to keep abreast of evolving scientific literature 
and new molecular discoveries.  The use of clinical decision support tools and 
involvement on molecular tumor boards is encouraged.  
This study identified several non-clinical disparities in utilization of erlotinib, 
including insurance type, that should be further examined.  Additionally, we found a 
reduced risk of death for patients treated with erlotinib.  Future research could explore the 
impact erlotinib on survival in among patients with and without EGFR mutation in the 












Tables and Figures 
 
Table 6.1. Patient, physician, and disease characteristics for the overall population and erlotinib subgroups 
 
  All Patients                    
(N, %) 
Erlotinib                                              
(N, %) 
No Erlotinib                 
(N, %) 
P-value 
  1623 100 227 13.99 1396 86.01 - 
Patient/Physician Characteristics N % N % N  % - 
   Age at Diagnosis (years)             0.001* 
   Mean (SD) 56.8   54.9   57.1     
   Median 57.0   56.0   57.0     
   Range 23-90   30-80   23-90     
   Age at Diagnosis (years)             0.008*  
   <52  452 27.9 71 31.3 381 27.3  
   52-57  420 25.9 70 30.8 350 25.1   
   58-62 385 23.7 53 23.4 332 23.8   
   63+ 366 22.6 33 14.5 333 23.9   







   Male 956 58.9 116 51.1 840 60.2  
   Female 667 41.1 111 49.0 556 39.8   
   Race             0.701  
   White 943 58.1 135 59.7 808 57.9  
   Black 663 40.9 89 39.2 574 41.1   
   Other 17 1.1 3 1.3 14 1.0   
   Hispanic             0.497  
   Non-Hispanic 1596 98.3 222 97.8 1374 98.4  
   Hispanic 12 0.7 3 1.3 9 0.6   
   Unknown 15 1.0 2 0.9 13 0.9   
   Marital Status             0.004*  
   Not married 827 51.0 97 42.7 730 52.3  
   Married 531 32.7 96 42.3 435 31.2   
   Unknown 265 16.3 34 15.0 230 16.6   
   Insurance             <0.001*  







   Medicaid 1324 81.6 153 67.4 1171 83.9   
   Patient Metropolitan Status             0.361  
   Non-metropolitan 400 24.7 50 22.0 350 25.1  
   Metropolitan 1223 75.3 177 78.0 1046 74.9   
   Provider State             0.035*  
   Out of state 487 30.0 82 36.1 405 29.0  
   In state 1136 70.0 145 63.9 991 71.0   
Disease Characteristics               
   AJCC Stage             0.210  
   IIIB 391 24.1 47 20.7 344 24.6  
   IV 1232 75.9 180 79.3 1052 75.4   
   Grade             0.357  
   Low 194 12.0 27 11.9 167 12.0  
   High 463 28.5 56 24.7 407 29.2   
   Unknown 966 59.5 144 63.4 822 58.9   







   Adenocarcinoma 607 37.4 125 55.1 482 34.5  
   Large cell 143 8.8 8 3.5 135 9.7   
   Squamous 389 24.0 33 14.5 356 25.5   
   Mixed or other NSCLC 484 29.8 61 26.9 423 30.3   
   Primary Site              0.969 
   Main bronchus 96 5.9 12 5.3 84 6.0  
   Lobe 1155 71.1 164 72.3 991 71.0   
   Overlapping lesion 48 3.0 7 3.1 41 2.9   
   Lung and bronchus, NOS 324 20.0 44 19.4 280 20.1   
   Year of Diagnosis             0.753  
   Prior to 2010 1152 71.0 159 70.0 993 71.1  
   2010 or later 471 29.0 68 30.0 403 28.9   
   Molecular Testing              0.002* 
   No 1583 97.5 214 94.3 1369 98.1  
   Yes 40 2.5 13 5.7 27 1.9   
Abbreviations: N, number; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; SD, standard deviation 








Table 6.2. Univariable and multivariable logistic regression results for receiving erlotinib 
 
  Univariable Logistic Regression Multivariable Logistic Regression 
  Unadjusted OR 95% CI P-value Adjusted OR 95% CI P-value 
Patient/Physician Characteristics             
   Age at Diagnosis (years) 0.97 0.96-0.99 0.001* 0.97 0.96-0.99 0.004* 
   Sex     0.010*     0.048* 
   Male Reference Reference 
   Female 1.45 1.09-1.92   1.35 1.00-1.81   
   Race     0.779       
   White Reference       
   Black 0.93 0.70-1.24         
   Other 1.28 0.36-4.52         
   Hispanic     0.557       
   Non-Hispanic Reference       







   Unknown 0.95 0.21-4.25         
   Marital Status     0.004*       
   Not married Reference       
   Married 1.66 1.22-2.26         
   Unknown 1.11 0.73-1.68         
   Insurance     <0.001*     <0.001* 
   State health plan Reference Reference 
   Medicaid 0.40 0.29-0.54   0.29 0.20-0.42   
   Patient Metropolitan Status     0.324       
   Non-metropolitan 0.84 0.60-1.18         
   Metropolitan Reference       
   Provider State     0.031*     <0.001* 
   Out of state 1.38 1.03-1.86   2.03 1.43-2.89   
   In state Reference Reference 
Disease Characteristics             







   IIIB Reference       
   IV 1.25 0.89-1.77         
   Grade     0.359       
   Low Reference       
   High 0.85 0.52-1.39         
   Unknown 1.08 0.69-1.69         
   Histology     <0.001*     <0.001* 
   Adenocarcinoma Reference Reference 
   Large cell 0.23 0.11-0.48   0.28 0.13-0.60   
   Squamous 0.36 0.24-0.54   0.44 0.29-0.68   
   Mixed or other NSCLC 0.56 0.40-0.78   0.64 0.46-0.91   
   Primary Site     0.964       
   Main bronchus 0.86 0.46-1.62         
   Lobe Reference       
   Overlapping lesion 1.03 0.46-2.34         







   Year of Diagnosis     0.738       
   Prior to 2010 Reference       
   2010 or later 1.05 0.78-1.43         
   Molecular     0.001*     0.018* 
   No Reference Reference 
   Yes 3.08 1.57-6.06   2.37 1.16-4.85   
Abbreviations: CI, confidence interval; N, number; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; OR, odds ratio 
*Significant at the p≤0.05 level. 
 
 
Table 6.3. Univariable and multivariable Cox proportional hazards regression for overall survival 
  Univariable Cox Proportional Hazards 
Regression 
Multivariable Cox Proportional 
Hazards Regression 
  Unadjusted HR 95% CI P-value Adjusted HR 95% CI P-value 
Patient/Physician Characteristics             
   Age at Diagnosis (years) 1.01 1.01-1.02 <0.001* 1.01 1.00-1.01 0.007* 
   Sex     0.080       







   Female 0.91 0.82-1.01         
   Race     0.768       
   White Reference       
   Black 0.96 0.87-1.07         
   Other 0.97 0.59-1.59         
   Hispanic     0.370       
   Non-Hispanic Reference       
   Hispanic 0.67 0.35-1.28         
   Unknown 1.21 0.71-2.05         
   Marital Status     0.914       
   Not married Reference       
   Married 0.98 0.87-1.10         
   Unknown 1.01 0.87-1.16         
   Insurance     0.547       
   State health plan Reference       







   Patient Metropolitan Status     0.902       
   Non-metropolitan 0.99 0.88-1.12         
   Metropolitan Reference       
   Provider State     <0.001*     <0.001* 
   Out of state 0.74 0.66-0.83   0.76 0.68-0.85   
   In state Reference Reference 
Disease/Treatment Characteristics             
   AJCC Stage     <0.001*     <0.001* 
   IIIB Reference Reference 
   IV 1.82 1.60-2.06   1.96 1.73-2.23   
   Grade     0.005*       
   Low Reference       
   High 1.28 1.07-1.54         
   Unknown 1.31 1.11-1.55         
   Histology     0.074       







   Large cell 1.20 0.99-1.45         
   Squamous 1.13 0.99-1.29         
   Mixed or other NSCLC 1.15 1.02-1.31         
   Primary Site     0.001*     0.010* 
   Main bronchus 1.19 0.96-1.48   1.20 0.97-1.49   
   Lobe Reference Reference 
   Overlapping lesion 1.38 1.02-1.85   1.37 1.02-1.82   
   Lung and bronchus, NOS 1.25 1.10-1.42   1.18 1.04-1.35   
   Year of Diagnosis     0.078     0.020* 
   Prior to 2010 Reference Reference 
   2010 or later 0.90 0.80-1.01   0.87 0.77-0.98   
   Molecular     0.005*     0.024* 
   No Reference Reference 
   Yes 0.59 0.41-0.85   0.65 0.45-0.95   
   Erlotinib     <0.001*     <0.001* 







   Yes 0.68 0.59-0.79   0.65 0.56-0.75   
Abbreviations: CI, confidence interval; HR, hazards ratio; N, number; NOS, not otherwise specified; NSCLC, non-small cell lung 
cancer 
*Significant at the p≤0.05 level. 
 
Table 6.4. Comparison of adjustment methods for estimating the impact of erlotinib utilization on overall survival 
 
  Comparison of Adjusted Cox Proportional Hazards 
Regression Methods  
Method Adjusted HR 95% CI P-value 
Cox PH model, individual 
covariates 
0.65 0.56-0.75 <0.001* 
Propensity score,  
parsimonious 
0.57 0.46-0.71 <0.001* 
Propensity score,  
non-parsimonious 
0.59 0.48-0.73 <0.001* 
Abbreviations: CI, confidence interval; HR, hazards ratio; PH, proportional hazards 





Abbreviations:  NSCLC, non-small cell lung cancer; SCCCR, South Ca160rolina Central 
Cancer Registry; SHP, State Health Plan 
 








Figure 6.2. Overall survival for all non-small cell lung cancer patients, stratified by 
















This dissertation focused on two approaches to improving outcomes for patients 
with lung cancer --- early diagnosis through screening with low-dose computed 
tomography and utilization of precision medicine.  The latter included two topics of 
interest, molecular testing and targeted therapies, specifically administration of erlotinib.   
Lung cancer screening with annual LDCT reduces all cause and lung cancer 
mortality and is recommended by leading public health agencies.  However, national 
rates of LDCT utilization remain low and this impedes early diagnosis of lung cancer.    
Family physicians reported feeling responsible for lung cancer screening discussions and 
LDCT follow-up.  While the majority of family physicians interviewed reported making 
at least one LDCT referral, they acknowledged that their knowledge of lung cancer 
screening is suboptimal.  To ensure that patients are receiving the appropriate information 
regarding the risks and benefits of lung cancer screening and are engaged in the decision-
making process, educational outreach initiatives highlighting the importance of lung 
cancer screening using LDCT in high risk patients, as well as the risks and benefits of 
LDCT, are warranted.  Additionally, education outlining the process for making a LDCT 
referral and billing for both the lung cancer screening counseling visit and LDCT is 




copay estimators, and to make LDCT referrals (e.g., easy to use electronic order forms) 
are likely to increase utilization of lung cancer screening in the primary care setting. 
Along with early detention, new precision medicine tools are available to help 
providers guide treatment decisions for patients with advanced lung cancer.  Tumor 
molecular testing was low in South Carolina (~2%), as was erlotinib utilization (~14%), 
but patients who received these had a 7 month increase in survival over patients who did 
not receive molecular testing or erlotinib.  Educational efforts should be targeted towards 
oncologists and oncology advanced care practioners and should focus on demonstrating 
the importance of molecular testing to provide the information needed to select the most 
appropriate treatment option.  Additionally, institutional efforts to support oncologists, 
such as molecular tumor boards, care pathways, and electronically accessible order 
forms, should continue to be developed and implemented.  
In a traditionally underserved disease area, we must continue to raise awareness 
of the ability of emerging technologies, such as LDCT and molecular testing, to support 
improved lung cancer outcomes.  Additionally, we should advocate for insurance 
coverage of these services.  We should also continue to provide information to providers 
and patients that these services are available and provide direction on how to access the 
services.   
Future Research 
 Additional research in the areas of lung cancer screening and molecular testing 
are needed and this dissertation identified specific areas to target.  Utilization rates for 




for this should be further explored.  Additionally, utilization of molecular testing in other 
cancer sites (e.g., colorectal) could be explored.   
With regards to lung cancer screening, areas of further research interest include 
identifying how family physician practices follow up with their patients after a referral 
for a LDCT and determining the best approaches to documenting and billing for lung 
cancer screening counseling visits.  Additionally, future research could assess the 
perspectives and practices of non-physician providers (e.g. nurse practioners, physician 
assistants), who are also able to engage in shared decision-making discussions with high 
risk patients and provide referrals for lung cancer screening.  
 Future research into precision medicine utilization in lung cancer should also 
consider use of datasets that include patient level (e.g., smoking history, molecular test 
results) and provider level variables (e.g., geographic location) that we were not able to 
include in our analyses of molecular testing and erlotinib utilization.  Now that new CPT 
codes are available that provide additional detail on the specific genes tested, we 
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The Carolina Physicians’ Lung Cancer Screening Survey is a survey of family 
physicians in North and South Carolina. In this survey, we request that you answer 
questions about your attitudes and practices related to lung cancer screening procedures, 
even if you are not currently recommending screening to your patients.  This topic 
has relevance for clinicians and health care researchers because lung cancer is the most 
common cause of cancer-related death in the U.S. and our state. 
 
All information you provide in this survey will remain confidential.  Participation is 
voluntary; however, we would greatly appreciate your participation since not responding 
could affect the accuracy of our results, and your point of view may not be adequately 
represented in the survey findings. We request you fill out the survey within one week of 
receiving our invitation via email. You cannot save the survey and return to it later; it 
must be completed in one session. All your information will be kept confidential and 
results will only be reported in aggregate form. Your name will not be connected with 
any information you provide.  
 
If you have any questions, please call the study Principal Investigator Dr. Jan Eberth at 
803-576-5770 or at jmeberth@mailbox.sc.edu. You can also contact Dr. Scott Strayer, a 
fellow family practitioner, at Scott.Strayer@uscmed.sc.edu or Dr. Edward Kim, a 





By proceeding to the survey/questionnaire on the next page you are indicating that you 
have read and understood this consent form and agree to participate in this research 
study.   
 




Practice Setting and Demographics 
 
1. Please select your practice setting: 
[  ] Hospital 
[  ] Private practice 
[  ] Group practice 
[  ] Health Maintenance Organization 
[  ] Community health center 
[  ] Medical school/university 
[  ] Other; please specify: 
_______________________________________________________ 
 







3. Please select your gender: 
[  ] Male 
[  ] Female 
 
4. Please select your race (Check all that apply) 
[  ] White 
[  ] Black or African American 
[  ] American Indian or Alaska Native 
[  ] Asian 
[  ] Hawaiian/Pacific Islander 
[  ] Other 
 
      4a. Do you consider yourself Hispanic/Latino? 
[  ] Yes 
[  ] No 
 
5. Please select your age range: 
[  ] 20-29                     [  ] 60-69 




[  ] 40-49                     [  ] 80+ 
[  ] 50-59 
 
6. What is your specialty? 
[  ] Family medicine 
[  ] General medicine 
[  ] Internal medicine 
[  ] Other, please specify:  
 
LDCT Screening Recommendations & Guidelines 
 
7. Which, if any, lung cancer screening test would you recommend for the 
following patients? Assume that these patients have: 
• No symptoms of lung cancer 
• Never been screened for lung cancer before 
• Expressed no interest for lung cancer screening  
• Have no occupational exposure to lung carcinogens 






50-year-old nonsmoker with: 
• 30 years second-hand 
smoke exposure from 
spouse 
   
50 year old current smoker 
with: 
• 20 pack-years of smoking 
• Family history of lung 
cancer 
   
60 year old current smoker 
with: 
• 30-year pack history 
   
70 year old former smoker 
with: 
• 30-year pack history 
• Quit smoking 20 years ago 
   
 
8. How often should patients at high risk for lung cancer be screened using low-
dose CT (assuming low-dose CT is performed solely for lung cancer screening)? 
       [  ] Every 6 months 
[  ] Every year 
[  ] Every 2 years 
[  ] Every 3 years 
 
9. To the best of your knowledge, do the following organizations recommend the 
use of low-dose CT for lung cancer screening in asymptomatic, high risk 












U.S. Preventive Services 
Task Force 
   
American Cancer Society    
National Comprehensive 
Cancer Network 
   
American College of 
Radiology 
   
American Academy of 
Family Physicians 
   
 
10. I have the time I need to stay abreast about current cancer screening guidelines. 
                                     [  ] Agree     [  ] Disagree 
 
Benefits and Risks of Screening 
 
11. What do you consider to be the benefits of low-dose CT (for lung cancer 
screening) for patients at high risk for lung cancer? Check all that apply. 
[  ] Reduces lung cancer mortality  
[  ] Increases the chances of finding lung cancer at an earlier stage 
[  ] Low rate of false positives 
[  ] It is beneficial for all patients, regardless of smoking history 
[  ] No benefits 
 
12. What do you consider to be the risks of low-dose CT for lung cancer screening 
for patients at high risk for lung cancer? (Check all that apply) 
[  ] Positive screening results rarely result in a lung cancer diagnosis 
[  ] High rate of false negatives, leading to inaccurate reassurance given to people 
with lung cancer 
[  ] Psychological stress or anxiety for the patient 
[  ] May lead to unnecessary diagnostic procedures  
[  ] Exposure to radiation increasing cancer risk 
[  ] No risks 
Cost of Screening 
 
13. Do Medicare/Medicaid cover the cost of low-dose CT for lung cancer screening 
for high risk patients? 
[  ] Yes 
[  ] No 
[  ] Not Sure 
 
14. Do most private insurers cover the cost of low-dose CT for lung cancer screening 




[  ] Yes 
[  ] No 




15. During the past year did any of your patients ask if they can or should be 
screened for lung cancer? 
 
[  ] Yes               About how many patients?                
[  ] No 
 
16. How many patients have you referred for low-dose CT (for lung cancer 
screening) in the past month? (Give your best estimate) 




17. How many patients have you referred for low-dose CT (for lung cancer 





18. Medicare/Medicaid require that patients considering LDCT screening for lung 
cancer first have a shared decision-making visit with a healthcare provider. A 
shared decision-making visit should include a discussion of the benefits and 
harms of LDCT screening, follow-up diagnostic testing, over-diagnosis, the false 
positive rate and total radiation exposure.  
 
To what extent do you feel comfortable engaging in a discussion of this nature 
with your patient? 
      [  ] I was not aware of this requirement 
[  ] Very comfortable 
      [  ] Somewhat comfortable 
      [  ] Somewhat uncomfortable 
      [  ] Very uncomfortable 
      [  ] Unsure 
  
 
19. Medicare/Medicaid require that providers counsel their patients on smoking 
cessation, or encourage them to remain abstinent from smoking if former 
smokers, before referring them for lung cancer screening.   
To what extent do you feel comfortable engaging in a smoking 
cessation/abstinence discussion with your patient? 





      [  ] Very comfortable 
      [  ] Somewhat comfortable 
      [  ] Somewhat uncomfortable 
      [  ] Very uncomfortable 
      [  ] Unsure 
 
20. How likely would you be to engage in this shared decision-making and smoking 
cessation discussion with your patient if the visit took: 
 




< 5 minutes     
5-10 minutes     
>10 minutes     
 
21. How often to you discuss the risks and benefits of low-dose CT with patients you 
recommend for lung cancer screening?  
 




    
 
22. Which best describes your practice style concerning low-dose CT for lung cancer 
screening?  (Please check only one box.). 
 
Recommend screening to 
patients without discussion of 
risks and benefits  
 
Discuss risks and benefits, then 
recommend screening 
 
Discuss risks and benefits, then 
let patient decide to be screened 
 
Discuss risks and benefits, then 
recommend against screening 
 
Do not discuss risks and 
benefits or recommend 
screening 
 
Recommend against screening  
 
23. If a patient recommended for low-dose CT initially declines screening, I still 
encourage him/her to participate in the screening procedure. 
                                      [  ] Agree      [  ] Disagree 
 





24. Tell us about your opinions about low-dose CT for lung cancer screening. Check 
one box per row. 
 
 
 Strongly Agree          Strongly 
Disagree 
1 2 3 4 5 
The benefits of low-dose CT 
outweigh the risk for 
patients at high risk for lung 
cancer. 
     
There is clear evidence that 
low-dose CT for lung cancer 
screening saves lives. 
     
Low-dose CT screening for 
lung cancer is cost-effective. 
     
The rate of false positives 
for low-dose CT is too high. 
     
Low-dose CT creates 
enough anxiety to negate the 
value of screening. 
     
The scientific evidence is 
strong enough to warrant a 
screening guideline for high 
risk patients. 
     
There is no need to educate 
patients about low-dose CT 
because in general they 
want to be screened. 
     
If cost were not an issue, I 
would recommend low-dose 
CT screening to my patients 
at high risk for lung cancer. 
     
I am not sure how to refer 
my patients for LDCT 
screening. 














Management of LDCT Screening Results 
 
25. If a patient is found to have a positive low-dose CT scan for lung cancer, to what 
extent would you be comfortable managing the follow-up of your patient? 
[  ] Very comfortable 
[  ] Somewhat comfortable 
[  ] Somewhat uncomfortable 
      [  ] Very uncomfortable 




26. Are you interested in being contacted at a later date to provide further 
information on your opinions regarding lung cancer screening? 
                               [  ] Yes        [  ] No 
 
26a. If you answered yes to Question 26, please provide contact information that 
you would like us to use to reach you in follow-up studies (name, address, phone 
and email). Note that we will use this information solely to contact you for 
gathering data in future studies, and we will not share your name or contact 
information with any third parties or outside groups. Your name and contact 
















FAMILY PHYSICIAN INTERVIEW GUIDE 
Introduction to physician via email (Initial contact attempt): 
Greetings Dr. [INSERT NAME], 
Last year, you participated in a survey on lung cancer screening through the [Carolinas 
HealthCare System/South Carolina Academy of Family Physicians] and agreed to be 
contacted to assist us with future research on lung cancer screening. If you recall, you 
completed this survey [VIA AN ELECTRONIC SURVEY LINK/ON PAPER-SENT BY 
CAROLINAS HEALTHCARE SYSTEM/SC ACADEMY OF FAMILY PHYSICIANS-
AT THE ANNUAL MEETING].  
I am a graduate student working with University of South Carolina (USC), Medical 
University of South Carolina (MUSC), and Levine Cancer Institute (LCI) researchers, 
Jan Eberth, Scott Strayer, Kathleen Cartmell, and Edward Kim, to conduct a research 
project on physician’s perceptions of low-dose CT screening for lung cancer and we 
would like to hear more about your thoughts on this topic.  It’s important that we learn 
what physicians know and how they feel about screening patients for lung cancer using 
low-dose CT, since there are inherent risks and benefits.  
We realize that your time is valuable, and we are willing to provide an incentive for 
participation in a telephone interview.  We anticipate that the interview will take 
approximately 30-45 minutes.  Are you willing to participate in the telephone interview?  
If so, please respond to this email with your preferred date/time of the interview. If you 
do not wish to participate, please let us know and we will note this. 
Thank you for your time and we look forward to hearing from you! 
Jennifer L. Ersek, MSPH, PhD(c) 
(704) 654-0884 
ersek@email.sc.edu  
Dr. Jan M. Eberth (USC) 
Dr. Kathleen  Cartmell (MUSC) 
Dr. Scott Strayer (USC) 
Dr. Edward Kim (LCI)
Introduction to physician via email (Follow-up contact attempt): 




We are following up to see if you received our email sent to you on [DATE].  If you 
recall, you participated in a survey on lung cancer screening through the [Carolinas 
HealthCare System/South Carolina Academy of Family Physicians] and agreed to being 
contacted to assist us with future research on lung cancer screening. You completed this 
initial survey [VIA AN ELECTRONIC SURVEY LINK/ON PAPER-SENT BY 
CAROLINAS HEALTHCARE SYSTEM/SC ACADEMY OF FAMILY PHYSICIANS-
AT THE ANNUAL MEETING].  
Please let us know if you are willing to participate in our telephone interview.  For your 
valued time, we will provide a gift card to you.  If you agree, please respond to this email 
with potential dates/times for the interview.   
If you do not wish to participate, please also let us know and we will remove you from 
our contact list. 
Thank you again for your time.  We look forward to hearing from you soon! 
Jennifer L. Ersek, MSPH, PhD(c) 
(704) 654-0884 
ersek@email.sc.edu  
Dr. Jan M. Eberth (USC) 
Dr. Kathleen  Cartmell (MUSC) 
Dr. Scott Strayer (USC) 
Dr. Edward Kim (LCI) 
 
Reminder email to physician 1-3 days prior to scheduled interview: 
Greetings Dr. [INSERT NAME], 
I am looking forward to speaking with you soon about your thoughts on using low-dose 
computed tomography for lung cancer screening.  I just wanted to remind you that our 
interview is scheduled for [Date/Time].  I will call you at [Phone number] / please call 
me at (803) 580-5156. 
Please let me know if you have any questions. 
Thank you again for your time, 
Jennifer L. Ersek, MSPH, PhD(c) 
 
Introduction to receptionist answering phone (Final contact attempt or any attempt for 
physicians who did not provide a valid email):   
Hello, my name is Jennifer Ersek and I am calling from the University of South Carolina. 
Last year, Dr. [INSERT NAME] participated in a survey on lung cancer screening 
through the [Carolinas HealthCare System/South Carolina Academy of Family 
Physicians] and agreed to being contacted for a phone interview. What is the best way to 




Email/phone [EMAIL: Ask for email address.]  Is he/she available to speak or could I 
schedule another time to talk with Dr. [INSERT NAME] to discuss this interview?   
Introduction to physician via phone: 
Hi Dr. [INSERT NAME], my name is Jennifer Ersek and I am a graduate student at the 
USC.  We are contacting you today because you indicated interest in assisting us with 
future research on lung cancer screening when you participated in our survey through the 
Carolinas HealthCare System/SC Academy of Family Physicians last year. If you recall, 
you either completed this survey [ELECTRONICALLY THIS YEAR OR IN PAPER 
FORMAT AT THE SC ACADEMY OF FAMILY PHYSICIANS ANNUAL 
MEETING/VIA EMAIL SURVEY LINKLAST YEAR].  
I am working with University of South Carolina and MUSC researchers to conduct a 
research project on physician’s perceptions of low-dose CT screening for lung cancer and 
we would like to hear more about your thoughts on this topic.  It’s important that we 
learn what physicians know and how they feel about screening patients for lung cancer 
using low-dose CT, since there are inherent risks and benefits.  
We realize that your time is valuable, and we are willing to provide *AN INCENTIVE* 
for participation in the interview.  We anticipate that the interview will take 
approximately 30-45 minutes.  Are you willing to participate in the telephone interview?  
We can schedule a more convenient time for you if you prefer or we can even do the 
interview now.   
If yes:  Great! We are looking forward to learning about your thoughts and any 
experience you may have with lung cancer screening in your practice.   
If no:  Thank you very much; I hope you have a pleasant day. 
Consent: Let me quickly review a few specifics about this study before we continue. 
Dr. Jan Eberth, a professor at the University of South Carolina, and her research team are 
asking you to participate in this interview research study to learn more about your 
thoughts and use of lung cancer screening. You are being asked to take part because you 
are a family practice physician member of the South Carolina Chapter of the American 
Academy of Family Physicians or an employee at the Carolinas HealthCare System and 
you provided your contact information to us for future research. 
Your participation in this study is completely voluntary. You should feel under no 
pressure to be in the study.  If you decide not to be in the study, your decision to not 
participate will not in any way harm your relationship with the University of South 
Carolina or the study investigator.  You are free to stop being in the study if you change 
your mind after starting the interview.  As mentioned previously, for participation in this 
study, you will receive *AN INCENTIVE*.  
In this study, your interview responses (i.e., your study record) will be recorded.  We will 




identifying information in any manuscript or publication of any sort.  The risks of 
participation in this study are minimal but include the chance of study records being 
compromised.  However, the records of this study will be kept private to the best of our 
ability. Your name and the name of your practice will not be associated directly with any 
of the statements you make during the interview.  The data generated from this study (i.e. 
recorded interviews and transcripts) will be kept in a secure location.  Benefits of this 
study include the potential to better understand how physician’s view and utilize lung 
cancer screening in South Carolina.  
If you have any questions regarding the study, I will be happy to answer them today, or 
via email in the future. The email address of the Principal Investigator of this study is 
jmeberth@mailbox.sc.edu. If you have any questions regarding your rights as a study 
participant, please feel free to contact the University of South Carolina Institutional 
Review Board (IRB) by calling Lisa Marie Johnson, IRB Manager, Office of Research 
Compliance, University of South Carolina at (803) 777-7095 or emailing her at 
LisaJ@mailbox.sc.edu. Do you need me to repeat that phone number or email address? If 
there are no questions, do I have your consent to proceed with the survey?   
If yes:  Great!  We don’t expect you to know all of the answers to all of the questions we 
have for you today.  If you don’t know how to respond, please just let us know that. 
If no:  Thank you so much for your time today.  We appreciate you taking the time out of 
your busy day to take our phone call.  Have a great day. 
Interview Questions: 
1. About Your Practice 
 
1.1. How many physicians and advanced practioners, such as physician assistants or 
nurse practioners, are in your practice?  Do most practice full time? 
1.2. Does your practice accept Medicare/Medicaid?  What proportion of your patients 
are covered by Medicare/Medicaid? 
1.3. What can you tell me about the patients you see in your practice?  Do you see 
many cancer/lung cancer patients?  Have you ever had any patients diagnosed 
with lung cancer?  If so, what can you tell me about them? 
 
2. Current Evidence and Guidelines for LDCT Screening for Lung Cancer 
First, we’d like to talk about current evidence and guidelines for lung cancer screening 
with low-dose computed tomography. 
2.1. How do you find out about new guidelines? 
2.2. What can you tell me about the current lung cancer screening guidelines?  What 
is recommended?  [Probe: If they don’t specifically mention the organizations 
that make these recommendations ask, ‘What organization specifically 




2.3. What can you tell me about the type of person who should be recommended for 
lung cancer screening?  [Probe:  Is screening recommended for everyone?  
Former smokers?] 
2.4. What can you tell me about the scientific evidence surrounding LDCT screening 
for lung cancer?  [Probe:  Have you heard about the National Lung Screening 
Trial or the Prostate Lung Colon Ovarian Cancer Screening Trial?  If yes:  What 
have you heard?  If no: PLCO-no mortality benefit with chest x-ray; NLST-20% 
reduction in mortality with LDCT.] 
 
3. Who to Talk to About Lung Cancer Screening in the Clinic 
Next, let’s talk about who you talk to about lung cancer screening. 
3.1. How do you make the decision on who to talk to about lung cancer screening?  
[Probe: What types of patients would you discuss lung cancer screening with?  
Do you have a way to systematically identify candidates for screening?]   
3.2. What (if any) types of patients in your clinic ask on their own to be screened for 
lung cancer or ask for your opinion about screening?  
3.3. Patients considered to be high risk for lung cancer by the National 
Comprehensive Cancer Network (Category B) are defined as those ages 55 to 80 
years, asymptomatic, 30 pack year smoking history, current or have quit in past 
15 years.] 
How would you manage a patient who is not considered to be high risk, but is 
requesting a referral for low-dose computed tomography screening?  Are there 
any circumstances where you would NOT recommend LCDT to someone who 
may fit the definition of high risk?  
 
4. Discussing LDCT in the Clinic 
The goal of the next set of questions is to learn more about how you and your colleagues 
recommend (or do not recommend) LDCT to patients in your offices, clinics.   
4.1. To what extent do you think other healthcare providers in your region are 
recommending LDCT?  
4.2. What is your experience with recommending or not recommending LDCT 
screening for high risk patients? [Probe:  If they never use LDCT screening, why 
not and do they intend to in the future? Can you describe the process for how you 
discuss lung cancer screening with your patients?  [Probe:  Does this process 
include shared decision making?  Shared decision making is typically defined as 
a ‘collaborative process that allows patients and their providers to make health 
care decisions together”.  SDM considers the best scientific evidence available, 
as well as the patient’s values and preferences.  Probe:  Did you know that you 
can bill for the shared-decision making visit? Describe how this communication-
oriented visited that can be billed for Medicare beneficiaries and that the purpose 




comfortable are you with conducting a shared decision-making visit for lung 
cancer screening with your patients, given the various pros and cons? 
4.3. What are your thoughts on taking time during the patient’s appointment to 
discuss lung cancer screening when the patient’s original purpose was a sick visit 
or annual checkup?   
4.3.1. How much time (if any) could you dedicate to this discussion?  Would 
you request the patient schedule a new appointment to talk specifically about 
lung cancer screening? 
4.4. How would you approach LDCT screening among patients who lack insurance?  
[Probe:  How would you discuss the costs of follow-up care and treatment if lung 
cancer is found during screening?] 
4.5. Do you feel that integrating lung cancer screening visit is feasible in your 
clinic?  If yes, what are some facilitators?  If no, what are some barriers to 
integration? 
 
5. Making the Low-Dose Computed Tomography Referral and Following Up 
 
Next, let’s talk about making the LDCT referral and subsequent follow-up with the 
patient. 
 
5.1. How do you feel about the role primary care providers have in regard to lung 
cancer screening?   
5.1.1. Would you prefer to refer patients directly to a pulmonologist or 
radiologist for the shared decision-making visit OR would you prefer to do it 
yourself?   
5.2. Have you ever referred anyone for LDCT screening?  If yes, continue to 5.3. If 
no, do you intend to do so in the future?  What are the reasons why you would 
not refer anyone?  (Probe: Administrative reason, complexity with billing, etc)   
5.3. For patients you have referred, did you have any difficulty making the LDCT 
referral?  [Probe: not know where to refer them, what to document on the referral 
paperwork, etc…]  Did you have any difficulty getting the scan reports? 
5.4. What is the process for following-up with a patient with a positive lung nodule?  
[Probe:  What type of follow up would you recommend for a patient with a 
pulmonary nodule? Is there a pulmonary nodule clinic in your area? Who do you 
think should review the results with the patient?] 
7/7/16 ADDITIONAL QUESTION--For physicians who do not appear to be supportive of 
lung cancer screening with LDCT:  What would kind of information or evidence would be 
needed to gain your support for LDCT screening? 
Conclusion: 
Well, I think that about covers the questions we had for you today.  Is there anything else 




In the next few days, I will also be emailing you a document containing additional 
information and resources for you about low-dose computed tomography screening.   
One last thing, we think we will have enough physicians participating in these qualitative 
interviews, however, in case some physicians change their mind about participating, do 
you know of any other physicians that might like to participate?  [If so, ask if they prefer 
to reach out to the physician with our contact information or if they would like to provide 
us with the physician’s contact information that is fine also.]   
Thank you again, so much, for the time you spent with us today.  Please feel free to 
contact us if you have any questions about the study or lung cancer screening.  We will 









COMMON PROCEDURE TERMINOLOGY 
 BILLING CODES FOR MOLECULAR TESTING 
Code Short Description Long Description 
83890 MOLECULE ISOLATE 
Molecular diagnostics; molecular 
isolation or extraction, each nucleic 
acid type (ie, DNA or RNA) 
83891 MOLECULE ISOLATE NUCLEIC 
Molecular diagnostics; isolation or 
extraction of highly purified nucleic 
acid, each nucleic acid type (ie, DNA or 
RNA) 
83892 MOLECULAR DIAGNOSTICS 
Molecular diagnostics; enzymatic 
digestion, each enzyme treatment 
83893 MOLECULE DOT/SLOT/BLOT 
Molecular diagnostics; dot/slot blot 
production, each nucleic acid 
preparation 
83894 MOLECULE GEL ELECTROPHOR 
Molecular diagnostics; separation by 
gel electrophoresis (eg, agarose, 
polyacrylamide), each nucleic acid 
preparation 
83896 MOLECULAR DIAGNOSTICS 
Molecular diagnostics; nucleic acid 
probe, each 
83897 MOLECULE NUCLEIC TRANSFER 
Molecular diagnostics; nucleic acid 
transfer (eg, Southern, Northern), each 
nucleic acid preparation 
83898 MOLECULE NUCLEIC AMPLI EACH 
Molecular diagnostics; amplification, 
target, each nucleic acid sequence 
83900 MOLECULE NUCLEIC AMPLI 2 SEQ 
Molecular diagnostics; amplification, 
target, multiplex, first 2 nucleic acid 
sequences 
83901 
MOLECULE NUCLEIC AMPLI 
ADDON 
Molecular diagnostics; amplification, 
target, multiplex, each additional 
nucleic acid sequence beyond 2 (List 
separately in addition to code for 
primary procedure).  Used in 
conjunction with 83900 
83902 MOLECULAR DIAGNOSTICS 





83903 MOLECULE MUTATION SCAN 
Molecular diagnostics; mutation 
scanning, by physical properties (eg, 
single strand conformational 
polymorphisms [SSCP], heteroduplex, 
denaturing gradient gel electrophoresis 
[DGGE], RNA'ase A), single segment, 
each 
83904 MOLECULE MUTATION IDENTIFY 
Molecular diagnostics; mutation 
identification by sequencing, single 
segment, each segment 
83905 MOLECULE MUTATION IDENTIFY 
Molecular diagnostics; mutation 
identification by allele specific 
transcription, single segment, each 
segment 
83906 MOLECULE MUTATION IDENTIFY 
Molecular diagnostics; mutation 
identification by allele specific 
translation, single segment, each 
segment 
83907 LYSE CELLS FOR NUCLEIC EXT 
Molecular diagnostics; lysis of cells 
prior to nucleic acid extraction (eg, 
stool specimens, paraffin embedded 
tissue), each specimen 
83908 NUCLEIC ACID SIGNAL AMPLI 
Molecular diagnostics; amplification, 
signal, each nucleic acid sequence 
83909 NUCLEIC ACID HIGH RESOLUTE 
Molecular diagnostics; separation and 
identification by high resolution 
technique (eg, capillary 
electrophoresis), each nucleic acid 
preparation 
83912 GENETIC EXAMINATION 
Molecular diagnostics; interpretation 
and report 
83913 MOLECULAR RNA STABILIZATION 
Molecular diagnostics; RNA 
stabilization 
83914 MUTATION IDENT OLA/SBCE/ASPE 
Mutation identification by enzymatic 
ligation or primer extension, single 
segment, each segment (eg, 
oligonucleotide ligation assay [OLA], 
single base chain extension [SBCE], or 
allele-specific primer extension 
[ASPE]) 
88384 EVAL MOLECULAR PROBES 11-50 
Array-based evaluation of multiple 
molecular probes; 11 through 50 probes 
88385 EVAL MOLECUL PROBES 51-250 
Array-based evaluation of multiple 
molecular probes; 51 through 250 
probes 
88386 EVAL MOLECUL PROBES 251-500 
Array-based evaluation of multiple 
molecular probes; 251 through 500 
probes 
 
